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The	   liver	   plays	   a	   central	   role	   in	   haemostasis,	   producing	   the	   majority	   of	   both	   pro	   and	  
anticoagulant	   proteins.	   Liver	   disease	   has	   been	   seen	   to	   be	   the	   archetypal	   acquired	  
coagulopathy	   as	   it	   has	   been	   assumed	   that	   the	   associated	   abnormalities	   in	   conventional	  
coagulation	  tests	  such	  as	  prothrombin	  time	  (PT)	  and	  international	  normalized	  ratio	  (INR)	  are	  
indicative	  of	  hypocoagulability	  and	  a	  bleeding	  diathesis.	  However,	  directly	  observed	  study	  of	  
liver	   bleeding	   times	   (1),	   and	   a	   systematic	   review	   of	   the	   association	   of	   bleeding	   with	  
abnormal	  coagulation	  tests	  (2)	  demonstrate	  that	  these	  tests	  are	  in	  fact	  very	  poor	  predictors	  
of	   bleeding	   risk.	   Further	   evidence	   that	   these	   tests	   are	   inadequate	   for	   assessing	   potential	  
bleeding	  risk	  has	  accrued	  as	  an	   increasing	  number	  of	  patients	  with	  end	  stage	   liver	  disease	  
undergo	   liver	  transplantation	  without	  the	  need	  for	  transfusion	  of	  blood	  or	  blood	  products	  
(3).	  
The	  complexity	  of	   the	  coagulation	  changes	   in	  chronic	   liver	  disease	  was	   first	  highlighted	   in	  
2005,	  when	  Tripodi	  et	  al.	   demonstrated	  using	   a	  novel	   assay	  of	   coagulation,	   the	   thrombin	  
generation	   test,	   that	   people	   with	   cirrhotic	   liver	   disease	   generated	   similar	   amounts	   of	  
thrombin	   as	   a	   normal	   control	   population	   (4).	   Indeed,	   as	   liver	   disease	   advances,	   some	   of	  
these	  patients	  demonstrate	  enhanced	   thrombin	  generation	   (5),	   and	   it	   is	   now	  appreciated	  
that	   these	   patients	   should	   not	   be	   considered	   “auto-­‐anticoagulated”	   solely	   because	   they	  
have	  an	  elevated	  PT/INR	   (6).	  Over	   the	   last	  decade	  a	  new	  paradigm	  of	   coagulation	   in	   liver	  
disease	  has	  emerged,	  and	  haemostasis	  is	  now	  described	  as	  being	  “re-­‐balanced”	  (7).	  This	  re-­‐
balancing	   is	   due	   to	   the	   concomitant	   decrease	   in	   both	   pro	   and	   anticoagulants,	   and	   also	  
increases	   in	   factor	  VIII	  and	  Von	  Willebrands	  factor.	  The	  conventional	  coagulation	  tests	  are	  
very	  responsive	  to	  falls	  in	  procoagulant	  factors,	  but	  fail	  to	  capture	  the	  parallel	  reduction	  in	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anticoagulants,	   and	   may	   therefore	   over-­‐estimate	   the	   bleeding	   risk	   in	   patients	   with	   liver	  
disease.	   Although	   haemostasis	   is	   described	   as	   “re-­‐balanced”,	   it	  must	   be	   appreciated	   that	  
this	   is	   a	   relatively	   fragile	   balance,	   and	   as	   the	   large	   haemostatic	   reserve	   seen	   in	   healthy	  
individuals	   is	   significantly	   reduced,	   the	   balance	   can	   readily	   be	   tipped	   towards	   either	  
bleeding	  or	  thrombosis,	  if	  the	  system	  is	  stressed	  in	  any	  way,	  as	  for	  example	  by	  infection.	  	  
In	  liver	  disease,	  and	  also	  following	  major	  liver	  resection,	  mild	  to	  moderate	  prolongations	  of	  
PT/INR	  are	  common,	  and	  although	  the	  evidence	  that	  they	  are	  predictive	  of	  bleeding	  is	  poor	  
to	  non-­‐existent,	   these	   tests	  are	   routinely	  used	   in	  clinical	  practice	  as	   the	  basis	   for	  decision	  
making,	   including	   whether	   or	   not	   to	   administer	   fresh	   frozen	   plasma	   prior	   to	   invasive	  
procedures,	  or	  when	  to	   initiate	  pharmacological	  thromboprophylaxis.	  As	  a	  consequence,	  a	  
significant	  amount	  of	   fresh	  frozen	  plasma	   is	  used	   in	  patients	  with	  cirrhosis	   for	  prophylaxis	  
without	  evidence	  of	  utility	  or	  efficacy	   (8).	   In	  addition,	   there	   is	   some	   reticence	   to	   institute	  
thromboprophylaxis	   due	   to	   the	   perception	   that	   bleeding	   risk	   is	   increased	   as	   a	   direct	  
consequence	  of	  an	  elevated	  PT/INR.	  To	  complicate	  matters	  even	  further,	  there	  is	  wide	  inter	  
laboratory	  variation	  in	  the	  INR	  in	  patients	  with	  liver	  disease(9),	  and	  this	  also	  has	  an	  impact	  
on	  the	  calculated	  MELD	  score.	  In	  terms	  of	  defining	  bleeding	  and	  thrombotic	  risk,	  it	   is	  clear	  
that	  standard	  coagulation	  tests	  have	  many	  limitations	  when	  used	  to	  direct	  clinical	  practice	  
in	  the	  setting	  of	  liver	  disease.	  
Given	  the	  complexity	  of	  the	  changes	  that	  occur	  in	  the	  haemostatic	  system	  in	  these	  patients,	  
the	  question	  arises	  whether	  global	  viscoelastic	  tests	  of	  coagulation	  (	  thromboelastography	  
[TEG]	  and	  thromboelastometry	  [ROTEM])	  which	  are	  performed	   in	  whole	  blood,	  and	  which	  
incorporate	   all	   the	   cellular	   elements	   involved	   in	   coagulation,	   may	   provide	   more	  
comprehensive	  and	  clinically	  useful	   information	  about	   the	  coagulation	   status,	  and	   thus	  of	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bleeding	   and	   thrombotic	   risk,	   than	   the	   conventional	   tests	   of	   coagulation.	   The	   purpose	   of	  
this	  thesis	  is	  to	  explore	  this	  hypothesis	  in	  more	  detail.	  
Outline	  of	  this	  thesis	  
This	  thesis	  focuses	  on	  what	  is	  currently	  known	  about	  the	  haemostatic	  changes	  that	  occur	  in	  
liver	   disease,	   and	   also	   those	   that	   follow	   major	   liver	   resection.	   Although	   there	   has	   been	  
considerable	  work	  on	  the	  changes	  in	  coagulation	  in	  both	  acute	  and	  chronic	  liver	  disease	  in	  
recent	  years,	  there	  has	  been	  far	  less	  attention	  to	  hepatic	  resection.	  This	  is	  also	  an	  important	  
area	  for	  study	  as	  an	  elevation	  of	  PT/INR	  is	  common	  in	  the	  first	  few	  days	  after	  resection,	  yet	  
these	  patients	  are	  known	  to	  have	  a	  high	  incidence	  of	  thromboembolic	  complications	  in	  the	  
early	   post	   operative	   period,	   and	   this	   risk	   appears	   to	   increase	   with	   the	   extent	   of	   liver	  
parenchyma	  resected(10).	  
	  It	   is	   the	   central	   hypothesis	   of	   this	   thesis	   that	   global	   viscoelastic	   tests	   (TEG/ROTEM)	   by	  
facilitating	   assessment	   of	   all	   the	   cellular	   components	   of	   the	   coagulation	   process	   in	   an	  
integrated	  manner,	   and	   their	   summative	   effect	   on	   ultimate	   clot	   formation,	   strength	   and	  
stability,	  provide	  more	  clinically	  relevant	  information	  than	  do	  conventional	  coagulation	  tests	  
which	  only	  assess	  single	  end	  points	  of	  coagulation	  in	  plasma	  rather	  than	  in	  whole	  blood.	  
Chapter	  one	   focuses	  on	  models	   of	   coagulation	   (traditional	   cascade	  model	   and	   the	  newer	  
cell	  based	  model	  of	  haemostasis)	  and	  the	  limitations	  of	  traditional	  coagulation	  tests	  in	  liver	  
disease.	  	  
Chapter	   two	   discusses	   the	   principles	   of	   viscoelastic	   tests,	   their	   limitations	   and	   also	   their	  
correlation	  with	  conventional	  coagulation	  tests.	  It	  also	  highlights	  that	  these	  tests	  can	  detect	  
General	  introduction	  and	  outline	  of	  thesis	  
18	  
	  
“hypercoagulability”	  which	  may	  relate	  to	  an	  increased	  thrombotic	  risk,	  and	  also	  fibrinolysis,	  
neither	  of	  which	  is	  readily	  detected	  using	  conventional	  tests	  of	  coagulation.	  
Chapter	   three	   is	   a	   review	  and	  critical	   appraisal	  of	   the	  available	   literature	  on	   the	  utility	  of	  
viscoelastic	   tests	  of	   coagulation	   in	  patients	  with	  both	  acute	  and	  chronic	   liver	  disease.	  The	  
majority	  of	  patients	  with	  liver	  disease	  have	  “normal”	  coagulation	  as	  assessed	  by	  these	  tests,	  
and	  this	  may	  be	  seen	  as	  supporting	  the	  hypothesis	  of	  “re-­‐balanced”	  haemostasis.	   	  Aspects	  
such	  as	  hypercoagulability	  and	  the	  relation	  to	  thrombotic	  risk,	  and	  endogenous	  heparinoids	  
as	  markers	  of	  infection	  and	  endothelial	  injury	  are	  highlighted.	  
Chapter	   four	   is	   a	   review	   and	   critical	   appraisal	   of	   the	   available	   literature	   on	   the	   utility	   of	  
viscoelastic	  tests	  of	  coagulation	  in	  patients	  undergoing	  liver	  transplantation.	  The	  literature	  is	  
reviewed	   to	   determine	   their	   efficacy	   in	   predicting	   bleeding	   risk,	   and	   also	   to	   guide	  
haemostatic	  therapy	  in	  the	  presence	  of	  active	  bleeding.	  
Chapter	   five	   is	   a	   retrospective	   study	   to	   assess	   the	   prevalence	   of	   fibrinolysis	   in	   patients	  
undergoing	   liver	   transplantation,	   and	   how	   this	   relates	   to	   subsequent	   need	   for	   blood	  
transfusion.	  Historically	  aprotinin	  (Trasylol)	  was	  given	  to	  high	  risk	  liver	  transplant	  patients	  to	  
minimise	   the	   bleeding	   associated	  with	   fibrinolysis.	   Aprotinin	  was	  withdrawn	   from	   clinical	  
practice	   in	  2008,	  and	  since	   that	   time	   treatment	  with	  antifibrinolytic	   therapy	  has	  generally	  
moved	  towards	  a	  treatment	  only	  regime,	  rather	  than	  prophylaxis.	  Comparing	  retrospective	  
propensity	   matched	   cohorts	   (prophylactic	   versus	   treatment	   only	   with	   anti-­‐fibribrinolytics	  
agents)	   the	   impact	   of	   fibrinolysis	   on	   transfusion	   requirements	  was	   investigated,	   and	   also	  
whether	  the	  timing	  of	  the	  appearance	  of	  fibrinolysis	  at	  different	  stages	  of	  the	  operation	  has	  
different	  prognostic	  significance.	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Chapter	   six	   describes	   the	  prevalence	  of	  hypercoagulability	  during	   liver	   transplantation,	   as	  
determined	   by	   thromboelastography	   performed	   at	   the	   start	   of	   the	   procedure,	   and	   at	  
various	  time	  points	  during	  the	  operation,	  in	  a	  series	  of	  100	  consecutive	  patients	  undergoing	  
liver	   transplantation.	   This	   information	   gives	   an	   indication	   of	   the	   association	   of	  
hypercoagulability	  with	  underlying	  disease	  aetiology,	  and	  also	  whether	  there	  are	  changes	  in	  
this	  baseline	  profile,	  or	  de-­‐novo	  appearance	  of	  hypercoagulability	  during	  the	  intraoperative	  
period.	  
Chapter	   seven	   describes	   the	   sequential	   changes	   in	   coagulation	   parameters	   (conventional	  
coagulation	   tests,	   pro	   and	   anticoagulant	   factor	   levels,	   thrombin	   generation,	   and	  
thromboelastometry	  (ROTEM)	  in	  a	  prospective	  series	  of	  patients	  undergoing	  major	  hepatic	  
resection.	  Given	  that	  the	  INR	  is	  frequently	  prolonged	  in	  the	  early	  post	  operative	  period,	  the	  
question	  is	  whether	  this	  represents	  a	  true	  bleeding	  risk,	  as	  is	  currently	  assumed,	  or	  if	  other	  
tests	  of	  coagulation	  suggest	  that	  this	  assumption	  should	  be	  re-­‐evaluated.	  
Chapter	  eight	  describes	   the	  efficacy	   in	  vitro	  of	   two	  different	  dose	   regimes	  of	   fresh	   frozen	  
plasma	   (FFP)	   to	   correct	   coagulopathy,	   as	   determined	   by	   a	   prolonged	   INR,	   after	   major	  
hepatic	   resection,	   and	   also	   the	   effect	   of	   FFP	   on	   viscoelastic	   tests	   in	   the	   same	   group	   of	  
patients.	   These	   patients	   will	   frequently	   receive	   prophylactic	   FFP	   prior	   to	   procedures,	   but	  
there	  is	  little	  data	  on	  the	  effect	  of	  typical	  dose	  regimes	  on	  either	  conventional	  or	  viscoelastic	  
coagulation	   tests.	   This	   information	   could	   be	   of	   value	   in	   determining	   if	   FFP	   is	   useful,	   or	  
indeed	  even	  necessary,	  in	  these	  patients	  prior	  to	  undergoing	  an	  invasive	  procedure.	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Chapter	   nine	   summarises	   the	   findings	   from	   these	   chapters,	   and	   discusses	   whether	  
viscoelastic	   coagulation	   tests	   do	   indeed	   give	  more	   valuable	   oversight	   of	   the	   haemostatic	  
profile	   in	   patients	  with	   liver	   disease	   and	   following	  major	   hepatic	   resection.	  Directions	   for	  
future	  research	  based	  on	  these	  findings	  are	  also	  considered.	  
	  








Models	  of	  coagulation	  and	  limitations	  of	  standard	  coagulation	  tests	  
in	  liver	  disease	  





1.1	  Introduction	  	  
Coagulation	   and	   haemostasis	   is	   a	   dynamic	   process	   with	   interplay	   between	   primary	  
haemostasis	   and	   platelet	   plug	   formation,	   and	   secondary	   haemostasis	   with	   thrombin	  
generation	   resulting	   in	   the	   formation	   of	   a	   stable	   haemostatic	   clot,	   with	   several	   control	  
mechanisms	   responsible	   for	   the	  modulation	   and	   termination	  of	   the	   activated	   coagulation	  
cascade.	  Finally	  the	  mechanism	  of	  fibrinolysis	  is	  responsible	  for	  organising	  and	  removing	  the	  
formed	  clot	  to	  restore	  vessel	  patency.	  	  
Coagulation	  is	  a	  complex,	  carefully	  orchestrated	  and	  highly	  sophisticated	  process,	  involving	  
numerous	  checks	  and	  balances.	  Early	  models	  of	  coagulation	  concentrated	  on	  the	  role	  of	  the	  
coagulation	   proteins,	   as	   these	   are	   fundamental	   to	   describing	   and	   understanding	   the	  
hereditary	  coagulopathies,	   such	  as	  haemophilia,	  and	   for	  developing	  coagulation	   tests	   that	  
could	  identify	  these	  deficiencies	  and	  also	  be	  used	  for	  monitoring	  oral	  anticoagulant	  therapy	  
with	  warfarin.	  
The	   new	  model,	   or	   cell	   based	  model,	   emphasises	   the	   critical	   importance	   of	   cells,	  mainly	  
platelets,	  but	  also	  white	  blood	  cells	  and	  vascular	  endothelial	  cells,	  and	  their	  vital	  role	  in	  the	  
initiation	   and	   subsequent	   evolution	   of	   clot	   (11).	   It	   is	   apparent	   from	   this	   model	   that	  
conventional	  coagulation	  tests	  run	  on	  citrated	  plasma	  samples,	  with	  single	  end	  points,	  are	  
wholly	  inadequate	  for	  the	  purposes	  of	  determining,	  or	  fully	  understanding,	  the	  haemostatic	  
process	  in	  vivo.	  
1.2	  Primary	  Haemostasis	  




Platelets	   play	   an	   important	   role	   in	   localising	   clotting	   reactions	   because	   they	   adhere	   and	  
aggregate	   at	   the	   sites	   of	   injury	  where	   tissue	   factor	   (TF)	   is	   exposed,	   and	   they	   provide	   the	  
primary	   surface	   for	   generation	   of	   the	   burst	   of	   thrombin	   required	   to	   produce	   effective	  
haemostasis	   during	   the	   propogation	   phase	   of	   coagulation.	   Platelet	   localisation	   and	  
activation	  are	  mediated	  by	  Von	  Willebrand	  factor	  (VWF),	  thrombin,	  platelet	  receptors,	  and	  
vessel	  wall	  components	  such	  as	  collagen	  (12).	  Circulating	  platelets	  become	  in	  close	  contact	  
to	   the	   injured	  vessel	  wall	   by	  attachment	  of	   the	  platelet	   surface	  glycoprotein	   Ib	   (GP-­‐Ib)	   to	  
VWF	  in	  the	  wound.	  VWF	  is	  a	  large	  molecule,	  synthesised	  by	  endothelial	  cells,	  that	  circulates	  
in	  complex	  with	  coagulation	  factor	  VIII	  (FVIII).	  After	  binding	  to	  exposed	  collagen	  in	  a	  wound	  
it	  becomes	  structurally	  altered	  and	  able	  to	  bind	  GP-­‐Ib	  on	  the	  platelet	  surface.	  
During	  high	  shear,	  platelets	  “roll”	  along	  the	  wound	  surface,	  and	  lose	  speed	  and	  eventually	  
bind	  irreversibly	  to	  the	  wound	  surface.	  This	  binding	  is	  facilitated	  by	  the	  attachment	  of	  other	  
platelet	   surface	   glycoproteins,	   the	   GP-­‐Ia/IIa	   complex	   and	   GP-­‐VI	   to	   collagen,	   resulting	   in	  
platelet	  activation.	  Platelets	  are	  also	  able	  to	  bind	  to	  fibrinogen	  and	  fibrin	  via	  the	  GP-­‐IIb/IIIa	  
receptor.	   Once	   activated,	   platelets	   release	   a	   number	   of	   substances	   from	   their	   granules	  
including	   adenosine	   diphosphate	   (ADP),	   serotonin	   and	   thromboxane	   A2,	   which	   stimulate	  
and	   recruit	   additional	  platelets	   to	   the	  area.	   The	   thrombin	   that	   is	   generated	  as	   a	   result	  of	  
activation	  of	  the	  coagulation	  proteins	  on	  the	  surface	  of	  platelets,	  is	  also	  an	  extremely	  potent	  
platelet	   activator.	   The	   commonly	   used	   anti-­‐platelet	   drugs	   interfere	   with	   primary	  
haemostasis	   at	   various	   points.	   Aspirin	   inhibits	   cyclo-­‐oxygenase	   (COX),	   the	   enzyme	  
responsible	  for	  the	  formation	  of	  thromboxane	  from	  arachidonic	  acid	  in	  platelet	  membrane	  
phospholipids.	   The	   thenopyridine	   derivatives	   (clopidogrel	   and	   prasugrel)	   inhibit	   ADP	  




induced	  platelet	  activation	  by	  binding	   irreversibly	  to	  the	  P2Y12	  receptor.	  The	  most	  potent	  
anti-­‐platelet	  drugs,	  such	  as	  abciximab	  and	  tirofiban,	  block	  GP-­‐IIb/IIIa	  receptors.	  
	  
1.3	  Secondary	  Haemostasis	  
1.3.1	  The	  coagulation	  cascade	  	  
The	  model	   of	   coagulation	   that	  was	   conventionally	   taught	  was	   the	   “waterfall”	   or	   cascade	  
model	   of	   a	   series	   of	   proteolytic	   reactions	   that	   act	   as	   a	   biological	   amplifier,	   originally	  
proposed	   in	   the	   1960’s.	   This	   model	   conceptualised	   the	   process	   of	   coagulation	   as	   being	  
primarily	  dependant	  on	  adequate	  levels	  of	  the	  coagulation	  proteins.	  The	  interaction	  of	  the	  
coagulation	  proteins	  are	  described	  in	  the	  classic	  “Y”	  shaped	  scheme,	  with	  distinct	  “intrinsic”	  
and	   “extrinsic	   “	   pathways,	   activated	   by	   factor	   XII	   and	   Factor	   VIIa/	   tissue	   factor	   (TF)	  
respectively.	  The	  pathways	  converge	  on	  a	  final	  common	  pathway	  at	  the	  Factor	  Xa/Factor	  Va	  
(prothrombinase)	   complex,	   resulting	   in	   conversion	   of	   prothrombin	   to	   thrombin	   which	  
cleaves	  soluble	  fibrinogen	  to	  form	  fibrin	  strands	  (Figure	  1.1)	  
The	   coagulation	   complexes	   also	   generally	   require	   the	   presence	   of	   calcium	   and	  
phospholipids	   for	   their	   activity.	   This	   model	   was	   eventually,	   and	   mistakenly,	   taken	   to	  
represent	   a	   literal	   model	   of	   haemostasis	   in	   vivo,	   and	   abnormalities	   of	   coagulation	   tests	  
based	   on	   the	   intrinsic	   system	   (aPTT)	   and	   extrinsic	   system	   (PT)	   taken	   to	   be	   accurate	  
indicators	  of	  bleeding	  risk.	  However,	  when	  examined	  critically,	  there	  is	  limited	  evidence	  to	  
support	   the	   supposition	   that	   they	   are	   useful	   for	   predicting	   bleeding	   risk	   in	   the	   setting	   of	  
invasive	  interventions	  (2).	  




The	   limitations	   of	   this	   model	   of	   the	   haemostatic	   process	   become	   evident	   when	   certain	  
clinical	  observations	  are	  taken	  into	  account.	  Patients	  deficient	   in	  the	  initial	  components	  of	  
the	   intrinsic	  pathway	  (factor	  XIII	  or	  pre-­‐kallikrein)	  have	  a	  prolonged	  aPTT,	  but	  no	  bleeding	  
tendency.	  However,	  some	  components	  of	  the	  intrinsic	  pathway	  clearly	  have	  an	  essential	  
	  
Figure	  1.1	  Conventional	  coagulation	  cascade	  
role	   in	   haemostasis,	   as	   patients	   deficient	   in	   factor	   VIII	   (Haemophila)	   or	   IX	   (Christmas	  
Disease)	   have	   a	   serious	   bleeding	   tendency	   even	   though	   the	   extrinsic	   pathway	   is	   intact.	  
Similarly,	  patients	  with	  a	  deficiency	  of	  factor	  VII	  also	  have	  a	  serious	  bleeding	  tendency,	  even	  




though	  the	  intrinsic	  pathway	  is	  intact.	  The	  two	  pathways	  therefore	  cannot	  be	  operating	  as	  
independent,	  redundant	  pathways	  in	  vivo	  as	  they	  appear	  to	  do	  in	  the	  cascade	  model.	  It	  was	  
also	  recognised	  from	  the	  earliest	  studies	  on	  coagulation	  that	  cells	  are	  important	  participants	  
in	  this	  process,	  and	  that	  normal	  haemostasis	  requires	  cell	  associated	  tissue	  factor	  (TF)	  and	  
platelets,	   in	  addition	  to	  the	  proteins	  of	   the	  coagulation	  cascade.	  Although	  the	  coagulation	  
cascade	  model	  is	  a	  useful	  way	  of	  illustrating	  the	  interactions	  of	  the	  coagulation	  proteins,	  it	  is	  
far	  too	  simplistic	  a	  way	  to	  portray	  the	  coagulation	  process.	  It	  does	  not	  explain	  the	  complex	  
part	  coagulation	  has	   in	   the	  overall	   response	  to	   injury,	  nor	   the	   fact	   that	   it	   is	  primarily	  cells	  
that	  control	  the	  duration,	  intensity	  and	  localization	  of	  the	  haemostatic	  process.	  
 
1.3.2	  The	  cell	  based	  model	  of	  coagulation	  
	  This	   new	  model	   of	   coagulation	  was	   proposed	   in	   2001	   by	  Hoffman	   and	  Munroe,	   and	   has	  
become	  the	  accepted	  description	  of	  how	  haemostasis	  takes	  place	   in	  vivo	   (11).	   It	  describes	  
how	  cells,	  rather	  than	  the	  coagulation	  proteins,	  direct	  and	  control	  the	  coagulation	  process	  
(Figure	   1.2).	   The	   cell	   based	   model	   of	   haemostasis	   describes	   the	   process	   by	   which	   the	  
protease	  cascade	  waterfall	  events	  of	  the	  coagulation	  pathways	  occur	  on,	  and	  are	  controlled	  
by,	  ligands	  expressed	  on	  the	  surfaces	  of	  various	  cell	  types.	  	  
Haemostasis	  requires	  the	  formation	  of	  an	  impermeable	  platelet	  and	  fibrin	  plug	  at	  the	  site	  of	  
injury,	   and	   requires	   that	   the	   powerful	   procoagulant	   substances	   activated	   in	   the	   process	  
remain	   localised	   to	   the	   site	   of	   injury	   which	   is	   achieved	   by	   localising	   the	   procoagulant	  
reactions	   to	   the	   surface	   of	   cells.	   In	   vivo	   the	   coagulation	   reactions	   occur	   on	   specific	   cell	  
surfaces,	   rather	   than	   on	   phospholipid	   surfaces	   as	   they	   do	   in	   the	   PT	   and	   aPTT	   assays.	  	  
Different	   cells	   have	  different	   roles,	   platelets	  play	   a	  major	   role	   in	   supporting	  procoagulant	  




reactions,	   whereas	   the	   vascular	   endothelial	   cells	   play	   a	   key	   role	   in	   maintaining	   the	  
anticoagulant	   properties	   of	   the	   vasculature.	   The	   endothelium	   paves	   the	   wall	   of	   the	  
vasculature	   and	   controls	   its	   surrounding	   tissues	   blood	   flow	   and	   also	   creates	   a	   reactively	  
permeable	  barrier.	  The	  plasma	  facing	  surface	  of	  the	  endothelium	  is	  lined	  by	  the	  glycocalx	  
	  
Figure	  1.2	  Cell	  based	  model	  of	  coagulation	  
which	  is	  made	  up	  of	  proteoglycans	  that	  possess	  surface	  charge	  that	  repel	  serine	  proteases.	  
Embedded	   and	   attached	   to	   its	   surface	   are	   heparin	   glycosaminoglycans	   (GAGs).	   Heparan	  
binds	   circulating	   antithrombin,	   activates	   it	   and	   further	   creates	   an	   anti-­‐inflammatory/anti-­‐
thrombotic	  surface.	  	  	  




The	   cell	   base	  model	   proposes	   that	   haemostasis	   occurs	   in	   three	   distinct,	   but	   overlapping	  
steps:	   initiation,	   amplification	   and	   propogation.	   The	   process	   requires	   two	   cell	   types,	  
platelets	   and	   tissue	   factor	  bearing	   cells.	   These	   cells	   are	   kept	   separated	  until	   injury	  makes	  
activation	  of	  coagulation	  a	  desirable	  occurrence.	  
	  
1.3.3.	  Initiation,	  amplification	  and	  propogation	  of	  coagulation.	  
Initiation:	   the	   generation	   or	   exposure	   of	   tissue	   factor	   (TF)	   at	   the	   wound	   site,	   and	   its	  
interaction	   with	   FVII	   is	   the	   primary	   physiological	   event	   in	   initiating	   coagulation	   (13).	   The	  
initiation	   step	   is	   localised	   to	   cells	   that	   express	   TF	   which	   are	   normally	   kept	   outside	   the	  
vasculature.TF	  is	  a	  trans-­‐membrane	  protein	  that	  acts	  as	  a	  receptor	  and	  co-­‐factor	  for	  factor	  
VII.	  Once	  bound	  to	  TF	  factor	  VII	  is	  activated,	  and	  this	  complex	  of	  TF/VIIa	  catalyses	  activation	  
of	   factor	   X	   and	   IX.	   VIIa	   also	   interacts	   with	   its	   co-­‐factor,	   activated	   Va	   to	   generate	   small	  
amounts	  of	  thrombin	  on	  the	  TF	  bearing	  cells.	   In	  effect,	  the	  extrinsic	  system	  acts	   in	  vivo	   to	  
initiate	  coagulation	  (	  Figure	  1.3).	  	  
	  	  
Figure	  1.3	  Initiation	  of	  coagulation	  	  




Low	  levels	  of	  IXa,	  Xa	  and	  thrombin	  are	  produced	  on	  TF	  bearing	  cells	  all	  the	  time,	  and	  this	  is	  
known	  as	  “coagulation	  idlying”.	  These	  activated	  factors	  are	  normally	  separated	  from	  other	  
key	  components	  of	  the	  coagulation	  system	  by	  an	  intact	  vessel	  wall,	  as	  platelets	  and	  factor	  
VIII,	  bound	  to	  von	  Willebrand	  factor	  (vWF)	  are	  such	  large	  molecules	  that	  they	  only	  enter	  the	  
extravascular	   compartment	   when	   an	   injury	   disrupts	   the	   vascular	   endothelial	   wall	  
(glycocalyx).	  When	   a	   vessel	   wall	   is	   disrupted,	   platelets	   bind	   to	   the	   exposed	   collagen	   and	  
other	  extracellular	  matrix	  components	  at	  the	  site	  of	   injury	  and	  become	  partially	  activated.	  
This	  process	  forms	  the	  platelet	  plug	  that	  provides	  primary	  haemostasis.	  At	  this	  point,	  small	  
amounts	   of	   thrombin	   generated	   on	   TF	   bearing	   cells	   then	   interact	   with	   platelets	   and	   the	  
VIII/vWF	  complex	  to	  initiate	  the	  haemostatic	  process	  that	  ultimately	  enmeshes	  the	  primary	  
platelet	  plug	  in	  a	  stable	  fibrin	  clot	  (secondary	  haemostasis).	  
Amplification:	  During	  the	  amplification	  process,	  the	  small	  amounts	  of	  thrombin	  formed	  on	  
the	   TF	   bearing	   cells	   promote	   maximal	   platelet	   activation,	   and	   also	   activate	   additional	  
coagulation	  co-­‐factors	  on	  the	  surface	  of	  the	  platelet,	  “priming”	  the	  clotting	  system	  for	  the	  
subsequent	  thrombin	  burst	  on	  the	  platelet	  surface	  by	  activating	  V,VIII	  and	  XI.	  The	  activation	  
of	   XI	   by	   thrombin	   on	   platelet	   surfaces	   explains	   why	   XII	   is	   not	   necessary	   for	   normal	  
haemostasis.	  Factor	  IXa,	  activated	  by	  both	  TF	  bearing	  cells	  and	  by	  the	  platelet	  surface	  factor	  
XIa	  binds	  to	  factor	  VIIIa	  on	  the	  platelet	  surface	  to	  assemble	  IXa/VIIIa	  (“tenase”)	  complexes.	  
By	  the	  end	  of	  the	  amplification	  phase,	  the	  stage	  is	  set	  for	  large	  scale	  thrombin	  generation	  in	  
the	  propagation	  stage.	  
Propogation:	   The	   “burst”	   of	   thrombin	   generation	   needed	   for	   effective	   haemostasis	   is	  
produced	   on	   platelet	   surfaces	   during	   the	   propogation	   phase	   of	   coagulation	   [Figure	   1.4].	  
Factor	   IXa	  activated	  during	   initiation,	  binds	   to	  VIIIa	  on	   the	  platelet	  surface,	  and	  additional	  




IXa	   is	  supplied	  by	  the	  platelet	  bound	  XIa.	  Because	  Xa	  cannot	  effectively	  move	  from	  the	  TF	  
bearing	   cell	   to	   the	   platelet,	   it	   is	   provided	   directly	   on	   the	   platelet	   surface	   by	   the	   IXa/VIIIa	  
(Tenase)	   complex,	  and	   then	  Xa	   rapidly	  associates	  with	  platelet	   surface	  Va	  and	  produces	  a	  
burst	  of	  thrombin	  generation	  of	  sufficient	  magnitude	  to	  stabilize	  the	  initial	  platelet	  plug	  in	  a	  
durable	  meshwork	  of	  fibrin	  strands.	  The	  intrinsic	  pathway	  thus	  acts	  on	  the	  platelet	  surface	  
to	  generate	  large	  amounts	  of	  thrombin	  (propagation).	  
	  
Figure	  1.4	  	  Propagation	  of	  coagulation	  
Cell	  based	  versus	  cascade	  models	  of	  haemostasis:	  The	  cell	  based	  model	  suggests	  that	  there	  
are	  indeed	  “intrinsic”	  and	  “extrinsic”	  systems,	  but	  that	  they	  are	  closely	  and	  mutually	  inter-­‐
related,	  and	  they	  are	  not	  independent	  as	  suggested	  by	  the	  cascade	  model.	  The	  extrinsic,	  or	  
TF	  pathway	  consists	  of	  the	  VIIa/TF	  complex	  and	  the	  Xa/Va	  complex	  and	  operates	  on	  the	  TF	  
bearing	  cell	  to	  initiate	  and	  amplify	  coagulation.	  In	  contrast,	  the	  components	  of	  the	  intrinsic	  
system	   operate	   on	   the	   activated	   platelet	   surface	   to	   produce	   the	   burst	   of	   thrombin	   that	  




causes	   the	   formation	   and	   stabilization	   of	   the	   fibrin	   clot.	   Thus	   two	  different	   cell	   types,	   TF	  
bearing	  cells	  and	  platelets,	  are	  required	  and	  necessary	  for	  effective	  haemostasis.	  
The	  central	  role	  of	  thrombin:	  Thrombin	  plays	  two	  very	  distinctive	  roles	  depending	  on	  where	  
and	  when	   it	   is	   generated.	   The	   small	   amount	   of	   thrombin	   produced	  on	   TF	   bearing	   cells	   is	  
critical	   in	   amplifying	   the	   procoagulant	   response	   and	   that	   initiation	   of	   coagulation	   is	  
successful.	  Once	  formed,	  thrombin	  can	  move	  from	  the	  TF	  bearing	  cell	   to	  nearby	  platelets,	  
where	  it	  binds	  to	  its	  high	  affinity	  receptor,	  GPIb	  (14).	  This	  protein	  serves	  as	  a	  scaffolding	  that	  
facilitates	   the	   interaction	   of	   thrombin	  with	   substrates	   on	   the	   platelet	   surface,	   setting	   the	  
stage	   for	   subsequent	   large	   scale	   thrombin	   generation.	   Platelet	   surface	   thrombin	   cleaves	  
protease	  activated	  protein	  1	  (PAR-­‐1),	  which	  plays	  a	  key	  role	  in	  platelet	  activation,	  and	  also	  
activates	  factor	  VIII	  and	  releases	  it	  from	  vWF	  and	  activates	  FXI.	  
This	   large	   amount	   of	   thrombin	   generated	   on	   the	   platelet	   surface	   is	   responsible	   for	  
producing	  a	  stable	  haemostatic	  clot.	  Thrombin	  on	  the	  platelet	  surface	  continues	  to	  amplify	  
the	   procoagulant	   response,	   but	   as	   increased	   amounts	   are	   produced,	   some	   leaves	   the	  
platelet	  and	  acts	  to	  promote	  the	  stabilization	  of	  the	  platelet	  plug	  in	  the	  fibrin	  mesh.	  Platelet	  
produced	  thrombin	  has	  multiple	  actions	  in	  addition	  to	  converting	  fibrinogen	  to	  fibrin.	  It	  also	  
stabilizes	   the	   clot	   by	   activating	   factor	   XIII,	   activating	   thrombin	   activatable	   fibrinolysis	  
inhibitor	  (TAFI),	  cleaves	  the	  platelet	  PAR	  4	  receptor,	  and	  is	  incorporated	  into	  the	  structure	  of	  
the	  clot.	  
Studies	  in	  vitro	  show	  that	  the	  structure	  and	  stability	  of	  the	  fibrin	  clot	  are	  closely	  related	  to	  
the	  amount	  of	  thrombin	  added	  to	  a	  fibrinogen	  solution	  to	  initiate	  clotting.	  However,	  in	  vivo,	  
thrombin	   generation	   is	   an	   ongoing	   process,	   and	   the	   amount	   generated	   builds	   up	   as	  
activated	   factors	   and	   co-­‐factors	   accumulate	   on	   the	   platelet	   surface.	   The	   amount	   of	  




thrombin	  in	  the	  system	  is	  constantly	  changing	  during	  the	  process	  of	  clot	  formation	  and	  it	  is	  
the	   rate	   of	   thrombin	   generation	  which	   is	   a	  major	   determinant	   of	   ultimate	   clot	   structure	  
(15).	  Whilst	  clot	  formation	  begins	  after	  only	  a	  small	  amount	  of	  thrombin	  has	  been	  produced,	  
the	   structure	   of	   the	   clot	   evolves	   and	   remodels	   in	   response	   to	   the	   levels	   of	   thrombin	  
achieved	   after	   fibrin	   polymerization	   has	   begun.	   The	   ultimate	   clot	   structure	   is	   a	   complex	  
function	  of	  the	  pattern	  of	  thrombin	  generation	  and	  not	  just	  the	  total	  amount	  produced.(16)	  	  
It	   is	  has	  been	  proposed	   that	  different	  patterns	  of	  abnormal	   thrombin	  generation	  produce	  
clots	  with	  altered	  fibrin	  structure,	  and	  that	  these	  changes	  are	  associated	  with	  an	  increased	  
risk	   of	   bleeding	   or	   thrombosis	   (17).	   Reduced	   levels	   of	   thrombin	   generation	   have	   been	  
associated	   with	   bleeding	   in	   surgical	   patients	   (18).	   Conversely,	   high	   levels	   of	   thrombin	  
generation	  are	  associated	  with	  an	  increased	  tendency	  to	  thrombosis	  (19).	  
1.3.4	  Controlling	  active	  coagulation:	  the	  critical	  role	  of	  plasma	  protease	  inhibitors	  
	  Failure	  to	  properly	  limit	  or	  localise	  thrombin	  generation	  can	  lead	  to	  thrombosis.	  The	  vitally	  
important	   role	   of	   protease	   inhibitors	   in	   controlling	   the	   haemostatic	   process,	   is	   largely	  
overlooked	  in	  the	  early	  cascade	  models	  of	  coagulation.	  Several	  mechanisms	  act	  to	   localise	  
coagulation	   reactions	   to	   the	   site	   of	   an	   injury.	   Firstly,	   rapid	   localization	   and	   adhesion	   of	  
platelets	   to	   the	   site	   of	   injury,	   brings	   the	   platelet	   surface	   into	   close	   proximity	  with	   the	   TF	  
bearing	  cells,	  which	  are	  normally	  extravascular,	  thus	  removing	  the	  barrier	  to	  the	  movement	  
of	  pro-­‐coagulant	  proteases	  from	  the	  initiating	  cell	  surface	  to	  the	  platelet	  surface.	  
Secondly,	   plasma	   protease	   inhibitors	   are	   much	   less	   effective	   in	   inactivating	   coagulation	  
proteases	  on	   the	   surface	  of	   cells	   than	  when	   they	  are	   in	   solution.	  Consequently,	   activated	  
factors	   that	   diffuse	   away	   from	   the	   appropriate	   cellular	   location	   are	   susceptible	   to	   rapid	  
inhibition.	  Thirdly,	  an	  array	  of	  anti-­‐thrombotic	  mechanisms	  tends	  to	  prevent	  propagation	  of	  




coagulation	   on	   healthy	   intact	   vascular	   endothelium.	   These	   mechanisms	   include	   the	  
endothelial	  thrombomodulin	  (TM)/	  protein	  C/	  protein	  S	  system	  that	  inactivates	  Va	  and	  VIIIa,	  
and	   endothelial	   surface	   heparinoids	   that	   bind	   and	   enhance	   the	   activity	   of	   plasma	  
antithrombin	   (AT)(20).	   Protein	   C	   and	   S,	   are	   synthesised	   by	   hepatic	   parenchymal	   cells.	  
Protein	  C	  is	  localised	  to	  endothelial	  cell	  surfaces	  by	  a	  specific	  endothelial	  protein	  C	  receptor	  
(EPCR).	  Thrombomodulin	  (TM)	  is	  a	  cell	  surface	  receptor	  for	  thrombin	  that	  is	  also	  bound	  to	  
healthy	  endothelial	  cells.	  When	  thrombin	  escapes	  from	  the	  site	  of	  injury	  onto	  nearby	  intact	  
endothelial	  cells,	  it	  is	  bound	  by	  TM.	  This	  thrombin	  /TM	  complex	  can	  no	  longer	  carry	  out	  pro-­‐
coagulant	  reactions,	  and	  the	  complex	  activates	  protein	  C	  (aPC)	  which	  then	  binds	  to	  protein	  
S.	   	   The	   complex	   cleaves	   and	   inactivates	   any	   factor	   V	   that	   has	   been	   activated	   on	   the	  
endothelial	  surface.	  As	  Va	  is	  essential	  for	  activation	  of	  prothrombin	  by	  Xa,	  inactivation	  of	  Va	  
disables	   thrombin	  production	  on	   the	  endothelial	   surface	  and	  prevents	  propagation	  of	   the	  
procoagulant	   reactions	   throughout	   the	   vascular	   tree.	   	   While	   they	   are	   often	   called	  
“anticoagulant”	  proteins,	  they	  primarily	  act	  to	  prevent	  normal	  endothelial	  cells	  from	  acting	  
as	   a	   site	   for	   thrombin	   generation,	   ie	   they	   act	   in	   an	   antithrombotic	   capacity.	   The	   level	   of	  
expression	  of	  these	  different	  antithrombotic	  mechanisms	  varies	  between	  vascular	  beds,	  and	  
can	  be	  modulated	  by	  inflammatory	  stimuli	  and	  vascular	  pathology	  (21).	  	  Antithrombin	  (AT)	  
is	  one	  of	  the	  major	  natural	   inhibitors	  of	  thrombin,	  and	  as	  it	  only	  binds	  with	  thrombin,	  and	  
not	  prothrombin,	  it	  is	  only	  active	  when	  coagulation	  is	  activated.	  In	  addition,	  AT	  binds	  to	  the	  
activated	   coagulation	   factors,	   Xa,	   XIa	   and	   the	   VIIa/TF	   complex	   to	   form	   high	   molecular	  
weight	   complexes	   that	   are	   stable	   and	   inactive.	   As	   mentioned	   previously,	   the	   reaction	  
between	  thrombin	  and	  AT	  is	  accelerated	  by	  heparin,	  whether	  exogenous	  or	  endogenous.	  




Active	   thrombin	   remains	   associated	  with	   the	   fibrin/platelet	   clot	   and	   is	   thereby	   protected	  
from	  inhibition	  by	  AT.	  This	  provides	  a	  reservoir	  of	  procoagulant	  activity	  should	  the	  clot	  be	  
disrupted	  by	  physical	   trauma.	   Thrombin	  not	  only	   participates	   in	   the	  haemostatic	   process,	  
but	   also	   has	   cytokine	   and	   growth	   factor	   activities	   that	   play	   a	   role	   in	   inflammation	   and	  
wound	  healing	  (22).	  	  
1.4	  Fibrinolysis	  
	  Activation	   of	   fibrinolysis	   is	   part	   of	   the	   normal	   haemostatic	   response	   to	   vascular	   injury.	  
Plasmin	   is	   the	   final	   effector	   of	   fibrinolysis,	   and	   is	   produced	   by	   cleavage	   of	   its	   inactive	  
precursor	   plasminogen	   by	   various	   activators.	   	   The	   most	   important	   of	   these	   is	   tissue	  
plasminogen	   activator	   (tPA)	   which	   is	   released	   from	   endothelial	   cells.	   Both	   tPA	   and	   its	  
substrate	  plasminogen	  bind	  to	  the	  evolving	  fibrin	  polymer,	  where	  plasminogen	  is	  converted	  
to	   plasmin	   by	   the	   tPA,	  which	   then	   cleaves	   fibrin	   into	   soluble	   fibrin	   degradation	   products	  
(FDPs)	   resulting	   in	  dissolution	  of	   the	   fibrin	   clot.	  One	  of	   the	  major	   FDPs	   is	  D-­‐Dimer,	  which	  
consists	  of	  D	  domains	   from	  adjacent	   fibrin	  monomers	   that	  were	  cross	   linked	  by	  activated	  
factor	  XIIIa.	  The	  process	  of	  fibrinolysis	  is	  closely	  controlled	  in	  health,	  just	  as	  is	  the	  process	  of	  
coagulation.	  The	  cross	  linking	  and	  polymerization	  of	  fibrin	  fibres	  to	  form	  a	  dense	  meshwork	  
is	  activated	  by	  factor	  XIIIa,	  which	   increases	  resistance	  of	  the	  clot	  to	  fibrinolysis.	  The	  major	  	  
inhibitor	   of	   fibrinolysis	   is	   plasminogen	   activator	   inhibitor	   (PAI),	   which	   is	   a	   rapid	   and	  
irreversible	   inhibitor	  of	  both	  tPA	  and	  uPA(	  urokinase	   like	  plasminogen	  inhibitor).	   	  Any	  free	  
circulating	  plasmin	  is	  inactivated	  by	  the	  potent	  inhibitors	  alpha	  -­‐2	  antiplasmin	  and	  alpha	  -­‐2	  
macroglobin	   (23).	   Thrombin	   also	   inhibits	   fibrinolysis	   by	   activating	   thrombin	   activatable	  
fibrinolysis	   inhibitor	   (TAFI)	   that	   removes	   lysine	   residues	   from	  fibrin,	   thereby	   impairing	   the	  
capacity	  of	  fibrin	  to	  bind	  to	  plasminogen	  and	  tPA	  (Figure	  1.5).	  





Figure	   1.5	   Fibrinolysis:	   Fibrin	   is	   broken	   down	   by	   the	   action	   of	   plasmin	   into	   fibrin	  
degradation	   products.	   Figure	   illustrates	   key	   activators	   and	   inhibitors	   of	   the	   fibrinolytic	  
pathway	  
	  
1.5	  Coagulation	  and	  Liver	  Disease	  
The	  concept	  of	  a	  causal	  relationship	  between	  abnormal	  tests	  of	  coagulation,	  such	  as	  PT	  and	  
INR,	  and	  increased	  bleeding	  risk	  is	  widely	  accepted	  amongst	  clinicians,	  as	  demonstrated	  by	  
the	   common	  practice	   of	   using	   these	   tests	   to	   screen	  patients	   prior	   to	   invasive	   procedures	  
and	   treating	   abnormal	   values	   with	   transfusion	   of	   fresh	   frozen	   plasma	   (24).	   Although	   an	  
increased	  bleeding	  diathesis	  has	  been	  considered	  a	  traditional	  hallmark	  of	  acute	  and	  chronic	  
liver	  disease	  (25),	  it	  is	  now	  recognised	  that	  systemic	  	  hypercoagulability	  and	  thrombosis	  can	  
also	   be	   present,	   and	   these	   patients	   cannot	   be	   considered	   “auto-­‐anticoagulated”(6).	   The	  
typical	  patient	  with	  cirrhosis	  has	  multiple	  and	  opposing	  factors	  that	   influence	  haemostasis	  
and	   clot	   formation,	   and	   defects	   are	   seen	   in	   all	   components	   of	   the	   haemostatic	   system.	  




Stable	   patients	  with	   liver	   disease	   exhibit	   finely	   tuned	   “re-­‐balancing”	   of	   their	   haemostatic	  
profile	  (7)	  and	  this	  is	  reflected	  in	  an	  increasing	  number	  of	  patients	  with	  chronic	  liver	  disease	  
(CLD)	   who	   undergo	   major	   abdominal	   surgery,	   such	   as	   liver	   transplantation,	   without	   the	  
need	   for	   blood	   or	   blood	   product	   transfusion	   [	   Figure	   1.6](26).	   However,	   the	   haemostatic	  
balance	   is	   precarious	   and	   both	   endogenous	   and	   exogenous	   factors	   can	   readily	   tip	   the	  
balance	  towards	  either	  a	  bleeding	  tendency	  or	  a	  prothrombotic	  state,	  as	  these	  patients	  lack	  
the	   buffering	   capacity	   of	   a	   large	   functional	   reserve	   with	   its	   associated	   regulatory	  
mechanisms	  that	  is	  seen	  in	  health(27).	  	  
	  
	  
Figure	  1.6	  Schematic	  of	  “re-­‐balanced”	  haemostasis	  in	  liver	  disease.	  	  
	  
Quantifying	   this	   imbalance	   is	   the	   key	   to	   establishing	   a	   clinically	   useful	   paradigm	   for	  
managing	  patients	  with	  liver	  disease(28).	   Infection	  plays	  a	  pivotal	  role	  in	  variceal	  bleeding,	  




causing	   abnormalities	   in	   coagulation	   through	   endogenous	   heparinoids	   (29).	   Renal	   failure	  
and	  endothelial	  dysfunction	  are	  other	  contributory	  factors	  to	  the	  haemostatic	  imbalance	  in	  
cirrhotic	  patients(30).	  
1.5.1	  Primary	  Haemostasis	  in	  Liver	  Disease	  
Platelets	  exert	   important	  haemostatic	   functions,	   including	  primary	  platelet	  plug	   formation	  
(adhesion/aggregation)	   and	   provide	   a	   membrane	   surface	   for	   the	   assembly	   of	   complexes	  
necessary	   for	   thrombin	  generation.	  Alterations	   in	   the	  primary	  haemostatic	   system	   include	  
abnormal	  platelet	  numbers	  and	  function.	  In	  chronic	  liver	  disease,	  platelet	  numbers	  decrease	  
progressively	   in	   patients	   due	   to	   portal	   hypertension	   and	   hypersplenism	   with	   associated	  
splenic	   sequestration,	   and	   also	   impaired	   hepatic	   synthesis	   of	   thrombopoetin.	   In	   addition	  
there	  can	  be	  abnormalities	  in	  platelet	  function.	  However,	  increased	  levels	  of	  von	  Willebrand	  
factor	  (vWF)	  	  and	  reduced	  activity	  of	  its	  cleaving	  enzyme	  ADAMTS-­‐	  13	  ,	  produced	  by	  hepatic	  
stellate	  cells,	  compensate	  for	  some	  of	  these	  changes	   .(31).	  Platelet	  hyperactivity	  has	  been	  
reported	  in	  patients	  with	  cholestatic	  liver	  disease(32,	  33).	  	  
VWF	   is	   an	   adhesive	   glycoprotein	   secreted	   by	   the	   vascular	   endothelium	   in	   an	   ultra	   large,	  
multimeric	   form	   (ULVWF),	   which	   unfolds	   under	   conditions	   of	   high	   sheer	   stress,	   exposing	  
sites	  to	  which	  platelets	  avidly	  adhere	  and	  aggregate	  to	  promote	  haemostasis.	  Normally	  this	  
ultra	   large	   VWF	   is	   rapidly	   cleaved	   by	   ADAMTS13,	   enabling	   release	   of	   smaller,	   less	   active	  
forms	   of	   VWF	   in	   to	   the	   circulation.	   Deficiency	   of	   ADAMTS13	   results	   in	   a	   loss	   of	   VWF	  
regulatory	   control,	   and	  can,	   if	   extreme,	   lead	   to	  vessel	  occlusion	  by	  hyper	   reactive	  ULVWF	  
and	  platelet	   thrombi.	   It	   has	  been	   speculated	   that	   this	  mechanism	  may	   contribute	   to,	   and	  
exacerbate	  portopulmonary	  hypertension,	   and	   can	  also	   result	   in	   catastrophic	   reactions	   to	  
platelet	   transfusions	   (34).	   In	   a	   series	  of	  post	  mortem	  studies	   in	  patients	  who	  had	   sudden	  




cardiovascular	  collapse	  when	  undergoing	  liver	  transplantation,	  extensive	  platelet	  aggregates	  
were	   found	   occluding	   small	   pulmonary	   arterioles	   and	   alveolar	   capillaries,	   with	   no	  
macroscopic	   evidence	   of	   thrombi.	   A	   sudden	   fall	   in	   platelet	   count,	   and	   rise	   in	   pulmonary	  
arterial	   pressure	   were	   reported	   in	   most	   of	   these	   cases	   (35).	   It	   is	   of	   note	   that	   platelet	  
transfusion	   is	   a	   major	   independent	   risk	   factor	   for	   mortality	   in	   liver	   transplantation,	   and	  
acute	  lung	  injury	  was	  the	  only	  mechanism	  identified	  to	  account	  for	  this	  observation	  (36).	  
A	  systematic	  review	  evaluating	  qualitative	  and	  quantitative	  aspects	  of	  platelet	  function	  (31)	  
concluded	  that	  primary	  haemostasis	   is	  not	  normally	  defective	   in	  cirrhosis.	  Therefore	  a	   low	  
platelet	   count	   should	   not	   necessarily	   be	   considered	   as	   indicating	   an	   increased	   risk	   of	  
bleeding,	   with	   the	   caveat	   that	   with	   severe	   thrombocytopenia,	   correction	   is	   advised	   if	  
bleeding	  occurs,	  or	  prior	  to	  performing	  invasive	  procedures.	  There	  is	  consensus	  that	  platelet	  
transfusion	  is	  indicated	  in	  cirrhotic	  patients	  with	  low	  platelet	  counts	  (50,000	  or	  less)	  during	  
active	  bleeding	   (37).	   	  The	  evidence	   for	   the	  commonly	  set	   lower	  cut	  off	  values	   for	  platelet	  
count	  is	  sparse	  and	  limited	  by	  small	  sample	  size.	  A	  pre-­‐procedure	  platelet	  count	  of	  50,000	  is	  
considered	  adequate(38)	  and	  this	  is	  reinforced	  by	  endogenous	  thrombin	  generation	  studies	  
(39).	   Giannini	   studied	   121	   consecutive	   patients	   who	   were	   being	   evaluated	   for	   liver	  
transplantation	   and	  were	  undergoing	   invasive	   procedures.	   Bleeding	  occurred	   in	   31%	  with	  
severe	   thrombocytopenia	   and	   in	   none	   of	   those	   with	   moderate	   thrombocytopenia	   (40).	  
Platelet	  function	  was	  traditionally	  assessed	  by	  bleeding	  time	  (BT).	  (41)	  However	  in	  cirrhosis	  
there	  is	  a	  poor	  association	  between	  platelet	  count	  and	  BT	  and	  a	  prolonged	  BT	  can	  be	  seen	  in	  
patients	   with	   platelet	   counts	   >	   100,000	   and	   vice	   versa.	   (42)	   As	   platelet	   activation	   is	   not	  
diminished	   but	   may	   be	   increased	   in	   some	   patients	   with	   cirrhosis,	   it	   is	   possible	   that	   BT	  
prolongation	  is	  also	  a	  result	  of	  changes	  in	  vasoreactivity	  and	  /or	  arterial	  dysfunction	  	  (42)	  




1.5.2	  Secondary	  haemostasis	  and	  liver	  disease	  
In	   chronic	   liver	   disease	   (CLD)	   most	   pro-­‐coagulant	   factors	   concentrations	   are	   decreased,	  
except	  factor	  VIII,	  which	  is	  elevated.	  Decreased	  levels	  of	  pro-­‐coagulants	  are	  accompanied	  by	  
a	  concomitant	  decrease	  of	   the	  naturally	  occurring	  anticoagulants	   (antithrombin,	  protein	  C	  
and	   S.	   (4)	   In	   normal	   conditions	   the	   coagulation	   system	   is	   balanced	   by	   the	   two	   opposing	  
drivers	   and	   thrombin	   generation	   is	   no	   different	   or	   even	   increased	   in	   stable	   liver	   disease	  
compared	   to	   healthy	   individuals	   when	   the	   test	   is	   modified	   to	   incorporate	   the	   natural	  
anticoagulant	  pathways.	  (4,	  5)	  	  This	  apparent	  paradox	  is	  explained	  by	  the	  fact	  that	  Protein	  C	  
(PC)	  and	  antithrombin	  (AT)	  need	  to	  be	  activated	  to	  exert	  their	  full	  anticoagulant	  activity	  with	  
thrombomodulin	   and	   with	   glycosaminoglycans	   (GAGs)	   (43,	   44)	   which	   are	   located	   on	   the	  
vascular	  endothelium.	  	  This	  aspect	  is	  not	  evaluated	  in	  the	  majority	  of	  coagulation	  analyses	  
and	   this	   pitfall	   is	   particularly	   important	   in	   cirrhosis	   where	   both	   anti-­‐coagulants	   and	  
procoagulants	  are	  reduced.(45)	  
1.5.3	  Fibrinolysis	  and	  liver	  disease	  
Fibrinolysis	   is	   an	   important	   component	   of	   haemostasis	   and	   is	   a	   complex	   physiological	  
process	  involving	  the	  interaction	  and	  balance	  between	  a	  number	  of	  different	  activators	  and	  
inhibitors.	  In	  cirrhotic	  liver	  disease	  there	  is	  an	  enhancement	  of	  fibrinolysis	  due	  to	  a	  shift	  in	  
balance	  between	  pro	  and	  anti	  fibrinolytic	  factors	  (46).	  The	  increased	  fibrinolytic	  activity	  and	  
clot	   instability	   are	   due	   to	   increased	   levels	   of	   tissue	   plasminogen	   activator	   (tPA),	   due	   to	  
increased	  synthesis	  by	  the	  vascular	  endothelium	  and	  also	  decreased	  hepatic	  clearance	  and	  
the	   low	   levels	   of	   fibrinolytic	   inhibitors,	   alpha	   2	   antiplasmin	   and	   thrombin	   activatable	  
fibrinolysis	   inhibitor	   (TAFI),	   together	   with	   low	   levels	   of	   factor	   XIII,	   that	   is	   required	   for	  
effective	   polymerization	   and	   stabilisation	   of	   the	   fibrin	   clot.	   However,	   this	   is	   balanced	   by	  




increased	  levels	  of	  the	  acute	  phase	  reactant	  plasminogen	  activator	  inhibitor	  (PAI-­‐1),	  which	  is	  
the	  major	  inhibitor	  of	  tPA.	  	  Levels	  of	  PAI-­‐1	  are	  particularly	  high	  in	  acute	  liver	  failure	  and	  in	  
cholestatic	   liver	   disease,	   and	   significant	   fibrinolyisis	   is	   rare	   in	   these	   groups	   (47,	   48).	   In	  
addition,	  plasminogen,	  that	  is	  converted	  to	  plasmin	  by	  tPA,	  is	   low	  due	  to	  impaired	  hepatic	  
synthesis.	  
1.6	  Limitations	  of	  standard	  coagulation	  tests	  in	  patients	  with	  liver	  disease	  
	  
The	  in	  vitro	  tests	  of	  activated	  partial	  thromboplastin	  time	  (aPTT)	  and	  prothrombin	  time	  (PT)	  
are	   the	   most	   commonly	   used	   tests	   of	   coagulation	   and	   measure	   the	   time	   elapsed	   from	  
activation	  of	  the	  coagulation	  cascade	  at	  different	  points	  to	  the	  generation	  of	  fibrin.	  Citrated	  
plasma,	   an	  activator	   (tissue	   factor	   for	  PT	  and	  phospholipids	   for	   aPTT)	   are	  added	   together	  
and	   incubated	   at	   37oC.	   Calcium	   is	   added,	   and	   the	   time	   required	   for	   clot	   formation	   is	  
measured.	  The	  aPTT	  is	  used	  to	  assess	  the	  contact	  activation	  and	  the	  integrity	  of	  the	  intrinsic	  	  
coagulation	   pathway	   (factors	   XII,	   XI,	   IX	   and	   VIII)	   and	   final	   common	   pathway	   (	   factor	   II	  
(prothrombin),	  V,X	  	  and	  fibrinogen.	  A	  prolonged	  aPTT	  is	  found	  with	  isolated	  deficiencies	  of	  
(or	   inhibitors	  of)	   intrinsic	  and	  common	  pathway	   factors,	  and	  after	  heparin	  administration.	  
The	  PT	  is	  used	  to	  assess	  the	  integrity	  of	  the	  extrinsic	  pathway,	  which	  consists	  of	  TF	  and	  VIIa,	  
and	  coagulation	  factors	  of	  the	  common	  pathway.	  Causes	  of	  isolated	  prolongation	  of	  the	  PT	  
are	   inherited	  or	  acquired	  deficiencies	  of	  factor	  VII,	  vitamin	  K	  antagonist	   	  administration	  or	  
vitamin	  K	  deficiency	  (	  factors	  II,	  VII,	  IX	  and	  X),liver	  disease	  and	  inhibitors	  of	  factor	  VII.	  The	  PT	  
was	   standardised	   (for	   warfarin	   control)	   through	   the	   use	   of	   the	   international	   normalised	  
ratio.	  When	  both	  the	  aPTT	  and	  PT	  are	  prolonged,	  inherited	  or	  acquired	  deficiency	  of	  factors	  
X,V,	  prothrombin	  or	  fibrinogen	  may	  be	  the	  cause.	  	  




Prolongation	   of	   the	   PT	   and	   PT	   in	   liver	   disease	   reflects	   the	   impaired	   synthesis	   of	   clotting	  
factors	  by	   the	  diseased	   liver	  and	   is	  widely	  used	   in	   scoring	  systems	   (Child-­‐Pugh,	  MELD	  and	  
UKELD)	  in	  chronic	  liver	  disease	  and	  as	  a	  prognostic	  tool	  and	  for	  monitoring	  of	  liver	  function	  
in	   acute	   liver	   failure.	   	  As	  both	   these	   tests	   are	  more	  effected	  by	  procoagulant	   rather	   than	  
anticoagulant	   levels,	   they	  will	   be	   prolonged	   even	  when	   the	   reduction	   in	   procoagulants	   is	  
matched	  by	  a	  concomitant	   reduction	   in	  anticoagulant	   levels,	   resulting	   in	  normal	   thrombin	  
generation	   and	   “balanced”	   haemostasis	   (7).	   They	   therefore	   give	   a	   false	   impression	   of	   an	  
increased	  bleeding	  risk	  in	  these	  patients.	  	  
	  The	   PT/INR	   was	   developed	   to	   monitor	   oral	   anticoagulant	   therapy	   with	   the	   vitamin	   K	  
antagonist	  Warfarin,	  and	  the	  PTT	  to	  investigate	  the	  inheritable	  single	  factor	  deficiencies	  eg.	  
haemophilia,	  and	  to	  monitor	  heparin	  therapy.	  These	  tests	  were	  never	  intended	  to	  model	  	  in	  
vivo	  haemostasis	  or	  to	  assess	  perioperative	  bleeding	  risk.	  Many	  patients	  with	   liver	  disease	  
have	  a	  normal	  PTT,	  despite	  mild	  baseline	  deficiencies	  of	  multiple	  procoagulant	  factors.	  This	  
may	  be	  due	  to	  the	  elevated	  levels	  of	  factor	  VIII	  which	  shorten	  PTT	  and	  compensate	  for	  the	  
multiple	  procoagulant	  factor	  deficiencies.(49)	  The	  PT/INR	  is	  widely	  used	  	  to	  assess	  the	  risk	  of	  
bleeding	  in	  patients	  with	  liver	  disease,	  however,	  the	  evidence	  from	  clinical	  practice	  and	  the	  
literature	  is	  that	  it	  does	  not	  correlate	  with	  bleeding	  after	  liver	  biopsy	  or	  other	  procedures	  (1,	  
2).	   Despite	   this,	   transfusion	   of	   fresh	   frozen	   plasma	   (FFP)	   is	   often	   used	   in	   an	   attempt	   to	  
correct	   the	   INR(1,	   50).	   Epidemiological	   studies	   suggest	   that	   patients	   with	   chronic	   liver	  
disease	   have	   the	   greatest	   individual	   risk	   of	   transfusion	   related	   acute	   lung	   injury	   (TRALI)	  
compared	   to	   other	   populations	   (51).	   Observational	   studies	   show	   that	   even	   major	  
procedures,	  such	  as	   liver	  transplantation,	  can	  be	  performed	  without	  administration	  of	  FFP	  
despite	  an	  increased	  INR	  (52).	  Most	  importantly,	  the	  INR	  value	  varies	  between	  laboratories	  




in	   patients	   with	   liver	   disease,	   so	   defining	   a	   set	   cut	   off	   value	   is	   problematic	   (53)	   	   Other	  
limitations	  of	  PT/INR	  are	  that	  it	  is	  not	  possible	  to	  estimate	  the	  overall	  strength	  and	  stability	  
of	   the	   clot	   because	   these	   tests	   are	   	   read	   at	   the	   initiation	   of	   fibrin	   polymerisation	   which	  
happens	  at	  very	  low	  levels	  of	  thrombin	  generation	  	  of	  about	  10	  	  to	  20nM,	  which	  is	  less	  than	  
5%	  of	  the	  total	  thrombin	  that	  can	  be	  generated	  .(54)	  
The	   INR	  threshold	  of	  1.5	   for	  bleeding	  risk	   is	  derived	  from	  studies	  that	  originally	  used	  a	  PT	  
threshold	   and	   thromboplastin	   reagents	   which	   had	   an	   international	   sensitivity	   index	   (ISI)	  
greater	  than	  or	  equal	  to	  2.	  Whilst	  the	  calculated	  INR	  of	  1.5	  mathematically	  corresponds	  to	  a	  
PT	  ratio	  of	  1.5	  for	  thromboplastin	  reagents	  with	  an	  ISI	  of	  1.0	  as	  used	  currently,	  this	  does	  not	  
take	  into	  account	  the	  fact	  that	  many	  of	  the	  earlier	  studies	  on	  PT	  threshold	  were	  done	  with	  
less	  sensitive	  thromboplastins	  and	  the	  corresponding	  INR	  would	  actually	  be	  2.25	  to	  4.0	  (49)	  
This,	   together	   with	   the	   fact	   that	   the	   INR	   does	   not	   reflect	   the	   concurrent	   reduction	   in	  
anticoagulant	   levels	   in	  patients	  with	   liver	  disease,	  may	  explain	  why	   there	   is	  no	   consistent	  
relationship	  between	  bleeding	  and	  a	  mild	  to	  moderate	  increase	  in	  INR	  in	  patients	  with	  CLD.	  
There	   is	  no	  good	  evidence	  for	  administering	  prophylactic	  FFP	  according	  to	  baseline	   INR	  or	  
indeed	  to	   improve	  outcomes.(55,	  56)	  This	   leads	  to	  unnecessary	  and	  wide	  variability	   in	  the	  
use	  of	  FFP.	  Tripodi	  assessed	  the	  effects	  of	  in	  vitro	  addition	  of	  pooled	  normal	  plasma	  (PNP)	  to	  
the	  plasma	  of	  58	  adult	  patients	  with	  advanced	  cirrhosis	  and	  showed	  that	  although	  the	  PT	  
ratio	   shortened	   in	   many	   patients,	   there	   was	   no	   change	   in	   thrombin	   generation.	   These	  
results	   cast	  doubt	  on	   the	  efficacy	  of	   FFP	   to	   reduce	   the	  bleeding	   risk	   in	  patients	  with	   liver	  
disease	   who	   are	   undergoing	   invasive	   procedures	   (57)and	   is	   an	   area	   that	   needs	   urgent	  
research.	  




Standard	   coagulation	   tests	   have	   been	   shown	   to	   be	   inadequate	   for	   the	   purposes	   of	  
stratifying	  bleeding	  and	  thrombotic	  risk	   in	  patients	  with	   liver	  disease,	  and	  this	  mandates	  a	  
search	   for	   alternative	   means	   of	   assessment	   which	   better	   reflect	   functional	   changes	   in	  
coagulation.(58)	  
1.7	  Alternative	  global	  methods	  of	  monitoring	  coagulation	  
1.7.1	  Thrombin	  generation	  assays	  
Thrombin	   generation	   assays	   are	   global	   coagulation	   tests	   that	   measure	   the	   dynamics	   of	  
thrombin	  production.	  Platelet	  free	  plasma	  is	  incubated	  with	  small	  amounts	  of	  tissue	  factor	  
as	   a	   coagulation	   trigger	   and	   phospholipids	   that	   act	   as	   platelet	   substitutes	   (59).Thrombin	  
generation	  tests	  have	  been	  used	  to	  identify	  patients	  at	  increased	  risk	  of	  thrombosis	  (60-­‐62),	  
and	   a	   high	   endogenous	   thrombin	   potential	   (ETP)	   is	   associated	   with	   an	   increased	   risk	   of	  
recurrent	  	  thrombosis.	  Conversely,	  reduced	  thrombin	  generation	  is	  documented	  in	  patients	  
with	  a	  bleeding	  tendency	  (63,	  64).	  The	  normal,	  or	  even	  enhanced,	  thrombin	  generation	   in	  
stable	  patients	  with	  CLD	  explains,	  at	  least	  in	  part,	  why	  many	  of	  these	  patients	  do	  not	  have	  a	  
significant	  increased	  bleeding	  risk	  and	  may	  be	  at	  increased	  risk	  of	  thrombosis.	  (62)	  Following	  
Tripodi’s	   landmark	  paper,	   in	  which	   thrombin	  generation	   in	   cirrhosis	  was	   shown	   to	  be	   the	  
same	   as	   in	   healthy	   people	   when	   thrombomodulin	   was	   added	   to	   activate	   protein	   C	   (39),	  
further	   papers	   indicate	   that	   thrombin	   generation	   may	   actually	   be	   increased.(65)	   Gatt	   et	  
al(66)	   studied	   73	   adult	   patients	   with	   cirrhosis	   and	   also	   38	   healthy	   individuals.	   Thrombin	  
generation	  was	  assessed	  using	  the	  calibrated	  automated	  thrombography	  (CAT)(67).	  	  Rather	  
than	  thrombomodulin,	  Protac®	  modified	  TG	  was	  used.	  (Protac	  is	  a	  snake	  venom	  extract	  that	  
activates	  PC).This	  study	  showed	  a	  hypercoagulable	  TG	  profile	  in	  plasma	  in	  cirrhosis,	  with	  an	  
increased	  velocity	  of	  TG	  and	  higher	  endogenous	  thrombin	  potential	  (ETP)	  ratios.	  This	  is	  the	  




same	  profile	  as	  patients	  with	  protein	  C	  /	  protein	  S	  deficiency	  and	  factor	  V	  Leiden,	  in	  whom	  a	  
greater	   risk	   of	   thrombosis	   is	   well	   documented	   (68).	   Overall,	   the	   data	   on	   TG	   velocity	   and	  
Protac	   resistance	   demonstrate	   a	   prothrombotic	   tendency	   in	   plasma	   of	   patients	   with	  
cirrhosis.	  These	  findings	  are	  in	  keeping	  with	  reports	  that	  patients	  with	  liver	  disease	  are	  not	  
protected	  against	  thrombosis	  despite	  a	  raised	  INR	  (69,	  70)	  and	  have	  an	  increase	  thrombotic	  
risk	   compared	   with	   age	   matched	   controls.	   Although	   thrombin	   generation	   studies	   have	  
increased	   our	   understanding	   of	   the	   coagulopathy	   in	   liver	   disease,	   they	   are	   for	   the	   time	  
being,	  mainly	  research	  tools	  that	  are	  laboratory	  based.	  
1.7.2	  Viscoelastic	  tests	  of	  coagulation	  
	  These	  global	  viscoelastic	  and	  point	  of	  care	  coagulation	  tests	  have	  the	  potential	  to	  overcome	  
many	  of	  the	  limitations	  of	  routine	  coagulation	  tests,	  as	  they	  measure	  the	  entire	  coagulation	  
process,	   from	   fibrin	   formation	   through	   to	   final	   clot	   strengthening	   and	   retraction	   or	  
fibrinolysis.	   In	   addition,	   as	   the	   test	   is	   performed	   with	   whole	   blood,	   the	   plasmatic	  
coagulation	  system	   interacts	  with	  platelets	  and	   red	  cells,	  and	   therefore	   they	  more	  closely	  
reflect	   the	   situation	   in	   vivo.	   The	   principles	   of	   these	   tests,	   together	   with	   a	   discussion	  
regarding	   the	   potential	   advantages	   and	   limitations	   of	   these	   tests	  will	   be	   reviewed	   in	   the	  
next	  chapter.	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2.1	  Introduction	  	  
Although	   routine	   coagulation	   tests	   (PT,	   PTT)	   provide	   valuable	   information	   regarding	   the	  
quantitative	  status	  of	  procoagulant	  proteins,	  they	  ignore	  the	  interaction	  of	  cellular	  elements	  
and	  endogenous	  anticoagulant	   factors	   (71).	  At	   the	   time	   these	   tests	   are	   concluded,	  only	   a	  
fraction	   (<	   5%)	   of	   the	   total	   thrombin	   that	   will	   be	   generated	   during	   the	   process	   of	  
coagulation	   has	   formed,	   thus	   they	   can	   give	   only	   limited	   information	   about	   the	   overall	  
haemostatic	   status	   (19).	   In	   addition,	   they	   are	   insensitive	   to	   most	   thrombin	   dependent	  
reactions	  associated	  with	  normal	  haemostasis,	  that	  is	  platelets,	  protein	  C	  and	  factor	  V	  and	  
VIII	   activation(72).	   Haemostatic	   assays	   that	   demonstrate	   the	   interactivity	   of	   the	   major	  
phases	  and	  components	  of	  the	  haemostatic	  process	  better	  represent	  haemostatic	  capacity	  
and	  differentiate	  the	  mechanisms	  related	  to	  clotting	  abnormalities	  (73).	  
2.2	  Mechanical	  properties	  of	  the	  clot	  and	  relation	  to	  haemostasis	  
Clot	   formation	   involves	   the	   dynamic	   interaction	   between	   the	   vascular	   endothelial	   wall,	  
platelets,	   vWF,	   pro	   and	   anticoagulant	   factors	   and	   blood	   flow.	   The	   location	   and	   the	  
mechanical	  properties	  of	  the	  formed	  clot	  are	  essential	   for	  appropriate	  haemostasis.	  A	  clot	  
consists	  of	  a	  three	  dimensional	  network	  of	  cross	  linked	  fibrin	  fibres	  with	  platelets	  and	  other	  
blood	  cells	  trapped	  within	  the	  mesh	  of	  fibres.	  This	  fibrin	  network	  is	  fundamentally	  rigid	  with	  
sufficient	  elasticity	  to	  resist	  deformation	  by	  shear	  forces.	  This	  resistance	  to	  deformation	   is	  
measured	   by	   the	   shear	   elastic	  modulus,	   an	   index	   of	   clot	   strength.	   Platelets	   enhance	   the	  
elastic	   properties	   of	   the	   fibrin	   network	   by	   binding	   to	   fibrin	   through	   specific	   platelet	  
receptors	   (Glycoprotein	   IIb/IIIa).	   In	   the	   cell	   based	   model	   of	   haemostasis,	   thrombin	  
generation,	   fibrin	   structure	   and	   fibrinogen	   interaction	   with	   platelets	   are	   mutually	  
dependant	   processes	   that	   contribute	   to	   clot	   strength	   (74).	   It	   is	   thought	   that	   platelet	  




function	   is	  of	   greater	   importance	   to	   clot	   strength	  and	   stability	   than	  platelet	  number	   (75).	  	  
Abnormalities	  of	  clot	  strength	  are	  associated	  with	  both	  bleeding	  and	  thrombotic	  events.	  	  
The	   cell	   based	   model	   of	   haemostasis	   (11),	   as	   opposed	   to	   the	   traditional	   description	   of	  
intrinsic	   and	   extrinsic	   pathways,	   emphasizes	   the	   role	   of	   platelets	   in	   intact	   thrombin	  
generation	   and	   highlights	   the	   importance	   of	   the	   dynamics	   of	   thrombin	   generation	  
influencing	   the	   quality	   and	   stability	   of	   thrombus	   formed.	   The	  multifactorial	   aetiology	   and	  
sometimes	  unpredictable	  nature	  of	  many	  perioperative	  coagulopathies	  means	  that	  CCT	  are	  
inadequate	  for	  the	  purposes	  of	  monitoring,	  diagnosing	  and	  treating	  coagulopathy	  in	  a	  goal	  
directed	   fashion.	   For	   haemostasis	   to	   occur	   effectively	   there	   must	   be	   sufficient	   thrombin	  
generation	   (coagulation	   factors	   and	   platelets),	   adequate	   substrate	   (fibrinogen)	   and	   clot	  
stability.	  Viscoelastic	  haemostatic	  tests	  measure	  changes	   in	  clot	  tensile	  strength	  over	  time	  
and	   give	   information	   on	   the	   dynamics	   of	   clot	   formation	   (coagulation	   factor	   and	  
anticoagulant	  activity),	  clot	  strength	  (platelets	  and	  fibrinogen)	  and	  clot	  stability	  (fibrinolysis	  
and	  factor	  XIII).	  
2.3	  Principles	  of	  Thromboelastography	  
	  
There	  are	   two	  commercially	  available	  devices,	  both	  based	  on	  Hartert’s	   invention	   	   in	  1948	  
(76),	   the	   TEG®	   (Haemonetics	   Corporation,	   Braintree,	   MA,	   USA)	   	   and	   the	   ROTEM®	   (TEM	  
International	  GmbH,	  Munich,	  Germany).	  These	  viscoelastic	  tests	  provide	  rapid	   information	  
about	  global	  clotting	  in	  whole	  blood	  and	  have	  become	  widely	  used	  as	  a	  point	  of	  care	  (POC)	  
monitor	   in	   the	   setting	  of	   liver	   transplantation,	   cardiac	   surgery,	   trauma	  and	  obstetrics.	   	   In	  
this	  chapter	  the	  term	  thromboelastography	  will	  be	  used	  to	  describe	  general	  principles	  of	  the	  




common	  technology,	  but	  the	  difference	  between	  the	  two	  systems	  will	  be	  specified	  as	  TEG	  
or	  ROTEM	  respectively.	  
2.3.1	  Basic	  principles	  
Thromboelastography	   (TEG)	   &	   thromboelastometry	   (ROTEM)	   measure	   the	   viscoelastic	  	  
properties	  of	  a	  developing	  clot	  in	  a	  sample	  of	  whole	  blood	  after	  adding	  a	  specific	  activator,	  
under	  low	  sheer	  conditions.	  They	  provide	  real	  time	  information	  about	  the	  quality	  of	  the	  clot	  
and	   the	  kinetics	  of	   its	   formation.	  The	  viscoelastic	   (tensile)	   force	  between	   the	  cup	  and	   the	  
immersed	   pin	   results	   from	   the	   interaction	   between	   activated	   platelet	   glycoprotein	   (GP)	  
IIb/IIIa	  receptors	  and	  polymerising	  fibrin	  during	  endogenous	  thrombin	  generation	  and	  fibrin	  
degradation	   by	   fibrinolysis	   (77).	   In	   both	   machines,	   0.37	   micromls	   of	   whole	   blood	   are	  
pipetted	  into	  a	  heated	  cup	  into	  which	  a	  pin	  is	  suspended.	  	  
In	  the	  TEG,	  the	  platform	  on	  which	  the	  cup	  is	  placed	  oscillates	  through	  an	  angle	  of	  4o45’	  and	  
each	   rotation	   cycle	   lasts	   10	   seconds.	   A	   stationary	   pin,	   connected	   to	   a	   torsion	   wire,	   is	  
suspended	   into	   the	  blood	  sample.	  Once	  blood	  starts	   to	   clot,	   fibrin	   strands	   start	   to	   couple	  
the	  motion	  of	   the	  cup	  to	  the	  pin	  and	  the	  change	   in	   torque	   is	  converted	  via	  a	  mechanical-­‐
electronic	  transducer	  into	  an	  electronic	  signal.	  The	  output	  is	  directly	  related	  to	  the	  strength	  
of	  the	  formed	  clot	  (Figure	  2.1).	  
	  





Figure	  2.1	  Principles	  of	  thromboelastography	  (TEG®)	  
In	  the	  ROTEM,	  the	  pin	  is	  fixed	  to	  a	  rotating	  shaft,	  and	  the	  cup	  is	  stationary.	  As	  clot	  starts	  to	  
form	  and	  develop,	  the	  resistance	  to	  rotation	  of	  the	  shaft	  increases,	  and	  this	  is	  detected	  by	  
the	  angle	  of	  reflection	  of	  light	  onto	  a	  mirror	  (Figure	  2.2).	  	  
The	  rate	  of	  polymerisation	  and	  overall	  clot	  strength	  is	  displayed	  visually	  on	  the	  TEG/ROTEM	  
trace	  and	  also	  numerically	  and	  provides	  a	  complete	  picture	  of	  clot	  initiation,	  formation	  and	  
stability	  (78).	  Once	  blood	  starts	  to	  clot,	  fibrin	  strands	  start	  to	  couple	  the	  motion	  of	  the	  cup	  
to	  the	  pin.	  The	  change	   in	   torque	   is	  detected	  electronically	   in	  TEG	  and	  optically	   in	  ROTEM.	  
Dissociation	  of	  fibrin	  strands	  from	  the	  cup	  wall	  due	  to	  clot	  retraction	  or	  the	  degradation	  of	  
fibrin	  by	  fibrinolysis	  decreases	  the	  torque	  (79).	  	  The	  computer	  processed	  signal	  is	  presented	  
as	  a	  tracing	  of	  clot	  formation	  and	  if	  present,	  clot	  dissolution.	  





Figure	  2.2	  Principles	  of	  thromboelastometry	  (ROTEM®)	  	  
The	   initial	   torque	   is	   assumed	   to	   be	   zero	   (i.e.	   no	   clot)	   for	   the	   signal	   processing	   and	   it	   is	  
therefore	  essential	   to	   start	   the	  measurement	   immediately	   after	   a	   coagulation	  activator	   is	  
added	   to	   the	   sample.	   The	   parameters	   produced	   of	   the	   coagulation	   profile	   by	   VETs	   are	  
identical	  for	  TEG	  and	  ROTEM,	  but	  the	  terminology	  used	  to	  name	  the	  individual	  parameters	  
is	  slightly	  different	  for	  each	  machine	  (Figure	  2.3).	  Each	  parameter	  identifies	  a	  specific	  stage	  










Figure	  2.3	  Schematic	  of	  TEG/ROTEM	  parameters	  
	   TEG	   ROTEM	   	  
Clot	   initiation	   or	  	  
Clotting	  time	  
R	  	  (reaction	  time)	   CT	  (clotting	  time)	   Period	   of	   initial	   fibrin	  
formation	  
Clot	  Kinetics	   K	  (K	  value)	   CFT	   (clot	   formation	  
time)	  
A	   measure	   of	   the	  
speed	   to	   reach	   a	  
specific	   level	   of	   clot	  
strength	  
	   α	  (angle	  in	  degrees)	   α	   Measures	   the	   rate	   of	  
clot	   formation,	   reflects	  
fibrin	   rate	   of	   fibrin	  
build	   up	   and	   cross	  
linking	  
Clot	  strength	   MA	   (maximum	  
amplitude)	  
MCF	   (maximum	   clot	  
firmness)	  
Represents	   the	  
ultimate	   strength	   of	  
the	   clot	   (platelets	   &	  
fibrin)	   function	   of	  
maximum	   dynamic	  
properties	   of	   fibrin	   &	  
platelet	   bonding	   via	  
GPIIb/IIIa	  receptors	  
Clot	  stability	   Ly30	   (Lysis	   at	   30	  
minutes	   as	   ratio	   of	  
MA)	  
CLI	  (Clot	  lysis	  index)	   Measures	   rate	   of	  
amplitude	   reduction	  
from	   MA	   at	   30	  
minutes,	   detects	  
fibrinolysis	  
	  
Table	   2.1	   	   Description	   of	   TEG/ROTEM	   parameters.	   These	   parameters	  measure	   stages	   of	  
coagulation	   from	   clot	   initiation	   (R/CT),	   through	   clot	   development	   and	   kinetics	   of	   its	  
formation	   (k/CFT	   and	   alpha	   angle),	   to	   final	   clot	   strength	   (MA/MCF).	   	   Indices	   of	   clot	  
retraction	  or	  pathological	  fibrinolysis	  are	  described	  by	  Ly30/CLI.	  




Specific	   haemostatic	   defects	   give	   very	   characteristic	   traces	   on	   the	   TEG	   (Figure	   2.4).	   The	  














Figure	  2.5	  ROTEM	  traces	  	  
EXTEM	   (activated	  with	   TF),	   INTEM	   (contact	   activation),	   FIBTEM	   (TF	   and	   cytochalasin	  D	   to	  
remove	  platelet	  contribution),	  APTEM	  (TF	  and	  aprotinin,	  in	  vitro	  fibrinolysis	  inhibition)	  
	  
Although	   the	   two	  techniques	  provide	  essentially	  equivalent	   information,	  algorithms	  based	  
on	  one,	  are	  not	  directly	  transferrable	  to	  the	  other,	  as	  they	  use	  different	  activating	  reagents,	  
and	  the	  cups	  have	  slightly	  different	  physico-­‐chemical	  properties	  (80,	  81)	  .	  Clinical	  reference	  
values	  differ	  between	  the	  two	  systems	  and	  must	  be	  interpreted	  appropriately	  (82).	  	  Native	  
whole	   blood	   was	   used	   in	   the	   earlier	   studies	   with	   TEG(83),	   and	   is	   still	   used	   in	   some	  
institutions,	  as	  the	  lack	  of	  activating	  agents	  allows	  more	  subtle	  changes	  in	  coagulation	  status	  
to	   be	   better	   appreciated.	   However,	   this	   requires	   that	   the	   blood	   is	   placed	   in	   the	   cup	   for	  
testing	  2	  minutes	  after	  withdrawal	  of	   the	  sample.	  The	  use	  of	  citrated	  whole	  blood	   is	  now	  




standard	   for	   most	   thromboelastographic	   systems.	   Before	   testing,	   citrated	   samples	   are	  
recalcified	  by	  adding	  20µL	  of	  0.2mmol/l	  calcium	  chloride,	  this	  does	  result	  in	  minimal	  dilution	  
(10%)	  of	  the	  sample,	  in	  addition	  the	  timing	  of	  sample	  analysis	  is	  important,	  and	  the	  stability	  
and	  reproducibility	  of	  tests	  is	  best	  between	  30	  minutes	  and	  2	  hours	  following	  sampling(84)	  	  
Sample	   collection	  methods	  need	   to	  be	   standardised	  and	   reference	   ranges	   for	   the	   specific	  
method	   must	   be	   established.	   The	   possibility	   of	   using	   different	   reagents	   increases	   the	  
diagnostic	   capabilities	   of	   these	   tests:	   eg	   heparinase	   to	   reverse	   underlying	   heparin	  
(heparinase	   TEG/	   HEPTEM),	   tissue	   factor	   to	   accelerate	   clot	   initiation	   (rapid	   TEG),	   and	  
aprotinin	  to	  reverse	  fibrinolysis	  (APTEM).	  	  
2.3.2	  Limitations	  of	  VETs	  
Variation	  in	  reference	  ranges	  due	  to	  influence	  of	  type	  of	  activator	  and	  patient	  factors:	  
Many	  factors	  affect	  the	  TEG/ROTEM	  traces,	  and	  this	  is	  inevitable	  due	  to	  the	  “global”	  nature	  
of	   these	   tests.	  Using	  whole	  blood	  means	   the	   test	   can	  be	   influenced	  by	  all	   components	  of	  
whole	  blood,	  including	  white	  and	  red	  cell	  content,	  platelet	  number	  and	  function,	  fibrinogen	  
concentration	  as	  well	  as	  coagulation	  protein	  function	  and	  balance(85).	  	  The	  concentrations	  
of	   all	   cellular	   and	  plasmatic	   elements	   in	  whole	  blood	   should	  be	   taken	   into	   account	  when	  
interpreting	  results	  from	  VETs.	  
Normal	  values	  for	  thromboelastographic	  parameters	  depend	  on	  pre-­‐analytical	  factors	  such	  
as	   re-­‐calcification	   and	   time	   from	   blood	   sampling	   (86),	   and	   also	   on	   the	   type	   and	   final	  
concentration	  of	   the	  activator	   (85),	  which	   vary	   substantially	  between	   the	   two	   systems.	   In	  
particular,	   clotting	   time	   and	   clot	   formation	   time	   are	   strongly	   dependant	   on	   the	   type	   of	  
activator	   used,	   and	   the	   concentration	   of	   tissue	   factor	   will	   influence	   the	  
thromboelastographic	  parameters	  (87).	  The	  variation	  of	  test	  results	   is	   lower	  after	  extrinsic	  




activation	  with	  tissue	  factor	  (coefficient	  of	  variance	  [CV]	  3-­‐5%),	  but	  substantially	  higher	  with	  
intrinsic	  activation	  with	  kaolin	  or	  ellagic	  acid	  (CV	  12-­‐15%).	  The	  variation	  is	  least	  for	  MA/MCF	  
(CV	   5%)	   independent	   of	   the	   activator	   used	   (88).	   For	   all	   assays,	   final	   clot	   strength	   is	  
dependent	  on	  many	  factors,	   including	  the	  activator	  used,	  other	  factor	  concentrations	  such	  
as	  fibrinogen,	  haematocrit,	  and	  the	  amount	  and	  speed	  of	  initial	  thrombin	  generation.	  
Reference	   ranges	   need	   to	   be	   constructed	   for	   the	   specific	   population	   under	   study,	   as	   it	   is	  
known	  that	  gender,	  pregnancy,	  age	  and	  underlying	  co-­‐morbid	  conditions	  all	   influence	  VET	  
parameters.	  Paradoxically,	  increasing	  haematocrit	  results	  in	  a	  slight	  reduction	  in	  overall	  clot	  
strength	  as	  measured	  by	  the	  maximum	  amplitude	  (89),	  this	  is	  possibly	  due	  to	  a	  looser	  clot	  
structure	   when	   increasing	   amounts	   of	   RBC	   are	   incorporated	   into	   the	   fibrinogen	   mesh	  
network	  (90).	  There	  are	  significant	  gender	  related	  differences	  in	  TEG	  variables,	  with	  a	  trend	  
of	   increasing	   coagulability	   through	   men,	   nonpregnant	   women	   to	   pregnant	   women(91).	  
Threshold	   values	   for	   clinical	   outcomes	   or	   haemostatic	   interventions	   should	   be	   locally	  
evaluated	  for	  each	  system	  and	  relevant	  patient	  population.	  	  
Methodology	  not	  standardized	  and	  issues	  with	  quality	  assurance:	  	  These	  viscoelastic	  tests	  
have	   never	   undergone	   all	   the	   validation	   procedures	   that	   are	  mandatory	   for	   conventional	  
haemostatic	  tests,	  such	  as	  variability	  and	  repeatability,	  calibration	  and	  quality	  controls.(92)	  	  	  
A	   major	   criticism	   of	   these	   devices	   was	   the	   fact	   that	   they	   were	   not	   well	   standardised,	  
especially	   in	  relation	  to	  pre-­‐analytical	  and	  analytical	  factors.	   In	  an	  attempt	  to	  demonstrate	  
reproducibility	  and	  consistency	  using	  these	  devices,	  the	   international	  TEG/ROTEM	  working	  
group	  was	   formulated,	   and	   	   laboratories	   from	   a	   number	   of	   countries	   blind	   tested	   panels	  
from	  normal	  pooled	  and	   factor	  VIII	   deficient	  plasma	   (93).	   The	  CV	  varied	   for	  different	  VET	  
parameters,	  with	  K	  or	  CFT,	  being	  associated	  with	  the	  highest	  CV.	  There	  was	  also	  significant	  




inter	  laboratory	  variance	  with	  CV	  in	  excess	  of	  10%.	  (Figures	  5	  and	  6).	  In	  the	  UK,	  steps	  have	  
been	  taken	  to	  evaluate	  the	  provision	  of	  external	  quality	  assessment	  (EQA)	  material	  for	  these	  
devices,	  using	  lyophilised	  plasma	  samples	  to	  improve	  quality	  assurance	  and	  quality	  control.	  
It	  was	  of	  note	  that	  some	  centres	  returned	  results	  that	  were	  sufficiently	  different	  from	  other	  
participants	  to	  predict	  alterations	  in	  patient	  management	  decisions.	  It	  was	  concluded	  that	  a	  
mechanism	  of	  providing	  EQA	  and	  also	  regular	  proficiency	  testing	  of	   individuals	  performing	  
these	   tests	  was	  highly	  desirable	   (94).	  The	   issue	  of	  EQA	  and	  participation	   in	   formal	  NEQAS	  
monitoring	  is	  problematic	  as	  the	  material	  usually	  provided	  for	  EQA	  purposes	  is	  lyophylized	  
plasma,	  whereas	  whole	  blood	   samples	   are	   routinely	   analysed.	   Internal	  QC	   is	   available	   for	  
both	  TEG	  and	  ROTEM.	  These	  are	  used	  to	  check	  daily	  variation	  and	  permit	  early	  detection	  of	  
test	  problems	  that	  could	  affect	  patient	  results.	  
To	  bring	  these	  analysers	  to	  the	  next	  level,	  several	  improvements	  are	  desirable,	  including	  full	  
automation	  to	   improve	  ease	  of	  use,	  simultaneous	  testing	  with	  multiple	  activators	  to	  more	  
accurately	  define	  the	  nature	  of	  any	  underlying	  coagulopathy,	  integrated	  analysing	  software,	  
and	  increased	  robustness	  of	  these	  devices.	  
2.4	  Correlation	  of	  conventional	  coagulation	  tests	  and	  viscoelastic	  tests	  	  
2.4.1	  PT/INR	  	  	  
The	   plasma	   based	   tests,	   PT	   and	   aPTT,	   reflect	   the	   lag	   time	   for	   non	   polymerised	   fibrin	   gel	  
formation	   after	   extrinsic	   (tissue	   factor)	   and	   intrinsic	   (ellagic	   acid,	   kaolin)	   activation	  
respectively.	  Correlation	  between	  reaction	  time	  and	  clotting	  time	  (R/CT)	  and	  PT/INR	  is	  weak	  
[r=	  0.24-­‐0.37](95-­‐98).	  This	  can	  be	  partly	  explained	  by	  the	  use	  of	  different	  activators,	  but	  also	  
by	  the	  fact	  that	  R/CT	  unlike	  PT/INR	  reflects	  the	  balance	  of	  both	  pro	  and	  anticoagulants.	  This	  




may	   partially	   explain	  why	   the	   R/CT	   is	   not	   sensitive	   to	  mild	   to	  moderate	   increases	   in	   INR	  
(=<1.6)(99,	   100)	   and	   why	   there	   is	   no	   useful	   correlation	   between	   these	   CCT	   and	   the	  
viscoelastic	  parameters	  R	  and	  CT.	   	   In	  models	  of	  dilutional	  coagulopathy,	  an	   increase	   in	  CT	  
occurs	   only	   when	   clotting	   factor	   concentrations	   are	   reduced	   to	   levels	   below	   30%	   ((101).	  	  
The	  exponential	  relationship	  of	  coagulation	  factors	  on	  PT/INR	  is	  not	  always	  appreciated	  and	  
is	   one	   reason	   why	   fresh	   frozen	   plasma	   (FFP)	   does	   not	   contribute	   sufficient	   coagulation	  
factors	   to	  correct	  PT/INR	  by	  50%	   	  when	   there	   is	  a	  minimally	  prolonged	  PT/INR	   (102).	  The	  
R/CT	   may	   therefore	   be	   a	   better	   reflection	   of	   true	   bleeding	   potential	   than	   INR,	   as	   a	  
prolongation	  (in	  the	  absence	  of	  excess	  anticoagulants)	  	  usually	  is	  seen	  only	  	  if	  procoagulant	  
levels	   are	   less	   than	   the	   haemostatic	   threshold	   of	   30%	   (103).	   In	   addition,	   in	   contrast	   to	  
plasma	  based	  CCT,	   the	   inclusion	  of	   platelets	   (ie	  whole	   blood)	   in	  VET	  will	   affect	   the	  onset	  
(R/CT)	  and	  rate	  (K,CFT)	  of	  fibrin	  polymerization,	  due	  to	  the	  platelet	  mediated	  procoagulant	  
reactions	   and	   platelet-­‐fibrinogen	   interactions.	   In	   liver	   disease,	  wide	   derangements	   in	   INR	  
are	  not	  often	  mirrored	  by	  similar	  changes	  in	  VET	  parameters	  and	  this	  reflects	  the	  fact	  that	  
the	  INR	  is	  a	  poor	  predictor	  of	  clinically	  important	  bleeding	  (2).	  
2.4.2	  Platelet	  count	  	  
Clot	  strength	  as	  assessed	  by	  the	  maximum	  amplitude	  (MA)	  or	  maximum	  clot	  firmness	  (MCF)	  
is	   highly	   influenced	   by	   both	   fibrinogen	   levels	   and	   platelet	   count.	   VET	   are	   useful	   for	  
evaluating	  the	  overall	  interaction	  between	  platelet	  GPIIb/IIIa	  receptors	  and	  fibrinogen(104)	  
as	   activated	   platelets	   provide	   binding	   sites	   for	   fibrinogen.	   The	  minimal	   platelet	   count	   for	  
normal	  clot	  formation	  on	  VET	  is	  not	  certain	  and	  is	  markedly	  affected	  by	  the	  fibrinogen	  level.	  	  
In	  a	  study	  in	  patients	  with	  idiopathic	  thrombocytopenic	  purpura	  (ITP),	  it	  was	  found	  that	  the	  
critical	  cut	  off	  for	  platelet	  count	  to	  affect	  MCF	  was	  31	  x	  109	  and	  the	  critical	  fibrinogen	  level	  




was	  375mg	  dl-­‐1	  (105)	  The	  MCF	  was	  found	  to	  be	  the	  most	  important	  parameter	  in	  predicting	  
bleeding	  in	  patients	  with	  ITP.	  Others	  have	  found	  that	  the	  MCF	  is	  greatly	  decreased	  when	  the	  
platelet	   count	   falls	   below	  50,000	   x109	   (106)	   .	   In	   liver	   disease,	  where	   fibrinogen	   levels	   are	  
usually	   within	   the	   normal	   range,	   platelet	   count	   may	   have	   a	   more	   significant	   impact	   on	  
changes	  in	  MA/MCF.	  Tripodi	  et	  al	  found	  that	  in	  stable	  patients	  with	  cirrhosis	  the	  correlation	  
of	   platelet	   count	   with	   MCF	   was	   0.691	   compared	   to	   0.590	   for	   fibrinogen(98).	   	   As	   clot	  
strength	   (MA/MCF)	   is	   a	   composite	   reflection	   of	   platelet	   –fibrinogen	   interaction,	   even	   if	  
there	  is	  a	  low	  platelet	  count,	  adequate	  clot	  strength	  may	  still	  be	  achieved	  if	  the	  fibrinogen	  
levels	  are	  at	  the	  high	  end	  of	  normal	  or	  raised.	  The	  combination	  of	  both	  a	  low	  platelet	  count	  
and	  a	  low	  fibrinogen	  always	  results	  in	  a	  reduced	  MA/MCF	  and	  is	  strongly	  associated	  with	  an	  
increased	  bleeding	  tendency.	  (107)	  
2.4.3	  Clauss	  fibrinogen	  
Preoperative	  fibrinogen	  levels	  vary	  greatly	  among	  patients	  and	  low	  levels	  may	  be	  predictive	  
of	   bleeding	   during	   surgery.	   The	   Clauss	   method	   is	   currently	   the	   gold	   standard	   for	  
determination	   of	   fibrinogen.	   It	   is	   turbidometric	   and	   depends	   on	   thrombin	   induced	   fibrin	  
formation.	   It	   is	   affected	   by	   multiple	   factors	   including	   the	   presence	   of	   colloidal	   solutions	  
(starch	  and	  gelatins)	  and	  also	  direct	   thrombin	   inhibitors	   (108,	  109).	   In	   the	  ROTEM	  FIBTEM	  
test,	   the	   addition	   of	   cytochalasin	   D	   inhibits	   GPIIb/IIIa	   interaction	   thereby	   removing	   the	  
platelet	  contribution	  to	  MCF	  and	  has	  good	  correlation	  with	  plasma	  fibrinogen	  levels	  (110).	  A	  
functional	  fibrinogen	  (FF)	  assay	  is	  also	  available	  for	  the	  TEG.(111).	  However,	  until	  recently,	  it	  
has	  not	  routinely	  been	  used	  in	  TEG	  analyses,	  and	  the	  lack	  of	  a	  standardised	  protocol	  on	  the	  
TEG	   to	   distinguish	   hypofibrinogenaemia	   from	   thrombocytopenia	   is	   a	   major	   limit	   in	  
determining	   the	   need	   for	   fibrinogen	   replacement	   therapy	   (112)	   .	   A	   preliminary	  




observational	  study	  in	  liver	  transplant	  patients	  found	  that	  FF	  correlated	  strongly	  with	  Klauss	  
fibrinogen	  (r=0.9)	  at	  baseline,	  but	  overestimated	  levels	  after	  graft	  reperfusion,	  when	  plasma	  
fibrinogen	  levels	  are	  frequently	  less	  than	  1g/l	  	  (113).	  
A	   fibrinogen	   level	   of	   1.5g/l	   or	   less	   increases	   the	   risk	   of	   bleeding,	   and	   is	   considered	  
borderline	   for	  major	   surgery	   (114).	   	   In	   trauma	   induced	   coagulopathy	  a	   FIBTEM	  amplitude	  
after	  10	  minutes	  (A10)	  of	  less	  than	  5mm	  was	  reported	  to	  be	  a	  good	  predictor	  of	  low	  plasma	  
fibrinogen	   (<1g/l)	   with	   a	   sensitivity	   of	   91%	   and	   a	   specificity	   of	   85%	   (95).	   	   The	   ability	   to	  
monitor	   and	   determine	   fibrinogen	   levels	   at	   the	   bedside	   has	   led	   to	   increased	   use	   of	  
fibrinogen	   concentrates	   and	   cryoprecipitate	   in	   cardiac	   surgery	   and	   also	   in	   severe	   trauma	  
with	   a	   reduction	   in	   both	   total	   and	   massive	   transfusions	   (107,	   115,	   116).	   In	   dilution	   and	  
massive	   bleeding	   fibrinogen	   is	   the	   first	   factor	   to	   reach	   critical	   levels	   (117).	   Bollinger	  
investigated	  the	  minimum	  fibrinogen	  concentration	  above	  which	  clot	  formation	  normalises	  
and	  found	  that	  fibrinogen	  concentrations	  above	  2g/l	  are	  required	  (118).	  All	  VET	  parameters	  
are	  progressively	  affected	  during	  haemodilution	  or	  blood	  loss	  because	  viscoelastic	  strength	  
is	   highly	  dependent	  on	   fibrin	  polmerization,	   illustrating	   that	   fibrinogen	   is	   an	   indispensible	  
substrate	   of	   thrombin	   and	   critical	   for	   haemostasis.	   Fibrinogen	   supplementation	  may	   also	  
compensate	  for	  defects	   in	  fibrin	  polymerisation	  and	  also	  for	   low	  platelet	  counts(119)	   	  and	  
thereby	   reduce	   blood	   loss.	   In	   a	   prospective	   observational	   study	   in	   20	   liver	   transplant	  
patients	  administered	  fibrinogen	  concentrate	  to	  maintain	  the	  MCF,	  the	  transfusion	  of	  blood,	  
FFP	   and	   platelets	   was	   reduced	   by	   more	   than	   half	   and	   the	   percentage	   of	   patients	   who	  
received	  no	  transfusion	   increased	  from	  3.5%	  to	  20%	  compared	  to	  a	  historical	  cohort	   from	  
the	  previous	  year.	  (120)	  
	  





2.4.4	  Fibrinolysis	  	  
The	   euglobulin	   clot	   lysis	   time	   was	   the	   original	   method	   used	   to	   assess	   fibrinolysis,	   and	  
reflects	  overall	  fibrinolytic	  activity	  in	  the	  plasma,	  but	  has	  largely	  been	  superseded	  by	  specific	  
functional	  and	  immunological	  assays.	  Validation	  of	  VET	  to	  assess	  fibrinolytic	  activity	  and	  to	  
determine	   the	   underlying	   individual	   susceptibility	   to	   fibrinolysis	   	   is	   an	   area	   of	   increasing	  
interest	  (121,	  122).	  	  Clinically	  significant	  fibrinolysis	  is	  detected	  by	  the	  clot	  lysis	  index	  (CLI),	  
when	  there	  is	  a	  rapid	  decline	  in	  MA/MCF	  over	  time.	  A	  CLI	  of	  >15%	  (the	  decrease	  in	  MA/MCF	  
over	  1	  hour	  is	  more	  than	  15%	  )	  is	  considered	  hyperfibrinolysis	  (123).	  The	  ROTEM	  	  test	  which	  
uses	   an	   assay	   containing	   aprotinin	   (APTEM)	   confirms	   the	   diagnosis	   and	   in	   addition,	   by	  
reversing	   any	   fibrinolysis,	   	   allows	   pre-­‐assessment	   of	   the	   coagulation	   profile	   after	  
antifibrinolytic	   therapy	   has	   been	   administered	   to	   the	   patient,	   thus	   enabling	   earlier	  
administration	  of	  other	  prohaemostatic	  therapy	  if	  necessary.	  (88)	  Because	  plasma	  normally	  
contains	   high	   concentrations	   of	   plasminogen	   activator	   inhibitor	   (PAI-­‐1)	   and	   alpha	   2	   anti-­‐
plasmin,	  the	  fibrinolytic	  response	  is	  normally	  limited	  to	  the	  surface	  of	  the	  thrombus	  and	  the	  
absence	  of	  significant	  fibrinolysis	  on	  VET	  does	  not	  exclude	  fibrinolysis	  in	  a	  localised	  vascular	  
bed,	  however	  it	  does	  suggest	  that	  the	  systemic	  concentration	  of	  tPA	  is	  not	  high	  enough	  to	  
induce	  ex	  vivo	  hyperfibrinolysis.(124)	  The	  fibrin	  clot	  is	  more	  susceptible	  to	  fibrinolysis	  after	  








2.5	  Thrombin	  generation	  
The	  rate	  and	  amount	  of	  thrombin	  generation	   is	  considered	  predictive	  for	  both	  thrombosis	  
and	   haemorrhage.	   	   A	   thrombus	   velocity	   curve	   or	   V	   curve	   can	   be	   obtained	   from	   the	   TEG	  
waveform	  using	  a	  software	  programme.	  The	  V	  curve	   is	  plotted	  from	  the	  first	  derivative	  of	  
changes	   in	   clot	   resistance	  expressed	  as	  a	   change	   in	   clot	   strength	  per	  of	  unit	   time	   (dynes/	  
cm2/	  s)	  representing	  the	  maximum	  velocity	  of	  clot	  formation.	  Parameters	  obtained	  are	  total	  
thrombus	   generation	   (TTG),	   maximum	   rate	   of	   thrombus	   generation	   (MRTG)	   and	   time	   to	  
maximum	   rate	   of	   thrombus	   generation	   (TMRTG).	   This	   gives	   similar,	   but	   not	   identical	  
information,	  as	  the	  automated	  calibrated	  thrombogram.	  
	  
Figure	  2.6	  Thrombin	  generation	  and	  TEG	  “V”	  curve	  




A	   small	   study	   in	   healthy	   volunteers	   demonstrated	   that	   thrombin-­‐antithrombin	   (TAT)	  
complexes,	   a	   surrogate	  marker	   for	   thrombin	  generation,	   correlated	  well	  with	  TMRTG	  and	  
TTG	  (77).	  However,	  the	  rate	  of	  clot	  formation	  on	  the	  TEG	  can	  only	  be	  assumed	  to	  be	  directly	  
proportional	  to	  the	  rate	  of	  thrombin	  generation	  if	  the	  platelet	  count,	  fibrinogen	  and	  factor	  
XIII	  levels	  are	  normal.	  This	  means	  that	  thrombin	  generation	  data	  derived	  from	  the	  V	  curve,	  
in	  the	  setting	  of	  liver	  disease,	  should	  be	  interpreted	  with	  care	  as	  the	  platelet	  count	  affects	  
not	  only	  final	  clot	  firmness	  (MA)	  but	  also	  the	  rate	  of	  clot	  propagation.	  The	  TEG	  has	  also	  been	  
used	   to	   assess	   thrombin	   generation	   in	   haemophiliac	   patients	   (126,	   127).	   In	   patients	  
undergoing	  surgery,	  the	  fibrinogen	  level	  and	  platelet	  count	  can	  change	  rapidly	  and	  changes	  
in	   the	   first	   derivative	   of	   the	   TEG	   could	   be	   due	   to	   either	   hypofibrinogenaemia	   or	  
thrombocytopenia	  as	  well	  as	  a	  decrease	  in	  thrombin	  generation.	  Thrombin	  generation	  and	  
fibrin	   clot	   formation	   are	   closely	   interlinked	  and	   reductions	   in	  one	  or	  both	  will	   predispose	  
patients	   to	   bleeding	   complications(64)	   and	   explains	   why	   a	   reduced	  MA/MCF	   has	   such	   a	  
significant	  relationship	  with	  increased	  bleeding	  tendency.	  
2.6	  Conclusions	  
Understanding	  the	  principles	  of	  how	  VETs	  provide	   information	  on	  clot	   formation,	  strength	  
and	  stability	  is	  key	  to	  interpreting	  the	  results	  generated	  by	  these	  tests,	  and	  to	  using	  them	  in	  
an	   informed	   and	   consistent	   manner.	   It	   is	   important	   to	   appreciate	   the	   factors	   that	   can	  
influence	  the	  test	  results,	  and	  to	  also	  have	  some	  understanding	  of	  the	  limitations	  of	  these	  
tests.	   It	   is	   essential	   that	   the	   equipment	   is	  maintained	   to	   adequate	   standards	   for	   point	   of	  
care	  tests	  with	  quality	  assurance	  and	  standard	  operating	  procedures,	  and	  that	  all	  personnel	  
that	  use	  these	  machines	  are	  adequately	  trained,	  and	  regularly	  tested	  for	  proficiency.	  




Chapter	  3	  	  
	  
	  
Review	  of	  the	  clinical	  utility	  of	  viscoelastic	  tests	  of	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The	  prothrombin	  time	  (PT)	  and	  internationalised	  normalised	  ratio	  (INR)	  are	  used	  in	  scoring	  
systems	  (Child-­‐Pugh,	  MELD,	  UKELD)	  in	  chronic	  liver	  disease	  and	  as	  a	  prognostic	  tool	  and	  for	  
dynamic	  monitoring	  of	  hepatic	  function	  in	  acute	  liver	  disease.	  These	  tests	  are	  known	  to	  be	  
poor	  predictors	  of	  bleeding	  risk	  in	  liver	  disease,	  however	  they	  continue	  to	  influence	  clinical	  
management	  decisions.	  Recent	  work	  on	  coagulation	  in	  liver	  disease,	  in	  particular	  thrombin	  
generation	  studies,	  has	  led	  to	  a	  paradigm	  shift	  in	  our	  understanding	  and	  it	  is	  now	  recognised	  
that	   haemostasis	   is	   relatively	   well	   preserved.	   Whole	   blood	   global	   viscoelastic	   tests	  
(TEG®/ROTEM®)	  produce	  a	  composite	  dynamic	  picture	  of	  the	  entire	  coagulation	  process	  and	  
have	   the	   potential	   to	   provide	   more	   clinically	   relevant	   information	   in	   patients	   with	   liver	  
disease.	  	  
We	   searched	   MEDLINE	   and	   the	   Cochrane	   Library	   for	   papers	   published	   in	   English	   on	  
coagulation	  and	   liver	  disease	   from	  1	   January	  1980	  to	  31	   January	  2015	  using	   the	   following	  
keywords	   “liver	   disease”,	   “liver	   surgery”,	   “coagulation”,	   “coagulopathy”,	  
“thromboelastometry”	   and	   “thromboelastography”.	   Although	   the	   vast	  majority	   of	   studies	  
are	  observational	   ,	   small	   in	   size,	   and	   limited	   to	   single	   centres,	   it	   is	   clear	   that	  VET	  provide	  
additional	   information	   that	   is	   in	   keeping	   with	   the	   new	   concepts	   of	   how	   coagulation	   is	  
altered	  in	  these	  patients.	  This	  review	  provides	  the	  basis	  for	  large	  scale,	  prospective	  outcome	  
studies	  to	  establish	  the	  clinical	  value	  of	  these	  tests.	  
	  
	  




3.1	  Introduction	  	  
Conventional	  coagulation	  tests	  (CCT)	  are	  abnormal	  in	  acute	  and	  chronic	  liver	  disease	  and	  are	  
interpreted	   as	   demonstrating	   an	   underlying	   bleeding	   diathesis,	   this	   is	   because	   abnormal	  
results,	   and	   therefore	   a	   presumed	   “coagulopathy”	   as	   demonstrated	   by	   conventional	  
coagulation	   tests,	   are	   used	   interchangeably.	   	   However,	   standard	   coagulation	   tests	   do	   not	  
predict	  bleeding,	  nor	  do	  they	  provide	  sufficient	  information	  to	  optimise	  the	  management	  of	  
bleeding	   events	   (128,	   129).	   The	   shortcomings	   of	   this	   classical	   interpretation	   of	   the	  
coagulopathy	  of	  liver	  disease	  have	  been	  increasingly	  recognised	  	  in	  recent	  years	  (130).	  There	  
has	  been	  a	  paradigm	  shift	   in	  our	  understanding	  of	  haemostasis	   in	  these	  patients,	  and	   it	   is	  
now	  described	  conceptually	  as	  being	  	  “re-­‐balanced”	  (131).	  Thrombin	  generation	  	  in	  patients	  
with	   	   liver	   disease	   is	   much	   better	   conserved	   than	   previously	   thought	   when	   the	   test	  
conditions	  were	  adapted	  to	  reflect	  the	  contribution	  of	  the	  anticoagulant	  pathways	  (4)	  and	  it	  
is	   now	   recognised	   that	   there	   is	   an	   increased	   risk	   of	   thromboembolism	   in	   chronic	   liver	  
disease(70).	  
Thrombin	  generation	  tests	  (TGT)	  have	  revealed	  important	  new	  information	  on	  haemostasis	  
in	   liver	  disease,	  but	   these	   tests	   are	  not	   readily	   available,	   and	   therefore	  have	  poor	   clinical	  
applicability	  and	  furthermore,	  there	  are	  no	  studies	  comparing	  the	  TGT	  to	  a	  clinical	  endpoint.	  	  
In	  addition,	  TG	  assays	  are	  generally	  performed	   in	  platelet	  poor	  plasma	  and	   therefore	   lack	  
information	   on	   protein	   cell	   interactions.	   Whole	   blood	   global	   viscoelastic	   tests	   (VET)	   of	  
coagulation	   are	   increasingly	   used	   for	   point	   of	   care	   (POC)	   analysis	   of	   the	   complex	  
coagulopathies	  that	  can	  occur	  during	  cardiac	  surgery	  and	  following	  major	  trauma	  (132,	  133).	  
They	  differ	  from	  CCT	  as	  they	  evaluate	  the	  kinetics	  of	  coagulation	  from	  initial	  clot	  formation	  
to	   final	   clot	   strength.	   These	   dynamic	   tests	   provide	   a	   composite	   picture	   reflecting	   the	  




interaction	  of	  plasma,	  blood	  cells	  and	  platelets,	  and	  more	  closely	  reflect	  the	  situation	  in	  vivo	  
than	  do	  CCT,	  as	  these	  are	  performed	  solely	  in	  plasma	  and	  measure	  only	  isolated	  end	  points.	  
In	  addition	  VET	  provide	  valuable	  information	  on	  the	  presence	  and	  severity	  of	  fibrinolysis	  and	  
also	   hypercoagulability	   (134).	   	   Since	   the	   early	   1980’s,	   VET	   have	   been	   used	   for	   POC	  
coagulation	  monitoring	  during	  orthotopic	  liver	  transplantation	  (OLT)(83).	  The	  possibility	  that	  
there	   may	   be	   more	   clinical	   benefit	   in	   using	   VET	   rather	   than	   CCT	   to	   assess	   and	   stratify	  
bleeding	  or	  thrombotic	  risk	  in	  patients	  with	  liver	  disease	  is	  an	  idea	  that	  is	  gaining	  increasing	  
traction,	  but	  requires	  prospective	  clinical	  outcome	  studies	  to	  determine	  the	  validity	  of	  such	  
an	  approach	  (98).	  
The	  purpose	  of	  this	  chapter	  is	  to	  review	  relevant	  published	  studies	  on	  VET	  and	  liver	  disease,	  
in	  the	  context	  of	  the	  current	  understanding	  of	  the	  coagulopathy	  of	  liver	  disease,	  to	  establish	  
evidence	   if	  VET	   could	  be	  used	  as	   routine	   coagulation	   tests	   in	   this	   setting.	   To	   this	   end	  we	  
performed	  a	  systematic	  review	  of	  all	  relevant	  studies	  that	  have	  used	  viscoelastic	  tests	  (VET)	  
of	  coagulation	   in	  patients	  with	   liver	  disease.	  Although	  many	  studies	  are	  observational	  and	  
small	   in	  size,	   it	   is	  clear	  that	  VET	  provide	  additional	   information	  that	   is	   in	  keeping	  with	  the	  
new	  concepts	  of	  how	  coagulation	  is	  altered	  in	  these	  patients.	  	  
3.2	  Viscoelastic	  tests	  and	  Chronic	  Liver	  Disease	  (CLD)	  
3.2.1.	  VET	  parameters	  and	  CLD	  
Because	  TEG/ROTEM	  are	  global	  tests	  providing	  a	  composite	  analysis	  that	  reflect	  function	  of	  
plasma,	   blood	   cells	   and	   platelets,	   they	   are	   increasingly	   viewed	   as	   an	   appropriate	   tool	   to	  
investigate	   the	   coagulopathy	   of	   chronic	   liver	   disease.	   	   In	   agreement	  with	   the	   concept	   of	  
rebalanced	   haemostasis,	   patients	   with	   cirrhosis	   often	   maintain	   global	   haemostasis	   as	  




assessed	  by	  TEG.	   In	  a	  cohort	  of	  273	  patients	  with	  stable	  cirrhosis,	   it	  was	  found	  that	  mean	  
and	   median	   TEG	   parameters	   were	   all	   within	   normal	   limits,	   although	   the	   maximum	  
amplitude	   decreased	   in	   proportion	   to	   the	   severity	   of	   thromobocytopenia	   and	   severity	   of	  
liver	   disease	   (135).	   	   In	   a	   subset	   of	   48	   patients	   with	   more	   decompensated,	   but	   stable	  
cirrhosis	  (INR>1.5)	  the	  mean	  maximum	  amplitude	  was	  below	  normal	  limits,	  presumably	  due	  
to	   lower	   platelet	   counts	   in	   this	   sicker	   population.	   	   Tripodi	   et	   al.	   compared	   ROTEM	  
parameters	   between	   58	   healthy	   volunteers	   and	   51	   adult	   patients	   with	   cirrhosis	   (98).	  
Abnormal	  ranges	  were	  defined	  as	  above	  the	  95th	  percentile	  for	  CT	  and	  CFT	  or	  below	  the	  5th	  
percentile	   for	  MCF.	   ROC	   curves	  were	   constructed	   to	   identify	   patients	  with	   cirrhosis	   (true	  
positives)	   from	   healthy	   individuals	   (true	   negatives).	   The	   CT	   did	   not	   distinguish	   between	  
healthy	   and	   cirrhotic	   individuals	   and	   there	   was	   no	   correlation	   between	   PT	   and	   CT	   (r	   =	   -­‐
0.264)	  and	  only	  27%	  of	  patients	  with	  cirrhosis	  had	  any	  prolongation	  of	  CT	  despite	  the	  fact	  
that	  PT	  was	  prolonged.	  MCF	  was	  a	  good	  discriminator	  and	  76%	  of	  patients	  with	  cirrhosis	  had	  
an	  abnormal	   (low)	  value.	  The	  MCF	  also	  correlated	  well	  with	  MELD	  score.	  There	  was	  good	  
correlation	   between	   platelet	   count	   and	   MCF	   (r=0.691)	   and	   also	   CFT	   (	   r=	   0.741).	   Clauss	  
fibrinogen	  correlated	  reasonably	  well	  with	  MCF	  (	  r=	  0.590).	  It	  was	  concluded	  that	  VET	  may	  
be	   useful	   to	   assess	   the	   severity	   of	   chronic	   liver	   disease	   and	   can	   be	   used	   to	   distinguish	  
between	  healthy	  and	  cirrhotic	  individuals.	  	  
Others	  have	  also	   found	   that	  many	  patients	  with	  compensated	  cirrhosis	  have	  normal	  TEGs	  
(136),	  and	  this	  supports	  the	  observation	  that	  overall	  haemostasis	  is	  relatively	  well	  preserved	  
in	  these	  patients	  and	  that	  the	  compensatory	  mechanisms	  that	  occur	  in	  liver	  disease	  act	  to	  
maintain	   a	   state	   of	   balanced	   haemostasis.	   Another	   study	   evaluated	   plasma	   thrombin	  
generation	   (CAT),	   and	   whole	   blood	   clot	   formation	   	   (ROTEM	   activated	   with	   TF,	   with	   and	  




without	   tPA)	   in	   73	  patients	  with	   all	   cause	   cirrhosis	   (Child	   Pugh	  A	   =	   52,	   B	   =	   15,	   C	   =	   6)and	  
compared	   the	   results	   to	   20	   healthy	   controls.	   Activity	   of	   the	   coagulation	   pathway	   was	  
measured	   by	   assay	   of	   factor	   VIIa	   and	   Xa	   –antithrombin	   complexes.	   Thrombin	   generation	  
was	   increased	  with	   increasing	  severity	  of	  cirrhosis,	  whilst	   there	  was	  a	  progressive	  delay	   in	  
clot	  formation	  rate	  and	  reduced	  clot	  strength	  as	  the	  severity	  of	  cirrhosis	   increased	  [Figure	  
3.1].	  There	  was	  increased	  generation	  of	  VIIa,	  without	  apparent	  increased	  factor	  X	  activation.	  
The	   results	   indicated	   cirrhotic	   patients	   have	   an	  overall	   procoagulant	   plasma	  milieu,	   but	   a	  
reduced	  whole	  blood	  clot	  formation	  capacity	  with	  an	  apparently	  unaltered	  resistance	  to	  clot	  
lysis	  (137).	  
	  
Figure	  3.1	  Thrombin	  generation	  curves	  in	  cirrhosis	  
	  
	  
Thrombin	  generation	  curves:	  
Kleinegris	  et	  al,	  2014)	  
Normal	  plasma	  
Plasma	  from	  patients	  with	  Child	  
Pugh	  grade	  	  A,B,C.	  






Figure	  3.2	  Changes	  in	  ROTEM	  parameter	  in	  cirrhosis	  after	  Kleinegris	  et	  al.	  2014)	  There	  is	  a	  
progressive	  increase	  in	  clot	  formation	  time	  and	  a	  decrease	  in	  maximun	  clot	  firmness	  with	  increasing	  
severity	  of	  liver	  disease.	  There	  is	  no	  change	  in	  susceptibility	  to	  fibrinolysis.	  
	  
	  




The	   trigger	   for	  prophylactic	  platelet	   transfusion	  prior	   to	   invasive	  procedures,	   such	  as	   liver	  
biopsy,	  is	  commonly	  set	  at	  a	  platelet	  count	  of	  50	  x	  109	  (38).	  However,	  this	  does	  not	  take	  into	  
account	  the	  multiple	  changes	  in	  the	  haemostatic	  profile	  of	  patients	  with	  liver	  disease,	  such	  
as	  the	  elevated	  levels	  of	  VWF,	  or	  higher	  levels	  of	  fibrinogen	  that	  can	  occur	  in	  some	  patients	  
with	   liver	   disease,	   and	   result	   in	   relatively	   normal	   clot	   firmness,	   despite	  
thrombocytopenia.(138,	   139).	   The	   increased	   levels	   of	   VWF	   seen	   in	   patients	  with	   cirrhosis	  
means	   that	   simple	   platelet	   counts	   can	   be	  misleading	   as	   a	   diagnostic	   tool	   	   for	   predicting	  
bleeding	   in	   patients	   with	   liver	   failure.	   A	   randomised	   controlled	   study	   in	   patients	   with	  
cirrhosis	   of	   Eltrombopag,	   a	   thrombopoetin	   receptor	   agonist,	  was	   terminated	   prematurely	  
because	   of	   thrombotic	   complications	   in	   the	   treatment	   group	   (140).	   It	   was	   thought	   that	  
elevated	   levels	   of	   VWF	   together	   with	   normalized	   platelet	   counts	   were	   the	   major	  
contributing	  factor.	  	  
The	  value	  of	  prophylactic	  platelet	  transfusion	  in	  preventing	  bleeding	  as	  a	  result	  of	  invasive	  
procedures	   in	   cirrhotic	   patients,	   has	   been	   largely	   taken	   for	   granted	   until	   recently,	   but	  
without	  any	  confirmatory	  evidence.	  In	  a	  small	  observational	  study	  of	  26	  thrombocytopenic	  
patients	  with	  cirrhosis,	  undergoing	  variceal	  ligation	  who	  were	  given	  one	  standard	  adult	  dose	  
platelet	   transfusion,	   the	   effects	   on	   thrombin	   generation	   and	   ROTEM	   were	   evaluated.	  
Although	  there	  was	  a	  small	  increment	  in	  platelet	  count,	  from	  39	  (16-­‐64)	  to	  52	  (19-­‐91)	  there	  
was	  no	  significant	  effect	  on	  TG,	  and	  only	  very	  modest	  improvements	  in	  ROTEM	  parameters	  
with	   none	   reaching	   normal	   values	   following	   platelet	   transfusion	   (141).	   The	   success	   of	  
conservative	   transfusion	   policies	   employed	   in	   patients	   undergoing	   liver	   transplantation,	  
where	  very	  much	   lower	  platelet	  counts	  are	  tolerated,	  unless	  there	   is	  active	  bleeding,	  calls	  
the	   practice	   of	   prophylactic	   platelet	   transfusions	   for	   less	   invasive	   procedures	   into	   serious	  	  




question	  (142).	  A	  recent	  randomised	  controlled	  study	  in	  60	  patients	  with	  cirrhosis	  	  published	  
in	   2015,	   demonstrated	   that	   prophylaxis	   with	   FFP	   and/or	   platelets	   prior	   to	   invasive	  
procedures	   	   is	   significantly	   reduced	  when	  using	  TEG	  as	  compared	   to	  standard	  coagulation	  
tests	  [platelet	  count	  ≤	  50,000	  and	  INR	  ≥1.8],	  without	  any	  increase	  in	  bleeding	  complications	  
(De	   Pietri	   L	   et	   al.	   E-­‐pub	   Hepatology	   2015).	   Only	   16.7%	   of	   the	   TEG	   group	   received	   any	  
transfusion,	  whereas	  all	  patients	  in	  the	  standard	  of	  care	  group	  received	  a	  transfusion.	  There	  
was	  only	  one	  post	  procedural	  bleeding	  episode	  (high	  volume	  paracentesis)	  and	  this	  was	  in	  
the	  group	  using	  conventional	  coagulation	  parameters.	  
3.2.2.	  Heparin	  like	  effect	  (HLE)	  and	  CLD:	  	  
The	   native	   TEG	   is	   extremely	   sensitive	   to	   the	   presence	   of	   heparin	   and	   heparin	   like	  
substances.	   Coppell	   et	   al	   investigated	   the	   effects	   of	   unfractionated	   heparin	   (UFH),	   low	  
molecular	   weight	   heparin(LMWH)	   and	   danaparoid	   on	   native	   and	   heparinase	   TEGS.	   The	  
difference	  between	  parameters	  in	  these	  two	  tests	  was	  able	  to	  differentiate	  between	  a	  range	  
of	  low	  concentrations	  (0.005-­‐0.05U/ml)	  of	  these	  heparin	  like	  substances	  and	  demonstrated	  
a	  clear	  dose	  response,	  and	  in	  the	  case	  of	  UFH	  there	  was	  greater	  sensitivity	  than	  with	  anti-­‐Xa	  
activity.	  (143).	  Although	  the	  standard	  assay	  for	  monitoring	  LMWH	  is	  by	  inhibition	  of	  factor	  
Xa	  (anti-­‐Xa	  activity),	  this	  test	  is	  not	  routinely	  available	  at	  all	  institutions,	  and	  there	  are	  some	  
concerns	   relating	   to	   inter-­‐assay	   variability.	   	   Whilst	   native	   TEG	   is	   undoubtedly	   the	   most	  
sensitive	  method	  to	  detect	   low	  concentrations	  of	  heparin,	  kaolin	  activated	  TEGS	  have	  also	  
been	  found	  to	  be	  a	  useful	  method	  to	  monitor	  and	  guide	  LMWH	  therapy	  in	  sick	  hospitalized	  
patients,	   where	   co-­‐morbid	   conditions	   can	   impact	   on	   both	   the	   pharmacodynamics	   and	  
pharmacokinetics	  of	  LMWH	  (144)	  




In	  recent	  years	  there	  has	  been	  increasing	  interest	  in	  the	  detection	  of,	  and	  the	  significance	  of	  
endogenous	   heparins.	   Under	   conditions	   of	   endothelial	   stress,	   such	   as	   surgery	   or	   sepsis,	  
endogenous	   release	   of	   very	   small	   quantities	   of	   glycosoaminoglycans	   (GAGS)	   may	   be	  
detected	   systemically	   (145).	  Minor	   disturbances	   of	   the	   endothelial	   glycocalyx	   can	   lead	   to	  
the	   selective	   cleavage	   of	   heparan	   and	   chondrotin	   sulphate	   sidegroups	   from	   the	   luminal	  
layer	   of	   the	   glycocalyx.	   	   Where	   there	   is	   more	   significant	   damage	   to	   the	   vascular	  
endothelium	  from	  ischaemia	  or	  sepsis,	  systemic	  activation	  of	  coagulation	  is	  promoted,	  and	  
it	  is	  thought	  that	  this	  shedding	  of	  GAGS	  into	  the	  circulation	  is	  an	  adaptive	  response	  to	  keep	  
a	   progressively	   more	   pro-­‐coagulant	   microvasculature	   open	   by	   means	   of	   endogenous	  
heparinization	  (146).	  Five	  percent	  of	  patients	  with	  severe	  traumatic	  injury	  have	  evidence	  of	  
acute	  endogenous	  heparinization	  on	  TEG,	  and	  given	  that	  their	  levels	  of	  syndecan	  1	  are	  also	  
significantly	   increased,	   this	   can	   be	   mechanistically	   linked	   to	   endothelial	   glycocalyx	  
degradation.(147).	   	  When	  shed,	  the	  glycocalyx	  GAGs	  retain	  their	  anticoagulant	  activity	  and	  
this	   is	   detectable	   by	   a	   prolonged	   R	   value	   on	   TEG	   analysis.	   These	   endogenous	   GAGS	  may	  
represent	  an	  increase	  bleeding	  risk	  for	  some	  patients	  (29,	  148)	  and	  demonstration	  of	  their	  
presence	  may	  provide	  clinically	  useful	   information.	   In	  a	  prospective	  observational	  study	   in	  
30	  patients	  with	   cirrhosis,	  Mancuso	  et	   al	   demonstrated	   that	   citrated	   samples,	   (allowing	  a	  
delay	  in	  running	  the	  analysis)	  give	  comparable	  results	  to	  samples	  that	  are	  run	  immediately	  
and	  facilitates	  the	   logistics	  of	  using	  TEG	  when	  it	   is	  not	  close	  to	  the	  patient.(149).	  Bacterial	  
infection	   in	  cirrhosis	   induces	  a	  HLE	  detected	  by	  TEG	  (29)	  and	  this	  reverses	  with	  antibiotics	  
and	  resolution	  of	  the	  infection	  [Figure	  3.3].	  Of	  30	  patients	  with	  infection,	  28	  had	  significantly	  
improved	  TEG	  parameters	   in	   the	  heparinase	  modified	  TEG,	   indicating	  a	  significant	  heparin	  
effect,	  this	  HLE	  disappeared	  after	  the	  infection	  resolved.	  






Figure	  3.3	  	  Heparin	  like	  effect	  (HLE)	  demonstrated	  in	  cirrhotic	  patients	  with	  infection	  	  after	  
Montalto	  P	  et	  al.	  J	  Hepatology	  2002)	  
	  
HLE	   is	   associated	  with	  detectable	   anti-­‐Xa	   activity	   (150,	   151)	   	   and	   appears	   to	  differentiate	  
patients	   at	   increased	   risk	   of	   variceal	   re-­‐bleeding(152).In	   contrast,	   none	   of	   the	   standard	  
laboratory	   tests	  of	  haemostasis	   (INR,	  PTT	  and	  platelet	  count)	  differed	  between	  those	   that	  
re-­‐bled	  and	  those	  that	  did	  not.	  
	  	  A	   transient	   HLE	   in	   systemic	   venous	   blood	   after	   transjugular	   intrahepatic	   portosystemic	  
shunt	  (TIPS)	  has	  been	  reported,	  suggesting	  a	  high	  concentration	  of	  heparinoids	  in	  the	  portal	  
venous	  system	  prior	  to	  TIPS	  placement.	  (153)	  
3.2.3	  Hypercoagulability	  and	  CLD	  
Hypercoagulability	   may	   have	   an	   important	   role	   in	   many	   aspects	   of	   liver	   disease	   and	  
intrahepatic	  microthrombi	  have	  been	  	  implicated	  in	  the	  progression	  of	  fibrosis	  (154).	  Portal	  
vein	  thrombosis	  (PVT)	  is	  a	  common	  complication	  of	  liver	  cirrhosis,	  with	  an	  incidence	  of	  10-­‐
25%,	  with	  a	  greater	  tendency	  to	  thrombosis	  with	  more	  severe	  liver	  disease	  (155).	  Reduced	  
portal	  blood	  flow	  and	  blood	  vessel	  damage	  may	  play	  an	  important	  role	  in	  the	  increased	  risk	  




of	  PVT	   (156),	  but	   the	  haemostatic	  status	  may	  also	  be	  an	   important	  contributory	   factor.	   In	  
cirrhosis,	   the	  ratio	  of	   the	   two	  most	  powerful	  pro	  and	  anticoagulants	   in	   the	  plasma,	   factor	  
VIII	   and	   protein	   C	   respectively,	   show	   a	   balance	   strongly	   in	   favour	   of	   factor	   VIII	   indicating	  
hypercoagulability	   (157)	   and	   it	   is	   now	   appreciated	   that	   the	   risk	   of	   venous	   thrombosis	   is	  
often	  greater	  in	  patients	  with	  cirrhosis	  than	  in	  those	  without	  liver	  disease	  (158)	  
Ben-­‐Ari	  et	  al	  evaluated	  hypercoagulability	  in	  patients	  with	  primary	  biliary	  cirrhosis	  (PBC)	  and	  
primary	  sclerosing	  cholangitis	  (PSC)	  using	  TEG.	  28%	  of	  patients	  with	  PBC	  and	  43%	  of	  patients	  
with	   PSC	   were	   found	   to	   be	   hypercoagulable	   compared	   to	   only	   5%	   of	   non	   cholestatic	  
cirrhosis	  and	  none	  in	  healthy	  controls.	  (32)	  In	  contrast,	  INR	  did	  not	  differ	  between	  patients	  
with	   cholestatic	   versus	   non	   cholestatic	   cirrhosis.	   These	   observations	   may	   explain	   why	  
patients	   with	   PSC	   and	   PBC	   have	   fewer	   bleeding	   complications	   and	   lower	   intraoperative	  
transfusion	   requirements	   during	   liver	   transplantation.	   The	   relative	   hypercoagulability	   is	  
ascribed	   to	   increased	   platelet	   reactivity	   and	   higher	   fibrinogen	   concentrations	   in	   patients	  
with	  cholestatic	  liver	  disease	  (33)	  
	  In	  a	  prospective,	  observational	  study	  	  in	  non	  alcoholic	  fatty	  liver	  disease	  (NAFLD)	  using	  TEG,	  
a	   significantly	   stronger	   clot	   development	   was	   found	   in	   patients	   compared	   to	   healthy	  
controls	  (MA	  58.3	  +-­‐6.3vs52+-­‐10	  mm	  p=0.01,)	  	  and	  	  the	  platelet	  contribution	  to	  overall	  clot	  
strength	  was	  higher	  in	  NAFLD	  	  patients	  with	  a	  trend	  to	  reduced	  inducible	  clot	  lysis	  (p=0.03)	  
(159).	  It	  has	  been	  well	  described	  that	  patients	  with	  NAFLD	  are	  relatively	  prothrombotic	  and	  
have	  an	  increased	  incidence	  of	  thrombosis	  (160).	  	  In	  a	  prospective	  study	  in	  23	  patients	  with	  
obstructive	  jaundice,	  80%	  were	  found	  to	  be	  hypercoagulable	  on	  TEG	  analysis	  (increased	  MA)	  
and	  this	  was	   independent	  of	  prolonged	  PT	  times.	  A	  repeat	  TEG	  three	  weeks	  after	  a	  biliary	  
drainage	  procedure,	  showed	  all	  TEG	  parameters	  had	  returned	  to	  normal	  range.(161)	  




The	   clinical	   implications	   of	   these	   findings	   have	   yet	   to	   be	   evaluated.	   However,	   emerging	  
evidence	   suggests	   that	   hypercoagulability	   detected	   by	   VET	   puts	   patients	   in	   an	   “at	   risk”	  
group	  for	  both	  venous	  and	  arterial	  thrombotic	  events.	  (134,	  162,	  163)	  .	  A	  recent	  systematic	  
review	  of	  10	  studies	  in	  surgical	  patients	  showed	  an	  increased	  MA	  to	  be	  the	  most	  important	  
parameter	  to	  predict	  postoperative	  TE	  events.	  However,	  there	  was	  considerable	  variability	  
as	   to	   which	   parameters	   were	   used	   to	   define	   hypercoagulability	   and	   no	   study	   was	  
adequately	  powered.	  Nevertheless,	  the	  vast	  majority	  of	  patients	  who	  had	  a	  TE	  event	  were	  
hypercoagulable	  on	  one	  or	  more	  TEG	  parameters	  (164)	  and	  future	  prospective	  studies	  are	  
recommended.	  
3.3	  Viscoelastic	  Tests	  and	  Acute	  Liver	  Disease	  (ALD)	  
	  
3.3.1	  VET	  parameters	  and	  ALD	  	  
In	  over	  1000	  patients	   reviewed	  by	  The	  Acute	  Liver	  Failure	  Study	  Group	   (ALFSG)	   the	  mean	  
INR	  was	  3.8	  (165)	  Patients	  with	  ALF	  are	  assumed	  to	  have	  a	  bleeding	  diathesis	  based	  on	  an	  
elevated	  INR.	  However,	  clinically	  significant	  bleeding	  is	  rare.	  	  Although	  blood	  clot	  formation	  
by	  TEG	  is	  generally	  preserved	  in	  stable	  patients	  with	  cirrhosis	  (29)	  patients	  with	  acute	  liver	  
injury	  (ALI)	  and	  ALF	  have	  not	  been	  extensively	  studied.	  
As	  an	  ancillary	  project	  of	  the	  ALFSG,	  Stravitz	  prospectively	  studied	  51	  patients	  with	  ALI/ALF	  
with	   kaolin	   initiated	   TEG	   (166).	   Despite	   a	   mean	   INR	   of	   3.4	   (range	   1.5	   -­‐9.6)	   mean	   TEG	  
parameters	  were	  within	  normal	   limits	   for	   the	  entire	   study	  population,	  and	  all	  5	   individual	  
TEG	  parameters	  were	  completely	  normal	  in	  63%	  of	  patients	  suggesting	  that	  the	  dynamics	  of	  
clot	   formation	   are	   generally	   well	   preserved.	   Moreover,	   8%	   of	   patients	   were	  
hypercoagulable.	  The	  TEG	  was	  significantly	  more	  sensitive	  than	  INR	  for	  predicting	  bleeding,	  




with	  the	  R	  time	  being	  significantly	  more	  prolonged	  in	  those	  that	  bled	  (6.4	  vs	  4.5	  secs)	  [Table	  




Table	  3.1	  TEG	  parameters	  and	  complications	  in	  patients	  with	  ALI/ALF	  	  (Todd	  Stravitz	  et	  al.	  
J	  Hepatology	  2011)	  
	  
The	  MA	  was	  higher	   in	  ALF	   than	  ALI	   and	  correlated	  with	   increasing	   severity	  of	   liver	   injury.	  	  
The	  preservation	  or	  even	  increase	  in	  MA	  in	  patients	  with	  ALI/ALF	  may	  be	  due	  to	  increased	  
factor	   VIII	   levels,	   decreased	   ADAMTS13	   activity,	   increased	   vWF	   and	   increased	   levels	   of	  
fibrinogen	  and	  or	  platelets	  as	  acute	  phase	   reactants.	  As	   the	   severity	  of	   the	  SIRS	   response	  
increased	  there	  was	  a	  corresponding	  increase	  in	  MA	  [Figure	  3.4].	  
	  





Figure	  3.4	  Change	  in	  MA	  with	  increasing	  severity	  of	  SIRS	  response	  
This	  important	  study	  demonstrates	  TEG	  parameters	  in	  ALF/ALI	  are	  generally	  well	  preserved	  
and	  potentially	  provides	  an	  explanation	  for	  why	  clinical	  bleeding	  is	  rare	  despite	  the	  elevated	  
INR.	  The	  authors	  conclude	   that	   INR,	  although	  a	  valid	   indicator	  of	  prognosis,	   is	  not	  a	  good	  
guide	  for	  administration	  of	  procoagulant	  therapy.	  
In	   a	   prospective	   study,	   in	   our	   own	   institution	   of	   20	   patients	   with	   ALF	   admitted	   to	   the	  
intensive	  care	  unit,	  coagulation	  analysis	  was	  performed	  on	  admission	  and	  at	  48	  hours.	  CCT	  
suggested	   a	   markedly	   hypocoagulable	   state	   with	   a	   significantly	   raised	   INR	   (mean	   4.3),	  
however	  TEG	  values	  were	  hypocoagulable	   in	  only	  20%	  of	  patients,	  whilst	  45%	  had	  normal	  
and	  35%	  had	  	  hypercoagulable	  profiles.	  	  All	  patients	  with	  hypocoagulable	  TEGs	  had	  platelet	  
counts	  <	  100,000	  (167).	  The	  fact	  that	  80%	  of	  these	  patients	  with	  ALF	  had	  normal,	  or	  even	  
hypercoagulable	  TEG	  profiles	  is	  evidence	  of	  the	  rebalancing	  of	  haemostasis,	  with	  the	  fall	  in	  
procoagulant	  levels	  counterbalanced	  by	  low	  levels	  of	  anticoagulant	  proteins,	  together	  with	  










Figure	  3.5	  Pro	  &	  anticoagulant	  levels	  in	  acute	  liver	  failure	  (Banwari	  et	  al.	  J	  Hepatology	  2012)	  
3.3.2	  Heparin	  like	  effect	  &	  ALF	  
A	  HLE	  is	  commonly	  seen	  in	  ALF	  (168,	  169).	  This	  HLE	  is	  thought	  to	  be	  due	  to	  the	  release	  of	  
endogenous	  heparinoids	   	   and	   reflects	   the	  vascular	  endothelial	   injury	   	   inherent	  with	  acute	  
liver	   injury	   .	   In	  ALF,	  the	  R	  time	   is	  significantly	   increased	   in	  the	  presence	  of	   infection,	  renal	  
failure	  and	  in	  those	  with	  bleeding	  complications	  (166).	  In	  an	  observational	  study	  comparing	  
TEG	  parameters	  in	  ALF	  to	  those	  in	  cirrhosis,	  Senzolo	  et	  al	  found	  that	  R	  and	  K	  time	  and	  alpha	  
angle	   on	   native	   TEGs	  were	   significantly	  more	   hypocoagulable	   in	   ALF	   patients	   undergoing	  
OLT	  compared	  to	  control	  stable	  patients	  with	  cirrhosis.	  These	  TEG	  changes	  were	  ascribed	  to	  
endogenous	  heparinoids	  as	  heparinase	  reversed	  these	  differences	  (170).	  	  Using	  the	  TEG	  “V”	  
curve	   as	   a	   surrogate	   for	   thrombin	   generation,	   TTG	   was	   generally	   found	   to	   be	   similar	   to	  
normal	   controls.	   Therefore,	   although	   endogenous	   heparinoids	   slow	   the	   velocity	   of	   initial	  




clot	   formation,	   they	  did	  not	  ultimately	  affect	   final	   clot	   strength.	  Heparinase	  modified	  TEG	  
should	  be	  considered	  as	  a	  useful	  adjunct	  in	  the	  assessment	  of	  coagulopathy	  in	  ALF.	  
3.4	  Anticoagulation	  and	  Liver	  Disease	  
Patients	   with	   liver	   failure	   have	   traditionally	   been	   managed	   with	   no,	   or	   minimal	  
anticoagulation,	  because	   the	  abnormal	  clotting	   tests	  are	  perceived	   to	   reflect	  an	   increased	  
bleeding	  risk.	  However,	  patients	  with	  cirrhosis	  can	  develop	  DVT	  despite	  a	  prolonged	  INR	  and	  
can	  do	  so	  even	  when	  receiving	  antithrombotic	  prophylaxis	  (171).	  In	  addition,	  as	  many	  as	  5-­‐
20%	  of	  patients	  with	  advanced	  liver	  disease	  will	  develop	  portal	  vein	  thrombosis	  (PVT)	  each	  
year	   (172).	  Anticoagulant	  drugs	  should	  be	  administered	  with	  caution	   in	  patients	  with	   liver	  
disease.	   The	   bioavailability	   of	   heparin	   and	   LMWH	   cannot	   be	   assumed	   to	   be	   stable	   in	  
patients	  with	  liver	  disease	  as	  this	  will	  be	  affected	  by	  fluctuations	  in	  liver	  synthetic	  function	  
and	  also	  changes	  in	  hepatic	  clearance	  and	  renal	  function(173).	  Anticoagulation	  with	  heparin	  
to	  reduce	  the	  incidence	  of	  vascular	  thrombosis	  after	  liver	  transplantation,	  is	  well	  known	  to	  
be	   difficult	   to	   control,	   and	   despite	   monitoring	   ACT	   levels	   ,	   neither	   thrombotic,	   and	  
particularly	   bleeding	   complications,	   are	   avoided	   (173).	   Alternative	  methods	   of	  monitoring	  
the	  anticoagulant	  status	  in	  these	  patients	  is	  a	  real	  necessity,	  that	  is	  yet	  unmet.	  It	  is	  known	  
that	  patients	  with	  cirrhosis	  show	  an	  increased	  response	  to	  LMWH	  and	  this	  correlates	  with	  
the	  severity	  of	  liver	  disease.	  (174)	  
LMWH	  are	  routinely	  prescribed	  for	  VTE	  prophylaxis	  in	  general	  medical	  and	  surgical	  patients	  
in	  a	  standardised	  dose	  and	  monitoring	  is	  generally	  thought	  to	  be	  unnecessary.	  	  However,	  in	  
patients	   with	   liver	   disease,	   effective	   and	   safe	   dosing	   is	   more	   problematic.	   Anti-­‐factor	   Xa	  
levels	  are	  the	  gold	  standard	  for	  monitoring	  LMWH	  activity	  but	  these	  tests	  are	  not	  routinely	  
available,	   they	  are	  expensive	  and	  standardisation	  between	  different	   laboratories	   can	  be	  a	  




problem	  (175).	  In	  addition	  monitoring	  anti-­‐Xa	  levels	  in	  cirrhosis	  is	  unreliable	  due	  to	  the	  low	  
levels	   of	   antithrombin(176).	   An	   increasing	   number	   of	   published	   papers	   suggest	   that	   VET	  
may	   be	   a	   useful	  way	   to	   assess	   the	   efficacy	   of	   LMWH	   therapy	   in	   general	   surgical	   patients	  
with	  various	  co-­‐mobidities	  that	  will	  affect	  the	  pharmacokinetics	  of	  these	  drugs	  .	  Van	  et	  al,	  
measured	  	  anti-­‐factor	  Xa	  levels	  and	  performed	  simultaneous	  kaolin	  and	  heparinase	  TEGS	  in	  
61	  surgical	  ICU	  patients	  (261	  time	  points)	  all	  receiving	  prophylactic	  therapy	  with	  Enoxaparin:	  
17	  patients	  developed	  a	  DVT.	  Overall	  there	  was	  a	  mean	  increase	  in	  TEG	  R	  value	  in	  the	  kaolin	  
trace	   compared	   to	   the	   heparinase	   trace,	   demonstrating	   that	   TEG	   is	   able	   to	   quantify	  
functional	   anticoagulation.	   In	   the	   group	   that	   developed	   a	   DVT,	   there	   was	   no	   significant	  
difference	   between	   R	   values	   of	   kaolin	   TEG	   and	   heparinase	   TEG,	   suggesting	   that	   these	  
patients	  were	  not	   receiving	  adequate	   thromboprophlyaxis(177).	   	  Performing	  simultaneous	  
kaolin	  and	  heparinase	  TEGs	  appears	  to	  be	  a	  sensitive	  methodology	  for	  detecting	  evidence	  of	  
anticoagulation	   with	   LMWH,	   and	   at	   the	   low	   doses	   used	   for	   prophylaxis	   is	   a	   better	  
differentiator	  than	  anti-­‐factor	  Xa.	  
A	  recent	  prospective	  randomised	  control	  study	  of	  fixed	  dose	  prophylactic	  LMWH	  versus	  no	  
therapy	   administered	   for	   one	   year	   in	   70	   patients	   with	   advanced	   cirrhosis,	   demonstrated	  
that	  no	  patients	  in	  the	  enoxaparin	  group	  developed	  PVT	  compared	  with	  17%	  in	  the	  control	  
group.	  In	  addition,	  the	  incidence	  of	  documented	  bacterial	  infections	  was	  significantly	  lower	  
in	   the	   enoxaparin	   group	   (8.8%	   vs	   33.3%).	   Surprisingly,	   there	   were	   no	   reports	   of	  
haemorrhagic	   complications	   in	   the	   treated	   group.(178)	   This	   study	   raises	   interesting	  
hypothesis	   as	   to	  whether	   LMWH	  act	  by	   improving	   intestinal	  microcirculation	  and	   thereby	  
reduce	   the	   frequency	   of	   portal	   endotoxaemia.	   In	   addition,	   it	   is	   possible	   that	   systemic	  
anticoagulation	  reduces	  the	  formation	  of	  intrahepatic	  microthrombi	  which	  are	  implicated	  in	  




the	   progression	   of	   portal	   hypertension	   and	   parenchymal	   extinction	   over	   time	   (179).	   The	  
ability	   to	   monitor	   the	   efficacy	   and	   safety	   of	   anticoagulant	   therapy	   in	   patients	   with	   liver	  
disease	  is	  becoming	  a	  real	  clinical	  dilemma,	  a	  challenge	  that	  could	  be	  met,	  in	  part,	  by	  using	  
point	  of	  care	  viscoelastic	  tests	  of	  coagulation.	  
It	   is	  known	  that	  following	   liver	  transplantation,	  there	  can	  be	  a	  temporary	  hypercoagulable	  
state,	  due	  to	  the	  imbalance	  between	  pro	  and	  anticoagulant	  systems	  and	  the	  post	  operative	  
fibrinolytic	  shutdown(180).	  It	  has	  been	  suggested	  that	  these	  haemostatic	  changes,	  as	  well	  as	  
technical	  and	  surgical	   factors,	  may	  have	  a	   role	   in	   the	  early	  development	  of	  hepatic	  artery	  
thrombosis	   (HAT)(181).	   	   In	   an	   observational	   study	   of	   298	   liver	   transplant	   patients,	   high	  
fibrinogen	  levels	  and	  low	  protein	  C	  levels	  were	  significantly	  associated	  with	  post-­‐transplant	  
thrombotic	  events(182).	  The	  optimal	  anticoagulant	  regime	  in	  these	  patients	  is	  still	  an	  open	  
question,	  and	  in	  the	  first	  week	  post	  transplantation	  using	  heparin	  with	  monitoring	  based	  on	  
CCT	   still	   leads	   to	   significant	   bleeding	   complications	   	   in	   certain	   patients	   (173,	   183).	   Large	  
scale	  prospective	  outcome	  studies	  are	  necessary	  to	  evaluate	  the	  impact	  of	  VET	  in	  managing	  
thromboprophylaxis	   in	   these	   groups	   of	   patients.	   Anticoagulant	   therapy	   in	   patients	   with	  
Budd	   Chiari	   syndrome	   (BCS)	   is	   also	   challenging	   and	   major	   bleeding,	   especially	   during	  
invasive	  procedures,	  is	  common	  (184).	  	  A	  recent	  case	  report	  of	  a	  complex	  patient	  with	  BCS	  
and	   a	   TIPS	   occluded	   with	   thrombus,	   describes	   the	   use	   of	   TEG	   to	   guide	   the	   successful	  
management	  of	  anticoagulant	  therapy	  	  and	  resultant	  re-­‐canalisation	  of	  the	  stent(185).	  
3.5	  Conclusions	  
The	   complex	   haemostatic	   changes	   that	   occur	   in	   liver	   disease	   are	   difficult	   to	   assess	   using	  
conventional	  coagulation	  tests.	  These	  tests	  are	  known	  to	  be	  poor	  predictors	  of	  bleeding	  risk	  
and	   also,	   importantly,	   thrombosis.	   Consequently,	   the	   routine	   use	   of	   CCT	   to	   assess	  




coagulation	  in	  patients	  with	  liver	  disease	  needs	  to	  be	  re-­‐assessed.	  VET	  have	  been	  used	  for	  
coagulation	  monitoring	  and	  to	  guide	  haemostatic	  therapy	  in	  liver	  transplantation	  for	  many	  
years,	  but	  to	  date	  they	  have	  not	  been	  used	  to	  any	  great	  extent	  in	  hospitalised	  patients	  with	  
liver	   disease.	   The	   summative	   information	  provided	  by	   these	   tests	   has	   the	  potential	   to	   be	  
used	  in	  future	  clinical	  studies	  to	  determine	  a	  means	  of	  stratifying	  bleeding	  and	  thrombotic	  
risk	  in	  these	  patients.	  It	  is	  clear	  that	  haemostasis	  is	  critically	  dependent	  on	  platelet	  number	  
and	  function	  and	  fibrin	  clot	  formation,	  which	  are	  not	  evaluated	  by	  CCT.	  The	  current	  lack	  of	  
randomised	  controlled	  trials	  of	  coagulopathy	  in	  liver	  disease	  is	  largely	  due	  to	  the	  inability	  to	  
develop	  satisfactory	  surrogate	  end	  points	  in	  measuring	  coagulation.	  Global	  coagulation	  tests	  
such	  as	  TEG/ROTEM	  could	  provide	   the	  basis	  on	  which	   to	  develop	   such	  criteria.	   It	   is	   to	  be	  
hoped	   that	   the	   new	   understanding	   of	   the	   haemostatic	   changes	   in	   liver	   disease,	   together	  
with	  the	  knowledge	  that	  VET	  give	  more	  clinically	  relevant	  and	  comprehensive	  	  information	  
than	   conventional	   coagulation	   tests	   will	   stimulate	   interest	   in	   producing	   the	   large	  
prospective	  outcome	  studies	  that	  are	  needed	  to	  establish	  the	  clinical	  utility	  of	  VET	   in	   liver	  
disease	  and	  to	  determine	  threshold	  values	  of	  VET	  that	  predict	  bleeding	  or	  thrombosis	  and	  
thus	  optimise	  haemostatic	  and	  antithrombotic	  interventions.	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4.1	  Bleeding	  and	  coagulopathy	  during	  Liver	  Transplantation.	  
Historically	   liver	  transplantation	  (LT)	  was	  accompanied	  by	  substantial	  blood	   loss,	  however,	  
improvements	   to	   all	   aspects	   of	   the	   process,	   from	   graft	   preservation	   through	   to	   surgical	  
techniques	   and	   anaesthetic	   management,	   have	   led	   to	   an	   increasing	   number	   of	   patients	  
being	   able	   to	   undergo	   LT	   without	   the	   need	   for	   transfusion	   of	   red	   blood	   cells	   or	   blood	  
products	   (3,	   186),	   although	   there	   continues	   to	   be	   a	   small,	   but	   significant	   proportion	   of	  
patients	  that	  will	  require	  massive	  transfusion.	  	  
Marked	   variations	   in	   inter-­‐institutional	   transfusion	   requirements	   for	   LT	   still	   persist	   (187).	  
Varying	   transfusion	   thresholds,	   particularly	   in	   relation	   to	   the	   use	   of	   fresh	   frozen	   plasma	  
(FFP),	   differences	   in	   the	  way	   coagulation	   is	   (or	   is	   not)	  monitored,	   the	   use	   of	   cell	   salvage,	  
fluid	  management	  strategies,	  and	  use	  of	  anti-­‐fibrinolytic	  therapy,	  all	  lead	  to	  wide	  variations	  
in	  blood	  product	  use	  (97,	  188).	  Preoperative	  hemoglobin	  is	  the	  most	  significant	  predictor	  of	  
the	  need	  for	  red	  cell	  transfusion	  (189).	  Fluid	  management	  is	  very	  important,	  and	  restrictive	  
fluid	  administration	  in	  the	  dissection	  phase	  can	  minimise	  haemodilution,	  with	  associated	  fall	  
in	  haemoglobin	  and	  	  clotting	  factor	   levels,	  as	  well	  as	   limiting	  rises	   in	  splanchnic	  and	  portal	  
pressure	   that	   will	   exacerbate	   bleeding.	   The	   aetiology	   of	   liver	   failure	   is	   an	   independent	  
parameter	   for	   the	  prediction	  of	  massive	  blood	   loss,	   	   for	  example	  patients	  with	  cholestatic	  
liver	   disease	   have	   reduced	   bleeding	   risk	   compared	   to	   patients	   with	   viral	   or	   alcoholic	  
cirrhosis	   	  (190).	   It	   is	  well	  known	  that	  preoperative	  PT/INR	  is	  not	  predictive	  of	  the	  need	  for	  
transfusion,	   although	   there	   is	   a	   suggestion	   that	   higher	   values	   of	   INR	   (>2.0)	   may	   be	  
associated	   with	   an	   increased	   bleeding	   risk	   (191).	   It	   is	   of	   note	   that	   transplant	   units	   that	  
report	   the	   lowest	   rate	   of	   blood	   and	   blood	   product	   use,	   have	   adopted	   aggressive	   fluid	  




restriction,	   tolerance	   of	   low	  haemoglobin	   thresholds,	   and	   treat	   only	  when	   there	   is	   active	  
bleeding,	  avoiding	  prophylactic	  therapy	  (3).	  
	  There	   is	  an	  obvious	  need	  to	  develop	  consensus	  guidelines	   for	   transfusion	  practice	   in	   liver	  
transplantation	   and	   to	   determine	   which	   method	   of	   coagulation	   monitoring	   and	   which	  
transfusion	  thresholds	  are	  optimal	   (192).	  The	   inverse	  relationship	  between	  the	  number	  of	  
units	  of	  RBC	   transfused	   intraoperatively,	   and	  patient	   survival	   is	  well	   known,	   consequently	  
any	  reduction	  in	  transfusion	  requirements	  will	   impact	  positively	  on	  patient	  outcome	  (193).	  
The	   concepts	   of	   Patient	   Blood	   Management	   programs,	   with	   a	   multimodal	   approach	   to	  
limiting	   inappropriate	   and	   unnecessary	   transfusions,	   should	   be	   advanced	   for	   all	   surgical	  
procedures,	  including	  liver	  transplantation	  ,	  as	  this	  leads	  to	  reduced	  exposure	  to	  allogeneic	  	  
products,	  with	   their	   immunomodulatory	   and	   other	   adverse	   consequences,	   and	   ultimately	  
reduces	  hospital	  costs	  (194).	  	  
4.2	  Viscoelastic	  tests	  and	  coagulation	  management	  in	  Liver	  Transplantation	  
	  
Coagulation	  monitoring	  with	   TEG/ROTEM	   can	   reduce	   overall	   transfusion	   requirements	   as	  
empirical	  therapy	  is	  eliminated	  and	  specific	  management	  of	  coagulation	  defects	  is	  instituted	  
at	  an	  early	  stage.	  (83,	  195).	  TEG-­‐guided	  transfusion	  algorithms	  to	  treat	  coagulopathy	  in	  OLT	  
were	   first	   introduced	   in	   the	   early	   1980’s	   by	   Kang	   at	   the	   University	   of	   	   Pittsburgh,	   who	  
showed	  that	  using	  an	  algorithm	  based	  on	  TEG,	  transfusion	  requirements	  were	  reduced	  by	  
30%	   compared	   to	   an	   historical	   cohort	   (83).	   In	   the	   context	   of	   bleeding	   during	   liver	  
transplantation,	   VETs	   are	   	   particularly	   useful	   for	   detecting	   the	   presence	   of	   systemic	  
fibrinolysis,	   and	   to	   also	   to	   detect	   poor	   clot	   strength,	   which	   is	   often	   the	   result	   of	   low	  
fibrinogen	  levels	  (196).	  Although	  there	  is	  moderate	  to	  good	  correlation	  of	  MCF	  with	  Clauss	  
fibrinogen	   (r=	  0.59)	   and	   	   platelet	   count	   (r=	  0.79),	   there	   is	   no	   correlation	  between	  CT	  and	  




PT/INR	  (r=0.22)(138)	  	  This	  consistent	  finding	  questions	  the	  routine	  use	  of,	  and	  need	  for	  FFP	  
in	   liver	   transplantation.	   Unless	   there	   is	   massive	   haemorrhage,	   the	   use	   of	   FFP	   may	   be	  
counterproductive	   as	   the	   volume	   loading	   will	   increase	   splanchnic	   pooling	   and	   portal	  
pressures	  and	  may	  increase	  blood	  loss	  (197).	  	  	  
Serial	   coagulation	  monitoring	  with	   VET	   can	   detect	   early	   deterioration	   of	   coagulation	   and	  
facilitates	  goal	  directed	  treatment	  therapy.	  (198)	  Roullet	  et	  al	  in	  a	  prospective	  observational	  
study	  of	  23	  patients	  undergoing	  liver	  transplantation	  compared	  standard	  coagulation	  tests,	  
coagulation	   factor	   levels	   (II,V,X	   and	   VIII	   and	   anti-­‐thrombin)	   	   and	   Euglobin	   clot	   lysis	   time	  	  
(ECLT)	  and	  PAI	  with	  ROTEM	  analysis	  (EXTEM,	  INTEM,	  APTEM	  and	  FIBTEM)	  at	  6	  time	  points	  
during	   the	  procedure.	  Clot	   amplitude	  on	  EXTEM	  at	  10	  minutes	   (A10)	   correlated	  well	  with	  
platelet	   count	   (R2=0.46)	   and	   fibrinogen	   (R2=0.52)	   and	   FIBTEM	   A10	   showed	   moderate	  
correlation	  with	  Clauss	   fibrinogen	   (R2	   =0.55)	  ROC	  analysis	   showed	   that	  EXTEM	  A10	  with	  a	  
threshold	  of	  26mm	  predicted	  hypofibrinogenaemia	  with	  a	  sensitivity	  of	  83%	  and	  specificity	  
of	   75%	   (199).	   The	   authors	   concluded	   that	   ROTEM	   is	   helpful	   for	   the	   detection	   of	  
hypofibringinaemia	  and	  thrombocytopenia.	  Blasi	  et	  al,	  in	  a	  prospective	  observational	  study	  
of	  236	  patients	  undergoing	  liver	  transplantation,	  found	  that	  whilst	  the	  MCF	  was	  reliably	  able	  
to	  detect	  low	  platelet	  and	  fibrinogen	  levels,	  correlation	  of	  CT	  and	  PT	  was	  poor	  and	  therefore	  
more	   studies	   are	   required	   to	   determine	  when	   FFP	   should	   be	   administered	   based	   on	   VET	  
(200).	  A	  recent	  small	  randomised,	  prospective	  study	  in	  28	  OLT	  patients	  showed	  a	  significant	  
reduction	  in	  transfusion	  in	  the	  TEG	  monitored	  group,	  most	  notably	  for	  the	  use	  of	  FFP,	  as	  the	  
trigger	  threshold	  for	  transfusion	  was	  reached	  much	  more	  frequently	  using	  conventional	  INR	  
values	   compared	   to	   R	   values	   on	   TEG	   (201).	   However	   transfusion	   trigger	   thresholds	  
described	   for	  viscoelastic	   tests	  have	  not	  been	  validated,	  and	   large	  controlled	  clinical	   trials	  




comparing	  strategies	  of	  coagulation	  management	  and	  cut	  off	  values	  for	  transfusion	  of	  blood	  
product	   components	   are	   needed	   (202).	   Transfusion	   algorithms	   using	   specific	   trigger	  
thresholds	  developed	  for	  use	  with	  the	  ROTEM	  are	  not	  directly	  transferable	  to	  TEG	  and	  vice	  
versa	  (97)	  
A	  prospective	   	  observational	   study	  of	  20	  OLT	  patients	   	   found	   that	   fibrinogen	   replacement	  	  
therapy	   	   based	   on	   VET	   reduced	   the	   requirement	   for	   platelet	   and	   red	   cell	   transfusion	  
compared	  to	  historical	  	  controls	  (120)	  Plasma	  fibrinogen	  levels	  control	  the	  mass	  amount	  of	  
fibrin	  formed	  by	  thrombin,	  and	  hence	  clot	  strength,	  and	  assessment	  of	  fibrinogen	  by	  VET	  is	  
critical	  for	  managing	  bleeding	  .	  
Prophylactic	   recombinant	   activated	   factor	   VII	   has	   not	   been	   found	   to	   reduce	   transfusion	  
requirements	  in	  OLT	  (203),	  but	  it	  is	  still	  occasionally	  used	  as	  “rescue	  therapy”	  in	  situations	  of	  
uncontrolled	  blood	  loss.	  It	  is	  of	  note	  that	  when	  POC	  coagulation	  testing	  with	  VET	  is	  routine,	  
there	  is	  rarely	  any	  necessity	  to	  use	  rVIIa	  as	  rescue	  therapy	  (107).	  Although	  rVIIa	  does	  effect	  
the	   physical	   properties	   of	   the	   clot	   as	  measured	   by	   VET,	   this	   does	   not	   necessarily	   reduce	  
transfusion	  and	  may	  lead	  to	  more	  thromboembolic	  events,	  especially	  arterial	  TE	  (204).	  In	  a	  
small	   pilot	   study	   in	   OLT	   patients,	   Hendriks	   et	   al.	   found	   that	   80mcg/Kg	   of	   recombinant	  
activated	  factor	  VIII	  shortened	  the	  INR	  and	  also	  reduced	  	  the	  R	  value	  and	  increased	  	  the	  α	  
angle	  and	  	  MA	  on	  the	  TEG(205),	  	  but	  did	  not	  affect	  transfusion	  requirements.	  
The	  use	  of	  goal-­‐orientated	  algorithms	  based	  on	  VET	  facilitate	  targeted	  transfusion	  therapies	  
with	   specific	   haemostatic	   agents	   and	   avoids	   the	   empirical	   administration	   of	   multiple	  
components	  with	  potentially	  hazardous	  effects	  ,	  and	  are	  recommended	  (Grade	  1C)	  in	  recent	  
guidelines	   for	   the	  management	   of	   severe	   bleeding	   (206).	   The	   short	   turn-­‐around	   times	   of	  
VET	   (10-­‐20	   minutes)	   are	   important	   for	   guiding	   therapy	   and	   preventing	   inappropriate	  




transfusion	  during	  surgery	  and	  on	  the	   ITU	  (207).	  The	  use	  of	  algorithms,	  although	  reducing	  
transfusion	  requirements	  compared	  to	  historical	  cohorts,	  often	  leads	  to	  changes	  in	  the	  type	  
and	   amount	   of	   hemostatic	   support	   given,	   with	   many	   European	   units	   using	   increasing	  
amounts	   of	   factor	   concentrates,	   including	   prothrombin	   complex	   concentrates	   (PCCs)	   and	  
fibrinogen	   concentrates	   (196,	   208).	   	   Monitoring	   coagulation	   with	   basic	   VETs,	   without	  
assessment	   of	   fibrinogen	   (FIBTEM	   or	   TEG	   functional	   fibrinogen)	   can	   lead	   to	   increased	  
transfusion	   of	   platelets	   to	   increase	   the	   MA/MCF	   (209).	   Using	   VETs	   to	   specifically	   assess	  
fibrinogen	   levels	   can	   avoid	   platelet	   transfusion,	   where	   goal-­‐directed	   substitution	   of	  
fibrinogen	   is	   more	   appropriate.	   This	   is	   especially	   important	   in	   liver	   transplantation	   as	  
platelet	   transfusion	   is	   associated	   with	   significant	   reductions	   in	   one	   year	   survival	   (36).	  
Although	  there	  does	  not	  appear	  to	  be	  increased	  risk	  of	  thromboembolic	  events	  as	  a	  result	  of	  
using	  fibrinogen	  concentrates,	  there	  remains	  some	  concern	  about	  the	  safety	  profile	  of	  PCCs,	  
as	   in	   the	   setting	   of	   trauma,	   it	   has	   been	   demonstrated	   that	   in	   patients	   receiving	   PCC,	  
compared	   to	   those	   that	   did	   not,	   endogenous	   thrombin	   potential	   is	   increased	   for	   several	  
days	   post	   operatively,	   and	   also	   that	   Antithrombin	   (AT)	   levels	   remain	   low,	   implying	   a	  
potential	  prothrombotic	  state	  not	  reflected	  by	  standard	  coagulation	  tests	  (210).	  The	  results	  
of	  the	  PROTON	  study,	  a	  randomised	  controlled	  study	  of	  PCC	  in	  LT	  are	  awaited	  with	  interest	  
(211).	  	  
There	  may	  well	  be	  a	  place	   for	  PCC	   in	   treating	   severe	  clotting	   factor	  deficiency,	   such	  as	   in	  
dilutional	   coagulopathy,	  where	   there	   is	  marked	   prolongation	   of	   the	   R/CT	   and	   loss	   of	   the	  
normal	  thrombin	  generation	  profile	  on	  VET	   	   (increased	  K/CFT	  and	  decreased	  α	  angle),	  but	  
this	  needs	  to	  be	  validated	  in	  future	  trials.	  It	  took	  a	  number	  of	  years	  before	  the	  increased	  risk	  
of	   arterial	   TE	   events	   associated	   with	   the	   use	   of	   recombinant	   factor	   VIIa	   (rFVIIa)	   was	  




recognized	   ,	   another	   drug	   that	   acts	   by	   enhancing	   thrombin	   generation	   (212).	   It	   is	   now	  
recommended	  that	  rFVIIa	  should	  only	  be	  used	  as	  rescue	  therapy	  (206),	  and	  as	  noted	  above,	  
the	  need	  to	  	  use	  rFVIIa	  in	  the	  circumstances	  of	  uncontrolled	  haemorrhage,	  is	  	  virtually	  	  never	  
necessary	  when	   coagulation	   is	   routinely	  monitored	  with	  VET,	   suggesting	   that	   this	   type	  of	  
monitoring	  results	  in	  earlier,	  and	  more	  effective,	  haemostatic	  inteventions	  (213).	  	  
Although	  there	  are	  many	  reports	  of	  the	  success	  of	  VET	  monitoring	   in	  reducing	  transfusion	  
requirements	   in	   LT,	   this	   must	   be	   seen	   in	   the	   context	   that	   the	   majority	   of	   these	   studies	  
generally	  compare	  these	  results	  with	  historical	  cohorts,	  where	   in	  many	  cases,	   there	  was	  a	  
relatively	  high	  baseline	  transfusion	  rate	  (120,	  195,	  201).	  A	  more	  recent	  prospective	  study,	  of	  
60	   LT	   patients,	  with	   and	  without	  ROTEM	  monitoring,	   did	   not	   demonstrate	   any	   significant	  
differences,	  but	  overall	  transfusion	  was	  low,	  with	  a	  significant	  number	  of	  patients	  receiving	  
no	   transfusion	  at	  all	   (214).	   It	   is	  difficult	   to	  extrapolate	   the	   results	  of	  earlier	   studies	   to	   the	  
current	  situation,	  as	  bleeding	  and	  transfusion	  management	  continues	  to	  evolve	  with	  many	  
interrelated	   factors	   leading	   to	   lower	   transfusion	   rates.	   It	   is	   clear,	   however,	   that	   the	  
implementation	  of	  dedicated	  liver	  transplant	  anaesthesia	  teams	  and	  the	  use	  of	  transfusion	  
protocols	  leads	  to	  improved	  transfusion	  practice	  (215).	  	  
4.3	  Conclusions	  
The	   transfusion	   trigger	   thresholds	   described	   for	   VET	   have	   not	   been	   validated,	   and	   values	  
may	  need	  to	  be	  substantially	  outside	  normal	  ranges	  before	  intervention	  is	  indicated	  (216).	  A	  
small	  proportion	  of	  patients	  undergoing	  LT	  will	  inevitably	  have	  massive	  blood	  loss,	  and	  there	  
is	  no	  doubt	  that	  VET	  can	  be	  useful	  in	  these	  circumstances	  to	  facilitate	  goal-­‐directed	  therapy,	  
and	  assess	  the	  efficacy	  of	  any	  treatment	  intervention.	  Finally,	  the	  fact	  that	  up	  to	  60%	  of	  VET	  
traces	   in	   patients	   with	   chronic	   liver	   disease	   are	   within	   normal	   ranges,	   despite	  




hypocoagulable	  CCTs,	  is	  commensurate	  with	  the	  concept	  of	  “re-­‐balanced”	  hemostasis,	  and	  
the	   reality	   that	   an	   increasing	   number	   of	   patients	   are	   able	   to	   undergo	   this	  major	   surgery	  
without	  the	  need	  for	  blood	  or	  blood	  products.	  	  
Conventional	   coagulation	   tests	   are	   unable	   to	   give	   any	   useful	   information	   on	   either	  
fibrinolysis	  or	  the	  presence	  of	  hypercoagulability.	  We	  were	  interested	  in	  exploring	  in	  more	  
detail	  the	  area	  of	  diagnosing	  and	  managing	  fibrinolysis	  during	  liver	  transplantation,	  and	  the	  
implications	   for	   reducing	   bleeding,	   and	   also	   in	   determining	   the	   relative	   prevalence	   of	  
hypercoagulability	  and	  the	  possible	  implications	  for	  bleeding	  and	  thrombotic	  complications	  
in	  patients	  undergoing	  liver	  transplantation.	  These	  two	  areas	  are	  examined	  in	  further	  detail	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Chapter	  5	  	  
	  
Fibrinolysis	  during	  Liver	  Transplantation	  
	  
A	  retrospective	  cohort	  study	  in	  liver	  transplant	  patients	  
comparing	  prophylactic	  versus	  treatment	  only	  with	  anti-­‐
fibrinolytic	  drugs	  forms	  the	  basis	  of	  this	  chapter.	  This	  was	  
published	  in	  Liver	  Transplantation	  in	  2014.	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5.1	  Introduction	  	  
Increased	  fibrinolytic	  potential	  is	  well	  described	  in	  patients	  with	  chronic	  	  liver	  disease	  and	  it	  
is	   known	   that	   enhanced	   fibrinolytic	   activity	   can	   occur	   at	   any	   point	   during	   liver	  
transplantation,	  but	  particularly	  during	   the	  anhepatic	  period,	  due	   to	  high	   levels	  of	   	   tissue	  
plasminogen	   activator	   (tPA)	   as	   hepatic	   clearance	   is	   compromised	   (217).	   This	   is	   often	  
followed	   by	   a	   dramatic	   increase	   in	   tPA	   immediately	   after	   reperfusion,	   which	   can	   be	  
associated	   with	   explosive	   primary	   hyperfibrinolysis	   (218),	   with	   some	   patients	   developing	  
diffuse	  uncontrolled	  bleeding.	  In	  the	  presence	  of	  good	  graft	  function,	  hyperfibrinolysis	  after	  
reperfusion	  is	  usually	  self-­‐limiting	  and	  does	  not	  require	  treatment,	  but	  in	  the	  presence	  of	  a	  
poorly	   functional	   or	   marginal	   graft	   it	   may	   persist,	   and	   will	   require	   treatment	   with	  
antifibrinolytic	  drugs	  such	  as	  tranexamic	  acid	  (1-­‐2	  g)	  (219).	  Fibrinolysis	  is	  rarely	  seen	  in	  acute	  
liver	  failure	  due	  to	  the	  high	  levels	  of	  PAI-­‐1.	  (220)	  
The	   use	   of	   antifibrinolytic	   therapy	   with	   the	   lysine	   analogue	   epsilon	   aminocaproic	   acid	  
(EACA)	   to	   reduce	   blood	   loss	  was	   first	   described	   in	   liver	   transplantation	   (LT)	   in	   the	   1980’s	  
(83).	   The	   success	  of	   aprotinin,	   a	   serine	  protease	   inhibitor	  of	  plasmin,	   and	  at	  higher	  doses	  
kallikrein,	   in	   reducing	   bleeding	   in	   cardiac	   surgery,	   resulted	   in	   its	   being	   used	   in	   liver	  
transplantation	   in	   European	   centres	   from	   the	   early	   1990s	   onwards,	   with	   reports	   of	  	  
reduction	  in	  the	  incidence	  of	  bleeding	  caused	  by	  fibrinolysis,	  compared	  to	  historical	  cohorts	  
(221).	  The	  first	  multicenter	  randomized	  controlled	  study,	  by	  Porte	  et	  al	  (222),	  showed	  that	  
the	  intra-­‐operative	  use	  of	  aprotinin	  in	  patients	  undergoing	  OLT,	  significantly	  reduced	  blood	  
and	  blood	  product	  transfusion	  (FFP)	  requirements.	  A	  subsequent	  systematic	  review	  in	  2008	  
of	   the	   use	   	   of	   aprotinin	   in	   LT	   confirmed	   statistically	   lower	   transfusion	   requirements	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compared	   to	   control	   groups,	   with	   no	   difference	   in	   the	   incidence	   of	   thrombotic	   events,	  
however,	   there	  were	   concerns	   about	   the	   power	   of	   these	   studies	   to	   satisfactorily	   exclude	  
this	  risk	  (223).	  
	  
The	  potential	  for	  thrombotic	  adverse	  effects	  from	  the	  use	  of	  aprotinin	  in	  cardiac	  surgery	  had	  
been	  known	  for	  some	  time,	  and	  in	  2008,	  the	  publication	  of	  ‘The	  Blood	  Conservation	  Using	  
Antifibrinolytics	   in	   a	   Randomized	   Trial’	   (BART),	   showed	   a	   strong	   and	   consistent	   negative	  
mortality	   trend	   associated	  with	   aprotinin,	   compared	   to	   lysine	   analogues,	   resulting	   in	   the	  
study	  being	  terminated	  early	  (224,	  225).	  Case	  studies	  reported	  concerns	  about	  the	  potential	  
increased	  risk	  of	  thrombotic	  events	  in	  patients	  undergoing	  liver	  transplantation	  (226,	  227),	  
but	  a	  systematic	  review	  and	  meta-­‐analysis	  did	  not	  confirm	  this	  association	  (228),	  nor	  did	  a	  
subsequent	  observational	  study	  in	  over	  1400	  LT	  patients	  (229).	  	  Nevertheless,	  the	  data	  from	  
the	   cardiac	   studies	  was	   sufficiently	   compelling	   that	   the	   product	   license	   for	   aprotinin	  was	  
withdrawn	  in	  many	  countries,	  with	  the	  result	  that	  there	  was	  a	  virtually	  complete	  cessation	  
of	  use.	  	  
	  
Although	   the	   use	   of	   antifibrinolytic	   therapy	   was	   standard	   practice	   in	   many	   centres	   that	  
undertook	   liver	   transplantation,	   there	  was,	  and	   remains,	   significant	  variability	  as	   to	  which	  
drug	  was	  used,	   the	  dose	  required,	  and	  the	  timing	  of	  administration.	  At	   the	  time	  aprotinin	  
was	   withdrawn	   from	   the	  market,	   most	   European	   centres	   were	   using	   it	   in	   a	   prophylactic	  
regime	   in	   all	   high	   risk	   cases.	   The	   abrupt	   withdrawal	   of	   aprotinin	   from	   clinical	   use	   led	   to	  
concerns	  that	  this	  would	  lead	  to	  an	  increased	  risk	  of	  bleeding	  and	  transfusion	  requirements	  
during	   LT,	   and	   this	   fear	   appeared	   to	   be	   confirmed	   in	   an	   observational	   study	   comparing	  
transfusion	  requirements	  with	  aprotinin	  and	  then	  after	  its	  withdrawal	  from	  routine	  clinical	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practice	   (230).	   However,	   as	   blood	   transfusion	   requirements	   for	   LT	   were	   already	   steadily	  
decreasing	  to	  a	  mean	  of	  2-­‐4	  units	  per	  case,	  many	  transplant	  units,	  including	  our	  own,	  went	  
from	  a	  regime	  of	  prophylactic	  treatment	  with	  aprotinin	  or	  tranexamic	  acid	  (TA)	  	  to	  a	  policy	  
of	  treatment	  with	  TA	  only	  in	  the	  case	  of	  diffuse	  bleeding	  and/or	  evidence	  of	  fibrinolysis	  on	  
viscoelastic	  tests.	  	  	  
	  
5.2	  Aims	  of	  Study	  
The	   presence	   of	   fibrinolysis	   can	   be	   detected	   using	   thromboelastography	   or	  
thromboelastography,	  by	  assessing	  alterations	  in	  the	  clot	  lysis	  index.	  In	  our	  institution	  TEG	  
studies	  are	  run	  at	  multiple	  time	  points,	  according	  to	  a	  standardized	  protocol	  during	  the	  peri-­‐
operative	   period,	   and	   blood	   and	   blood	   product	   transfusion	   is	   recorded	   by	   stage	   of	   the	  
procedure.	  We	  sought	   to	   identify	   firstly	  whether	   the	  aprotinin	  ban	  had	  had	  a	  detrimental	  
effect	  on	  blood	  loss	  during	  liver	  transplantation	  in	  our	  patient	  population,	  and	  secondly	  to	  
determine	   the	   prevalence	   of	   fibrinolysis	   in	   the	   absence	   of	   prophylactic	   anti-­‐fibrinolytic	  




The	  routine	  use	  of	  aprotinin	  in	  our	  institution	  was	  stopped	  in	  2007.	  This	  study	  was	  based	  on	  
a	   retrospective	   analysis	   of	   patients	   undergoing	   liver	   transplantation,	   between	   2004	   and	  
2010.	  All	  data	  routinely	  collected	  in	  our	  liver	  transplant	  database	  is	  anonymized,	  and	  as	  all	  
patients	  consent	  a	  priori	  to	  data	  collection	  for	  research	  purposes,	  institutional	  approval	  for	  
this	  analysis	  was	  waived.	  Consecutive	  patients	   treated	  with	  aprotinin	  prior	   to	  2007	   (APRO	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group,	  n=100)	  were	  compared	  with	  a	  group	  in	  which	  aprotinin	  was	  not	  used	  after	  2007	  (NO-­‐
APRO	  group,	  n=100).	  	  Patients	  were	  excluded	  from	  this	  analysis	  if	  aprotinin	  was	  not	  used	  in	  
the	  first	  time	  period	  or	  if	  there	  was	  incomplete	  data	  for	  analysis.	  A	  cross	  over	  period	  of	  two	  
years	  was	  used,	  in	  which	  patients	  were	  not	  included,	  as	  there	  was	  sporadic	  use	  of	  aprotinin	  
during	   this	   time.	  During	   the	   first	   time	  period	   (01/05/2004	   -­‐01/06/2007)	   a	   total	   of	   188	   LT	  
were	  performed.	  During	   the	   second	  period	   	   (01/10/2009	  –	  01/12/2010)	   a	   total	   of	   121	   LT	  
were	  performed.	  Propensity	  score	  matching	  was	  performed	  on	  each	  group	  to	   identify	  two	  
matched	  cohorts,	  and	  patients	  were	  matched	  for	  primary	  diagnosis	  and	  model	  for	  end	  stage	  
liver	  disease	  (MELD).	  This	  resulted	  in	  two	  matched	  cohorts	  of	  55	  patients	  in	  each	  group.	  
	  
Information	  was	  gathered	  using	  the	  hospital	  liver	  transplant	  database	  and	  case	  note	  review.	  
Blood	   product	   usage	   by	   stage	   of	   procedure	  was	   recorded.	   	   Cell	   saver	   blood	   conservation	  
was	  used	  during	  all	  LT.	  The	  anaesthetic	  and	  surgical	  teams	  were	   largely	  unchanged	  during	  
the	   study	   period,	   and	   intra-­‐operative	   management	   remained	   similar,	   although	   in	   more	  
recent	  years	  there	  was	  a	  trend	  to	  more	  active	  fluid	  restriction	  during	  the	  dissection	  period.	  
Transfusion	  protocols	  were	  the	  same	  for	  all	  groups	  of	  patients	  using	  an	  algorithm	  based	  on	  
TEG	  and	  point	  of	  care	  testing	  of	  haemoglobin	  and	  platelet	  count,	  taken	  at	  set	  periods	  during	  
the	   procedure	   according	   to	   our	   institutional	   practice.	   A	   transfusion	   trigger	   threshold	   of	  
80g/l	  was	  used	  for	  red	  blood	  cells	  (RBC)	  transfusion,	  and	  blood	  products	  were	  administered	  
only	   in	   the	   presence	   of	   diffuse	   bleeding	   and	   abnormal	   TEG	   findings,	   or	   during	   massive	  
uncontrolled	  haemorrhage.	  A	  prolonged	  R	  value	  was	   treated	  with	  FFP,	  and	  a	   reduced	  MA	  
treated	   with	   either	   cryoprecipitate	   (or	   fibrinogen	   concentrate)	   or	   platelet	   transfusion,	  
depending	  on	  the	  cause	  of	  the	  reduced	  clot	  strength.	  The	  presence	  of	  fibrinolysis	  (clot	  lysis	  
index	  (CLI)	  at	  30	  minutes)	  was	  reviewed	  in	  all	  heparinase	  samples.	  Fibrinolysis	  was	  graded	  as	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none	   (CLI	  <15%),	  mild	   (CLI	  15-­‐30%),	  moderate	   (CLI	  30-­‐60%)	  and	  severe	   (CLI	  >60%)	   (Figure	  
5.1).	  	  
	  
The	   timing,	   usage	   and	   dose	   of	   alternative	   antifibrinolytic	   therapy	   	   (tranexamic	   acid)	   was	  
correlated	   with	   TEG	   findings	   and	   stage	   of	   surgery.	   Data	   for	   patients	   receiving	   a	   massive	  
transfusion	  (six	  or	  more	  units	  of	  packed	  red	  cells)	  were	  also	  reviewed.	  Wilcoxon	  matched-­‐
pairs	   were	   used	   for	   non-­‐parametric	   transfusion	   data	   analysis	   between	   the	   two	   groups.	  
Fishers	  exact	  2x2	  two-­‐tailed	  test	  were	  used	  for	  comparison	  of	  massive	  transfusion	  data	  and	  
presence	   of	   lysis	   between	   groups.	   For	   comparison	   of	   transfusion	   to	   lysis	   a	   four	   group	  
Kruskal-­‐Wallis	  test	  was	  used.	  Parametric	  data	  was	  analysed	  using	  unpaired	  t	  test.	  Values	  of	  
p<0.05	   were	   considered	   statistically	   significant.	   Statistical	   analysis	   was	   performed	   using	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1	  Mild	  Fibrinolysis:	  CLI	  60	  >15	  and	  <	  30	  
 
 
2	  Moderate	  Fibrinolysis:	  CLI60	  >30	  and	  <60	  
 
	  
3	  Severe	  Fibrinolysis:	  CLI60	  >	  60	  
	  
Figure	  5.1	  Grading	  of	  Fibrinolysis	  on	  basis	  of	  TEG	  traces	  	  
	  






Within	  the	  two	  groups,	  prior	  to	  propensity	  matching	  there	  was	  evidence	  of	  both	  increased	  age	  in	  the	  
second	  group,	  and	   increased	  use	  of	  DCD	  grafts.	  After	  propensity	  matching,	  a	  group	  of	  55	  patients	  
treated	  with	  aprotinin	  were	  compared	  with	  a	  similar	  group	  in	  which	  aprotinin	  was	  not	  used.	  Patient	  
demographics,	  reason	  for	  transplantation,	  graft	  type	  and	  MELD	  score	  are	  shown	  (Table	  4.1	  and	  4.2).	  	  
	  
Demographics	   	   Aprotinin	   	   No	  	  Aprotinin	   	   P-­‐Value	   	  
Age	   	   51.04	  (9.65)	   	   52.96	  (10.95)	   	   0.37	   	  
MELD	   	   15.51	  (7.16)	   	   16.22	  (7.92)	   	   0.62	   	  
Child	  Pugh	  	   	   8.47	  (2.12)	   	   8.45	  (2.35)	   	   0.97	   	  
Weight	  (Kg)	   	   74.22	  (16.03)	   	   79.24	  (16.06)	   	   0.18	   	  
BMI	   	   25.98	  (4.93)	   	   27.26	  (4.95)	   	   0.17	   	  
Cold	  Ischaemia	  time	  (min)	   	   532.4	  (149)	   	   475.2	  (176)	   	   0.07	   	  
DCD,	  DBD	   	   2,53	   	   2,53	   	   NS	   	  
	  
Table	  5.1	  Baseline	  characteristics	  of	  both	  groups	  [mean	  (standard	  deviation)]	  
	  
Primary	  Diagnosis	   Aprotinin	   No	  Aprotinin	   Significance	  
	  
Alchoholic	  Liver	  Disease	   20	   19	   NS	  
Hepatitis	  C	   14	   15	   NS	  
Primary	  Biliary	  Cirrhosis	   6	   6	   NS	  
Primary	  Sclerosing	  Cholangitis	   3	   3	   NS	  
Hepatitis	  B	   4	   4	   NS	  
Cryptogenic	  cirrhosis	   3	   3	   NS	  
Chronic	  rejection	   1	   1	  	   NS	  
Primary	  graft	  non	  function	   1	   1	   NS	  
Acute	  liver	  failure	   3	   3	   NS	  
	  
Secondary	  Diagnosis	  	  
	   	   	  
Hepatocellular	  Carcinoma	   9	   9	   NS	  
	  
Table	  5.2	  Primary	  and	  secondary	  diagnosis	  for	  both	  groups	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5.4.1	  Prevalence	  of	  Fibrinolysis	  
No	  patient	  in	  the	  aprotinin	  group	  developed	  fibrinolysis	  (CLI	  <15)	  during	  transplantation.	  In	  
the	   No-­‐APRO	   group,	   23.6%	   (n=13)	   of	   patients	   developed	   lysis	   at	   some	   stage	   during	   the	  
operative	   period,	   of	  which	   5	   patients	   had	  mild	   lysis,	   6	   had	  moderate	   and	   2	   patients	   had	  
severe	   lysis.	   This	   difference	   in	   fibrinolysis	   between	   groups	   was	   statistically	   significant	  
(p<0.0001).	  When	  the	  presence	  of	  lysis	  was	  analysed	  by	  stage	  of	  operation:	  	  33%	  occurred	  in	  
the	  dissection	  phase;	  27%	  in	  the	  anhepatic	  phase;	  and	  40%	  occurred	  during	  the	  reperfusion	  
stage.	  In	  the	  No-­‐APRO	  group,	  of	  the	  patients	  that	  developed	  lysis,	  85%	  (n=11)	  had	  only	  one	  
episode	   of	   lysis	   and	   15%	   (n=2)	   had	   lysis	   on	   two	   samples,	   which	   were	   both	   consecutive	  
samples.	   	   Tranexamic	   acid	   (TA))	  was	   used	   as	   an	   anti-­‐fibrinolytic	   in	   a	   dose	   of	   1-­‐2g	   in	   62%	  
(n=8)	  of	  the	  No-­‐APRO	  group	  in	  whom	  lysis	  was	  present,	  which	  resolved	  the	  fibrinolysis	  in	  all	  
but	  one	  of	  these	  patients.	  In	  all	  but	  one	  patient	  with	  TEG	  evidence	  of	  fibrinolysis	  where	  the	  
decision	  was	  taken	  not	  to	  administer	  TA,	  the	  fibrinolysis	  had	  resolved	  spontaneously	  by	  the	  
next	  measurement.	   There	  was	   no	   significant	   difference	   in	   blood	   product	   requirements	   in	  
the	  no	  aprotinin	  group	  when	  analysed	  by	  the	  severity	  of	  lysis.	  However,	  there	  was	  a	  trend	  to	  
increased	  requirements	   in	  the	  two	  patients	  with	  severe	  lysis,	  but	  these	  numbers	  were	  too	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   RBC	   FFP	   Platelets	   Cryoprecipitate	  
No	  lysis	  (n=42)	   4	  (1.25,7.5)	   4	  (2,6)	   2	  (0,2)	   0	  (0,0)	  
All	  lysis	  (n=13)	   3	  (2,6)	  	   4	  	  (2,4)	   1	  (0,1)	   0	  (0,0)	  
Mild	  lysis	  (n=5)	   3	  (	  2,3)	   2	  (2,4)	   1	  (1,1)	   0	  (0,1.5)	  
Moderate	  lysis	   3	  (1.25,5.5)	   3.5	  (2.25,5.5)	   0	  (0,0.75)	   0	  (0,1.5)	  
Severe	  lysis	   12.5	  (8.25,16.75)	   7	  (5.5,8.5)	   3	  (1.5,4.5)	   0	  (0,0)	  
	  
Table	   5.3	   Comparison	   of	   blood	   component	   transfusion	   in	   the	   No	   Aprotinin	   group	   by	  
degree	  of	  lysis	  (median	  (inter-­‐quartile	  range).	  
	  
5.4.2	  Blood	  Product	  Transfusion	  and	  Blood	  Results	  
There	  was	   no	   significant	   difference	   in	   red	   cell	   or	   blood	   product	   transfusion	   between	   the	  
aprotinin	  and	  non	  aprotinin	  groups	  [Table	  5.4].	  A	  similar	  proportion	  in	  both	  groups	  received	  
no	   transfusion	   (19.61	   vs	   18.18%)	   (p=0.39)	   and	   the	   percentage	   of	   patients	   requiring	   a	  
massive	  transfusion	  (>6	  units)	  was	  similar	  in	  both	  groups	  (23%	  vs	  24%).	  	  At	  the	  start	  of	  the	  
case	   there	  was	  no	  significant	  difference	   in	  haemoglobin,	  platelets	  or	   INR,	  but	   there	  was	  a	  
significantly	   lower	   Hb	   and	   and	   higher	   INR	   in	   the	   aprotinin	   group	   at	   the	   end	   of	   the	   case.	  
There	  was	  no	  significant	  difference	  in	  TEG	  parameters	  in	  the	  two	  groups	  [Table	  5.5]	  
	  
	   Aprotinin	   No	  Aprotinin	   P	  	  value	  
Total	  RBC	   3	  (1.5,5)	   4	  (2,6)	   0.27	  
Total	  FFP	   4	  (3,7)	   4	  (2,6)	   0.72	  
Total	  Platelet	   1	  (0,2)	   1	  (0,2)	   0.07	  
Total	  Cryo	   0	  (0,0)	   0	  (0,0)	   0.25	  
	  
Table	   5.4	   Comparison	   of	   blood	   component	   transfusion	   between	   groups	   (median	  
(interquartile	  range)	  
Fibrinolysis	  in	  patients	  undergoing	  liver	  transplantation	  
101	  
	  
	   Aprotinin	   No	  Aprotinin	   P	  Value	  
Start	  of	  case	   	   	   	  
Hb	   102.8	  (16.8)	   104	  (9.8)	   0.95	  
Platelets	  (x	  109)	   70.58	  (29.77)	   87.44	  (47.05)	   0.15	  
INR	   1.76	  (1.06)	   1.87	  (1.01)	   0.57	  
TEG	  R	  time	  (s)	   21.7	  (12)	   17.3	  (9)	   0.53	  
TEG	  MA	  (mm)	   46.6	  (14.1)	   40.23	  (12.35)	   0.06	  
End	  of	  case	   	   	   	  
Hb	   85.0	  	  (12.3)	   107	  (21.0)	   0.001*	  
Platelets	  (x	  109)	   67.75	  (34.81)	   91.07	  (54.66)	   0.12	  
INR	   3.03	  (1.96)	   1.83	  (1.41)	   0.01	  *	  
TEG	  R	  time	  (s)	   20.5	  (9.10)	   21.3	  (10.57)	   0.92	  
TEG	  MA	  (mm)	   39.5	  (6.09)	   45.43	  (6.550	   0.32	  
	  
Table	  5.5	  comparison	  of	  conventional	  and	  viscoelastic	  coagulation	  tests	  in	  the	  two	  groups	  
at	  the	  start	  and	  end	  of	  case.	  (Mean	  (standard	  deviation)).	  	  
	  
5.5	  Discussion	  	  
Routine	  use	  of	  prophylactic	  antifibrinolytic	  agents	  was	  common	  in	  the	  early	  history	  of	  LT,	  as	  
the	  massive	  blood	   loss	  was	   relatively	   common,	  and	  any	  potential	   risk	  associated	  with	   the	  
use	   of	   antifibrinolytics	  was	   small	   in	   comparison.	   Concerns	   have	   always	   existed	   about	   the	  
potential	   for	   thromboembolic	   complications	   when	   prophylactic	   antifibrinolytic	   therapy	   is	  
routinely	  used.	  However,	  a	  review	  of	  over	  1400	  LT	  patients	  found	  no	  significant	  difference	  in	  
arterial	   or	   venous	   thromboembolism	   in	   patients	   receiving	   aprotinin	   compared	   to	   no	  
treatment	   (229).	   In	   addition	   a	   systematic	   review	   and	   meta-­‐analysis	   of	   antifibrinolytic	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therapy	   in	   LT	   found	   no	   increase	   in	   thrombotic	   complications	   (228).	   However,	   the	   lack	   of	  
difference	  in	  thromboembolic	  events	  does	  not	  necessarily	  mean	  that	  there	  is	  no	  increased	  
risk	   associated	  with	   the	  use	  of	   antifibrinoytics	   in	   a	   specific	   subset	  of	  patients,	   as	   relevant	  
subgroups	  may	  be	  missed	   in	  meta-­‐analysis.	   In	  addition,	  different	  drug	  doses	  were	  used	   in	  
different	   studies.	   The	   risk-­‐benefit	   balance	   has	   altered	   now	   that	   massive	   bleeding	   is	   less	  
frequent,	  and	  there	  is	  a	  move	  away	  from	  prophylactic	  therapy	  towards	  selective	  (high	  risk	  
patients)	  or	  treatment	  only.	  Prediction	  is	  difficult	  as	  hyperfibrinolysis-­‐induced	  bleeding	  may	  
become	  most	  pronounced	  in	  the	  post	  reperfusion	  stage	  of	  the	  operation	  and	  depends	  to	  a	  
great	   extent	   on	   the	  quality	   of	   the	  donor	   liver,	  which	   is	   not	   reflected	  by	   the	  preoperative	  
condition	   of	   the	   recipient	   (231).	   Treatment	   with	   antifibrinolytic	   therapy	   is	   increasingly	  
recommended	   only	   when	   there	   is	   evidence	   of	   microvascular	   ooze	   and/or	   documented	  
fibrinolysis	  (CLI	  >	  15)	  on	  TEG/ROTEM	  (196).	  	  
We	  have	  shown	  that	  since	  the	  withdrawal	  of	  prophylactic	  aprotinin	  in	  2007,	  that	  there	  is	  a	  
significant	   increase	   in	   the	   prevalence	   of	   fibrinolysis	   on	   TEG	   analysis	   in	   our	   patients	  
undergoing	   liver	   transplantation.	   However,	   the	   clinical	   significance	   of	   this	   is	   not	   entirely	  
clear.	   The	   incidence	   of	   fibrinolysis	   in	   our	   patients	   who	   did	   not	   receive	   prophylactic	  
antifibrinolytic	   therapy	   was	   only	   26%,	   much	   less	   than	   we	   had	   expected,	   and	   brings	   into	  
question	  the	  clinical	  case	  for	  prophylactic	  treatment	  in	  these	  patients.	  Indeed,	  in	  all	  but	  one	  
case	   in	  this	  study	  where	  no	  antifibrinolytic	  was	  administered,	  the	  fibrinolysis	  had	  resolved	  
spontaneously	  by	  the	  next	  measurement	  point.	  We	  have	  also	  shown	  that	  tranexamic	  acid	  is	  
an	   effective	   alternative	   to	   aprotinin,	   leading	   to	   resolution	   of	   fibrinolysis	   in	   85%	   of	   cases,	  
confirming	  the	  findings	  of	  other	  institutions	  (232).	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In	   the	  presence	  of	  good	  graft	   function,	   fibrinolysis	   is	  usually	   self	   limiting	  after	   reperfusion	  
and	  does	  not	  always	  require	  treatment	  (233).	  The	  decision	  to	  treat	  should	  be	  based	  on	  the	  
presence	   of	   diffuse	   bleeding,	   severity	   of	   fibrinolysis	   and	   the	   stage	   of	   the	   operation.	  
Fibrinolysis	   occurring	   during	   dissection	   and	   the	   early	   anhepatic	   phase	   of	   surgery	   is	  more	  
likely	  to	  require	  treatment,	  as	  it	  is	  unlikely	  to	  resolve	  spontaneously,	  and	  tends	  to	  increase	  
in	  severity.	  After	   reperfusion	  of	  a	  marginal	  graft,	   fibrinolysis	   is	  more	  common,	  and	  can	  be	  
severe,	  and	  we	  now	  routinely	  give	  tranexamic	  acid	  prior	  to	  reperfusion	  when	  a	  DCD	  graft	  is	  
used	  (234).	  
In	   contrast	   to	   expectations,	   and	   the	   findings	   of	   some	   other	   groups,	   we	   did	   not	   show	   an	  
increase	   in	   red	   cell,	   or	   other	   blood	   component	   transfusion	   requirements	   since	   the	  
withdrawal	   of	   aprotinin	   from	   our	   routine	   practice.	   This	   may	   be	   partly	   explained	   by	   the	  
ongoing	  reduction	  in	  transfusion	  requirements	  that	  are	  seen	  year	  by	  year,	  such	  that	  mean	  
transfusions	   are	   now	   only	   2-­‐4	   units	   (235),	   and	   the	   impact	   of	   antifibrinolytic	   therapy	  
correspondingly	  less	  pronounced.	  The	  number	  of	  patients	  receiving	  no	  transfusions	  was	  also	  
similar	  in	  the	  two	  groups,	  suggesting	  that	  the	  change	  in	  antifibrinolytic	  strategy	  has	  not	  had	  
a	  detrimental	  effect	  on	  bleeding	  and	  transfusion	  requirements.	  It	  is	  of	  note	  that	  there	  was	  a	  
trend	  to	  increased	  amounts	  of	  red	  cell	  transfusions	  as	  the	  degree	  of	  lysis	  increased,	  but	  this	  
was	   not	   significant,	   possibly	   due	   to	   the	   small	   number	   of	   patients	   that	   developed	   severe	  
lysis,	   and	   a	   type	   II	   error	   cannot	   be	   excluded.	   This	   is	   likely	   to	   be	   a	   useful	   area	   for	   further	  
study	  as	  it	  appears	  that	  more	  severe	  degrees	  of	  lysis	  warrant	  treatment	  with	  antifibrinolytic	  
drugs,	  and	  indeed	  is	  a	  factor	  in	  our	  decision	  to	  treat	  fibrinolysis.	  
Limitations	   of	   this	   study	   are	   the	   fact	   that	   data	  was	   compared	   from	   two	   non	   overlapping	  
cohorts	  in	  different	  but	  adjacent	  time	  periods.	  Therefore,	  the	  risk	  of	  unrecognised	  changes	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in	   practice	   cannot	   be	   excluded	   completely,	   but	   the	   study	   design,	   and	   the	   fact	   that	   the	  
known	   variables	  were	   comparable,	  minimise	   this	   risk.	   This	   observational	   study	   enrolled	   a	  
relatively	   large	   number	   of	   consecutive	   patients,	   however,	   the	   study	   did	   not	   have	   enough	  
power	  to	  detect	  all	  important	  differences	  between	  the	  treatment	  groups.	  
5.6	  Conclusions	  
In	   this	   study	   we	   have	   shown	   that	   the	   withdrawal	   of	   aprotinin	   from	   use	   in	   liver	  
transplantation	   surgery	   has	   not	   had	   the	   predicted	   deleterious	   effects	   with	   regard	   to	   red	  
blood	   cell	   and	   other	   blood	   component	   transfusion	   requirements.	  We	   have	   demonstrated	  
that	  a	  viscoelastic	  test	  guided	  strategy	  tailored	  to	  the	  individual	  patient’s	  risk	  of	  bleeding	  is	  
as	  effective	  as	  routine	  administration	  of	  aprotinin	  to	  all	  high	  risk	  patients	  undergoing	   liver	  
transplantation.	   Factors	   which	   may	   contribute	   to	   an	   increased	   risk	   of	   bleeding	   include	  
severity	  of	   fibrinolysis,	   stage	  of	  operation,	  on-­‐going	  bleeding	  and	  disease	  process.	  Further	  
study	  is	  needed	  to	  validate	  individual	  risk	  factors	  for	  bleeding.	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6.1	  Introduction	  	  
It	   is	   increasingly	   recognised	   that	   patients	   with	   liver	   disease,	   despite	   the	   “	   coagulopathy”	  
described	  by	  conventional	  coagulation	  tests,	  and	  the	  implied	  bleeding	  diathesis,	  are	  also	  at	  
increased	   risk	   of	   developing	   thromboembolic	   complications	   (6).	   	   Although	   stable	   liver	  
disease	   is	   characterised	   by	   a	   new	   “re-­‐balanced”	   haemostatic	   profile,	   with	   a	   reduction	   in	  
both	  pro	  and	  anticoagulants	  proteins,	  there	  is	  a	  limited	  quantitative	  reserve	  on	  either	  side	  
of	   this	   coagulation	   equation.	   	   These	   patients	   therefore	   have	   a	   reduced	   ability	   to	  
compensate	  for	  stresses	  to	  the	  system	  that	  would	  be	  effectively	  buffered	  in	  healthy	  patients	  
with	  a	  larger	  functional	  reserve	  (236).	  
Hypercoagulability,	  or	  a	  prothrombotic	  environment,	  may	  be	  associated	  with	  macrovascular	  
thrombosis,	   such	   as	   portal	   vein	   thrombosis,	   deep	   vein	   thrombosis	   and	   pulmonary	  
emobolism.	   In	   addition,	   accumulating	   data	   indicates	   that	   microvascular	   thrombosis	   as	   a	  
result	  of	  dysbalanced	  coagulation	  ,and	  also	  increased	  TF	  expression,	   	  may	  be	  implicated	  in	  
non	  hepatic	   end	  organ	  damage	  and	  also	   in	   the	  progression	   from	  hepatic	   inflammation	   to	  
fibrosis	  and	  atrophy	  (237).	  
Patients	   with	   chronic	   liver	   disease	   often	   have	   deranged	   conventional	   clotting	   tests	   (CCT)	  
including	  prolonged	  prothrombin	   time	   (PT)/INR	  and	  activated	  partial	   thromboplastin	   time	  
(APTT)	   as	   well	   as	   thrombocytopenia.	   It	   is	   well	   recognised	   that	   the	   coagulopathy	   of	   liver	  
disease	  does	  not	  necessarily	  translate	  into	  excessive	  bleeding	  during	  OLT	  (26,	  238),	  and	  an	  
increasing	  number	  of	  patients	  undergo	  the	  procedure	  without	  the	  need	  for	  red	  cell	  or	  blood	  
product	  transfusion	  (239)	  The	  INR	  reflects	  only	  the	  alterations	  in	  procoagulant	  factors,	  but	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not	   the	   concurrent	   reduction	   in	   naturally	   occurring	   anticoagulants.	   It	   is	   now	   known	   that	  
thrombin	  generation	   is	  normal	  or	  even	   increased	   in	  patients	  with	  chronic	   liver	  disease	   (4,	  
240).	   The	   changes	   that	   occur	   in	   both	   primary	   haemostasis	   (thrombocytopenia)	   and	  
secondary	  haemostasis	   (low	  pro-­‐coagulant	   factor	   levels)	   that	  might	  promote	  bleeding	  are	  
“counter-­‐	   balanced”	   by	   changes	   that	   might	   promote	   thrombosis	   i.e.	   high	   levels	   of	   the	  
platelet	  adhesive	  protein	  vWF	  with	  low	  levels	  of	  its	  regulator	  ADAMTS13,	  reduced	  levels	  of	  
protein	   C	   and	   AT,	   together	   with	   high	   levels	   of	   factor	   VIII	   (241).	   However,	   this	   balance	   is	  
relatively	   precarious,	   and	   due	   to	   the	   decreased	   haemostatic	   reserve,	   these	   patients	   are	  
more	  readily	  tipped	  into	  either	  a	  hypo-­‐	  or	  hypercoagulable	  state.	  This	  rebalancing	  has	  also	  
been	  shown	  to	  be	  the	  case	  in	  patients	  undergoing	  liver	  transplantation	  (242).	  
There	   is	   emerging	   evidence	   that	   thrombotic	   complications	   are	   common	   in	   patients	   with	  
both	  cirrhotic	  and	  non-­‐cirrhotic	   liver	  disease	  (6,	  243).	  Portal	  vein	  thrombosis	   is	  a	  common	  
complication	   with	   an	   incidence	   of	   10-­‐20%,	   and	   although	   altered	   local	   flow	   dynamics	  
probably	   play	   a	   large	   role,	   a	   relative	   hypercoagulable	   state	   and	   a	   genetic	   prothrombotic	  
predisposition	  may	   also	   be	   relevant	   (244).	   The	   aetiology	   of	   thrombosis	   in	   liver	   disease	   is	  
multifactorial,	  including	  flow	  obstruction,	  chronic	  inflammation,	  shear	  stress	  and	  also	  insulin	  
resistance	   in	   metabolic	   syndrome	   (245).	   Studies	   have	   reported	   the	   incidence	   of	   venous	  
thromboembolism	   (VTE)	   in	   patients	   with	   liver	   disease	   between	   0.5%	   and	   1.9	   %	   (246)	  
representing	  a	  relative	  risk	  of	  1.7-­‐1.9	  (247).	  Northup	  et	  al	  reported	  a	  VTE	  event	  in	  0.5%	  of	  
cirrhotic	  inpatients	  despite	  an	  elevated	  INR.(243).	  These	  findings	  highlight	  the	  complexity	  of	  
coagulation	  changes	  in	  liver	  disease.	  
In	   the	   setting	   of	   liver	   disease,	   conventional	   coagulation	   tests	   give	   no	   information	   as	   to	  
where	  the	  balance	  of	  coagulation	  lies,	  as	  discussed	  in	  detail	  in	  chapter	  1,	  and	  it	  is	  has	  been	  
Hypercoagulability	  in	  patients	  undergoing	  liver	  transplantation	  
108	  
	  
shown	  that	   these	   tests	  can	  be	  “hypocoagulable”	  when	   in	  contrast	  global	  viscoelastic	   tests	  
demonstrate	  hypercoagulability(248).	  Coagulation	  monitoring	  using	  viscoelastic	  coagulation	  
tests,	  (TEG®,	  thromboelastography	  and	  ROTEM®,	  thromboelastometry)	  has	  been	  used	  during	  
liver	   transplantation	   for	   many	   years	   (249,	   250),	   however,	   less	   than	   30%	   of	   centres	   use	  
viscoelastic	   tests	   routinely	   (251).	   Some	   patients	   with	   liver	   disease	   are	   at	   risk	   of	  
hypercoagulability	  and	  this	  may	  potentially	  be	  exacerbated	  during	  the	  transplant	  procedure	  
(242).	  Different	  aspects	  of	  the	  coagulation	  system	  have	  been	  implicated	  as	  responsible	  for	  
this	  phenomenon;	  for	  instance	  platelet	  hyper-­‐reactivity	  rather	  than	  plasmatic	  coagulation	  in	  
patients	   with	   cholestatic	   liver	   disease(252).	   Thromboembolic	   events	   during	   OLT	   are	  
associated	  with	  a	  high	  morbidity	  and	  mortality(253),	  and	  have	  a	  multimodal	  aetiology(254).	  
Case	   series	   have	   identified	   intraoperative	   cardiac	   emboli	   during	   transplantation	   with	   an	  
incidence	   between	   1.2%	   and	   4.25%	   and	   on-­‐table	   fatal	   cardiac	   arrest	   has	   been	   associated	  
with	  massive	  pulmonary	  embolism(255).	  	  
VET	   offer	   a	   rapid	   overview	   of	   the	   cumulative	   effect	   of	   all	   the	   individual	   components	   of	  
haemostasis	   and	   can	   demonstrate	   hypercoagulable	   profiles	   in	   some	   individuals,	   and	   it	   is	  
known	   that	   these	   may	   be	   associated	   with	   an	   increased	   risk	   of	   thromboembolic	  
complications	   (162).	  Normal	   to	   increased	   thrombin	   generation	  has	   been	  demonstrated	   in	  
liver	   transplant	   patients	   (65),	   and	   it	   is	   well	   known	   that	   thromboembolic	   compications,	  
including	   cardiopulmonary	   emboli	   and	   portal	   vein	   thrombosis	   can	   develop	   intra-­‐
operatively(256).	  	  	  
Demonstration	  of	  hypercoagulability	  on	  viscoelastic	  tests	  has	  shown	  to	  be	  associated	  with	  
an	  increased	  risk	  of	  thromboembolic	  events,	  both	  arterial	  and	  venous,	  in	  a	  general	  surgical	  
population(257),	  critical	  care	  and	  trauma	  patients(258)	  and	  in	  cardiac	  surgical	  patients(259).	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However,	  the	  definition	  of	  hypercoagulability	  using	  viscoelastic	  parameters	  is	  not	  standard.	  
Some	  authors	  use	  only	  a	   shortened	   r	   time	  or	   clotting	   time	   (plasmatic	  hypercoagulability),	  
whilst	  others	  define	  hypercoagulability	  based	  on	  a	  high	  MA	  (platelet/	  fibrinogen	  interaction)	  
or	  combinations	  of	  various	  parameters(258,	  260).	  
6.2	  	  Aims	  
The	   prevalence	   of	   pre-­‐existing	   hypercoagulability	   in	   patients	   presenting	   for	   liver	  
transplantation	  is	  unclear,	  and	  in	  addition,	  little	  is	  known	  about	  the	  de	  novo	  development	  of	  	  
hypercoagulability	  during	  the	  procedure.	  We	  sought	  to	  examine	  a	  sample	  of	  our	  patients	  to	  
quantify	   and	   describe	   this	   issue,	   to	   examine	   the	   relationship	   between	   conventional	  
coagulation	   tests	   and	  hypercoagulation,	   and	   to	   investigate	   adverse	   thrombotic	  outcomes.	  
We	  undertook	  a	  retrospective	  database	  review	  of	  intra-­‐operative	  TEG	  traces	  in	  124	  patients	  
undergoing	   liver	   transplantation	   in	  order	   to	  determine	   the	  prevalence	  of	  hypercoagulable	  
VET	   profiles,	   the	   	   relevance	   of	   disease	   aetiology,	   the	   effect	   of	   the	   various	   stages	   of	   the	  
intraoperative	  procedure,	  and	  any	  association	  with	  intraoperative	  thrombotic	  events.	  
	  
6.3	  Methods	  
In	   our	   institution,	   intra-­‐operative	   thromboelastography	   	   (TEG®),	   (Hemonetics	   Corporation,	  
USA),	   is	   performed	   by	   dedicated	   trained	   operatives	   throughout	   liver	   transplantation	  
according	  to	  a	  standard	  protocol.	  	  
A	   native	   and	   native	   heparinase	   TEG	   is	   performed	   at	   baseline,	   and	   during	   the	   dissection,	  
anhepatic	   and	   reperfusion	   stages.	   This	   is	   in	   conjunction	   with	   point	   of	   care	   (POC)	  
international	  normalised	  ratio	  –	   INR	  (Hemochron	  Signature	  Elite,	   ITC.	  US),	   full	  blood	  count	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(PocH-­‐100i,	   Sysmex	   Europe)	   and	   arterial	   blood	   gas	   analysis	   (RapidLab	   1265,	   Siemens	   AG,	  
Germany).	  This	  intra-­‐operative	  POC	  data	  is	  entered	  onto	  a	  database	  post-­‐operatively	  by	  the	  
anaesthetic	  liver	  transplant	  fellows.	  	  
We	  performed	  a	  retrospective	  analysis	  of	  the	  database	  for	  an	  18-­‐month	  period	  over	  2009-­‐
2010.	  All	  point	  of	  care	  and	  TEG	  data	  was	  analysed	  and	  compared.	   In	  advance	  of	  analysing	  
this	   data,	   advice	   was	   sought	   from	   the	   Local	   Ethics	   Committee	   who	   advised	   that	   formal	  
institutional	   approval	   was	   not	   required,	   as	   this	   was	   anonymised	   data	   that	   is	   routinely	  
collected	  on	  our	  liver	  transplant	  database.	  
Thromboelastography	  generates	  a	  number	  of	  variables	   from	  a	  sample	  of	  blood	  as	   it	  clots.	  
(Figure	   6.	   1).	   These	   describe	   differing	   parts	   of	   clot	   formation	   and	   dissolution.	   The	   r-­‐time	  
demonstrates	  time	  to	  initiation	  of	  clotting,	  the	  K	  time	  clot	  formation	  kinetics	  and	  MA	  is	  the	  
maximal	  amplitude	  of	  clot	  reflecting	  the	  overall	  strength	  of	  clot.	  The	  r	  value	  represents	  the	  
initiation	  of	  clot	  formation	  and	  plasmatic	  contribution	  to	  coagulation.	  
	  
	  
Figure	  6.1	  A	  graphical	  representation	  of	  thromboelastography	  showing	  the	  ‘r’	  time	  and	  MA.	  
Reference	  values	  shown	  on	  right.	  	  
	  
All	  thromboelastographic	  maximum	  amplitude	  (MA)	  data	  was	  converted	  to	  its	  respective	  G	  
value	   prior	   to	   analysis	   (a	   mathematical	   transformation:	   G=5000	   x	   MA/(100-­‐MA)).	   G	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represents	   overall	   clot	   strength	   and	   is	   a	   unit	   of	   force.	   The	   G	   value	   allows	   direct	   linear	  
comparison	   of	   net	   clot	   strength	   between	   two	   different	   values,	   whereas	   MA	   does	   not.	  	  
Therefore	  a	  G	  value	  of	  10000	  dyn	  cm-­‐2	  would	  reflect	  a	  clot	  twice	  as	  strong	  as	  one	  with	  a	  G	  of	  
5000	   dyn	   cm-­‐2.	   A	   twofold	   increase	   in	   MA	   does	   not	   represent	   a	   twofold	   increase	   in	   clot	  
strength.	  We	  also	  analysed	  plasmatic	  (enzymatic)	  coagulation	  by	  investigating	  TEG	  R	  values	  
across	  the	  database.	  	  
Definitions	  of	  hypercoagulability	  used	  in	  this	  study	  were	  as	  follows	  
r	  value	  below	  lower	  limit	  of	  normal	  value	  for	  native	  heparinase	  TEG	  	  (<	  12	  mins)	  =	  	  Plasmatic	  
hyper-­‐reactivity.	  
G	  value	  above	  upper	   limit	  of	  normal	   range	   (	   >	  7100	  dynes/cm2)	  =	   Increased	   clot	   strength	  
(high	  G):	  Hypercoagulation.	  
Given	   the	   significant	   effect	   of	   endogenous	   heparin-­‐like	   substances	   on	   the	   native	   TEG,	  
particularly	   at	   reperfusion,	   all	   calculations	  were	   performed	   on	   the	   native-­‐heparinase	   TEG	  
(261).	  We	   identified	   all	   patients	  who	  were	   ‘hypercoagulable’	   by	   TEG	  G	   value	   criteria	   (G>	  
7100	  dynes	  cm-­‐2)	  and	  further	  characterised	  their	  underlying	  pathology.	  
TEG	  data	  was	  also	  compared	  to	  conventional	  clotting	  tests	  and	  platelet	  counts.	  
We	   reviewed	   patients’	   radiological	   case	   notes	   for	   evidence	   of	   investigation	   for	  
thromboembolism	  (deep	  venous,	  pulmonary	  and	  hepatic	  arterial/venous).	  	  
All	   results	   were	   handled	   and	   analysed	   on	   Microsoft	   Excel	   2008	   for	   Mac	   with	   statistical	  
analysis	  performed	  at	  www.wessa.net.	  (Wessa,	  P.	  (2011),	  Free	  Statistics	  Software,	  Office	  for	  
Research	  Development	  and	  Education,	  	  version	  1.1.23-­‐r7,	  URL	  http://www.wessa.net/)	  





124	  consecutive	   liver	   transplant	  operations	  were	   included	   in	   the	  study.	  This	   reflected	  117	  
patients	  with	  7	  (6%)	  having	  a	  re-­‐transplant	  within	  the	  study	  period.	  The	  median	  Model	  for	  
end	  stage	  liver	  disease	  (MELD)	  was	  15	  (range	  16-­‐39)	  at	  the	  time	  of	  listing	  (not	  weighted	  for	  
hepatocellular	  carcinoma)	  
Within	   the	   re-­‐graft	   group,	   1	   was	   performed	   within	   two	   days	   of	   original	   transplant	   for	  
primary	   graft	   non-­‐function,	   4	  were	   performed	   between	   3	   and	   34	   days	   for	   hepatic	   artery	  
thrombosis	  (HAT),	  with	  the	  others	  taking	  place	  at	  various	  time	  points	  for	  chronic	  rejection.	  A	  
total	  of	  784	  separate	  TEG	  analyses	  were	  identified	  in	  the	  database,	  reflecting	  a	  mean	  of	  6.5	  
TEGs	   per	   transplant.	   108	   of	   the	   TEG	   panels	   were	   performed	   at	   baseline,	   258	   during	   the	  
dissection	   period,	   130	   during	   the	   anhepatic	   period,	   and	   288	   were	   performed	   after	  
reperfusion.	  
6.4.1	  Aetiology	  of	  liver	  disease	  in	  study	  population	  	  
The	  indication	  for	  the	  liver	  transplants	  is	  outlined	  in	  Table	  1.	  The	  most	  common	  aetiologies	  
were	   alcoholic	   liver	   disease	   (ALD)	   and	   the	   viral	   hepatitides.	   Thereafter,	   the	   cholestatic	  
pathologies	  account	  for	  the	  largest	  majority	  of	  the	  remainder	  of	  transplants.	  
A	   substantial	   proportion	   of	   OLTs	   (21%)	   were	   performed	   for	   patients	   with	   concurrent	  
hepatocellular	  carcinoma.	  	  
	  
	  




Aetiology	   Frequency	  [n	  (%)]	   Concurrent	  hepatocellular	  
carcinoma	  [n	  (%)]	  
Alcoholic	  liver	  disease	   20	  (16.1)	   1(5)	  
Alcoholic	  liver	  disease	  plus	  hepatitis	  B	  or	  C	   16	  (12.9)	   4	  (25)	  
Amyloidosis	   3	  (2.4)	   _	  
Autoimmune	  hepatitis	   1	  (0.8)	   _	  
Epithelioid	  tumour	   1	  (0.8)	   _	  
Fulminant	  hepatic	  failure	   6	  (4.8)	   _	  
Hepatitis	  B	   5	  (4.0)	   3	  (60)	  
Hepatitis	  C	   26	  (21.0)	   12	  (46)	  
Hepatitis	  B	  plus	  	  Hepatitis	  C	   2	  (1.6)	   2	  (100)	  
Nonalcoholic	  steatohepatitis	   8	  (6.5)	   2	  (25)	  
Primary	  biliary	  cirrhosis	   7	  (5.6)	   _	  
Polycystic	  liver	  disease	   2	  (1.6)	   _	  
Cryptogenic	   2	  (1.6)	   _	  
Drug	  induced	   1	  (0.8)	   _	  
Primary	  hepatocellular	  carcinoma	   1	  (0.8)	   _	  
Nodular	  regenerative	  hyperplasia	   1	  (0.8)	   _	  
Regraft	  for	  HAT	   4	  (3.2)	   _	  
Regraft	  -­‐	  other	   3	  (2.4)	   _	  
Oxalosis	   1	  (0.8)	   _	  
Primary	  sclerosing	  cholangitis	   14	  (11.3)	   _	  
Total	   124	   26	  
	  
Table	  6.1	  Aetiology	  of	  liver	  disease	  in	  the	  study	  population	  





6.4.2	  Prevalence	  of	  hypercoagulability	  
High	  G	  values	  
The	  median	  G	  value	  was	  3716	  dyn	  cm-­‐2	  (mean	  3673)	  with	  a	  range	  of	  107	  -­‐	  31496	  dyn	  cm-­‐2	  
(reference	  range	  3200-­‐7100	  dyn	  cm-­‐2).	  Overall,	  11.2%	  of	  the	  native	  TEG	  G	  values	  and	  13.1%	  
of	  the	  native	  heparinase	  TEG	  G	  values	  were	  above	  the	  reference	  range	  of	  7100	  dyne.cm-­‐2	  at	  
some	  stage	  during	  the	  procedure.	  27.4%	  (34/124)	  of	  the	  patients	  had	  a	  high	  G	  value	  on	  at	  
least	  1	  native	  TEG	  trace	  during	  OLT,	  and	  30.6%	  (38/124)	  had	  a	  high	  G	  value	  on	  at	  least	  1	  NH	  
TEG.	  
Shortened	  R	  Values	  
Overall,	  19.1%	  and	  20.3%	  of	  the	  N	  and	  NH	  TEG	  R	  times,	  respectively,	  were	  below	  the	  lower	  
reference	  range	  (12	  minutes)	  at	  some	  stage	  of	  the	  procedure:	  59.7%	  of	  the	  patients	  had	  a	  
shortened	  R	  time	  on	  at	  least	  1	  native	  TEG,	  and	  61.3%	  had	  a	  shortened	  R	  time	  on	  at	  least	  1	  
NH	  TEG.	  
As	   described	  previously,	  when	  more	   than	  1	   TEG	  panel	  was	  performed	  during	   a	   particular	  
stage	  for	  a	  given	  patient,	  only	  the	  first	  panel	  was	  used	  for	  analysis	  in	  this	  article.	  
6.4.3	  Hypercoagulabilty	  by	  stage	  of	  the	  procedure	  	  
Baseline:	  The	  mean	  values	  were	  compared	  for	  native	  and	  native-­‐heparinase	  TEG	  traces.	  The	  
mean	   R	   times	   were	   20.22	   and	   20.61	   minutes	   respectively	   (p=0.64	   [Student	   t	   test]).	   The	  
mean	  G	   values	  were	   significantly	   higher	   for	  NH	   TEG	   tracings	   (5322	   dyne.cm-­‐2)	   versus	   the	  
native	  tracings	  (4613	  dyne.	  cm-­‐2,	  p	  =	  0.001	  [Student	  t	  test]).	  This	  was	  reflected	  in	  the	  higher	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incidence	  of	  high	  G	  values	  on	  NH	  TEG	  (20.39%)	  versus	  native	  TEG	  (15.3%:	  Table	  6.2).	  There	  
was	  a	  6.80	  to	  10.68%	  prevalence	  of	  shortened	  R	  times	  in	  patients	  presenting	  for	  OLT.	  
TEG	  Type	   Parameter	   %	   Median	  
(Minutes)	  
Range	  (Minutes)	  
Native	   Short	  R	  time	   10.68	   10.2	   8.6-­‐11.9	  
	   Normal	  R	  time	   71.84	   17.1	   12.25.8	  
	   Long	  R	  time	   17.48	   33.55	   27.3-­‐58.8	  
Native-­‐Heparinase	   Short	  R	  time	   6.80	   10.3	   7.9-­‐11.3	  
	   Normal	  R	  time	   77.67	   18	   12.1-­‐26	  
	   Long	  R	  time	   15.53	   29.45	   26.4-­‐55.4	  




Native	   High	  G	  Value	   15.53	   8986.7	   7165-­‐16,097	  
	   Normal	  G	  value	   45.63	   4505.7	   3291-­‐7048	  
	   Low	  G	  Value	   38.83	   2407.99	   122-­‐3196	  
Native-­‐Heparinase	   High	  G	  value	   20.39	   9970.06	   7106-­‐19,752	  
	   Normal	  G	  value	   54.37	   4363.33	   3116-­‐6904	  
	   Low	  G	  value	   25.24	   2283.51	   117-­‐3077	  
Table	  6.2	  Native	  and	  Native-­‐Heparinase	  TEG	  parameters	  at	  Baseline	  
Bolded	  values	  are	  related	  to	  those	  reflecting	  an	  enhanced	  haemostatic	  potential.	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Dissection:	   The	   prevalence	   of	   high	   G	   values	   peaked	   during	   dissection:	   18.49%	   of	   native	  
traces	   and	   20.87%	   of	   NH	   traces	   demonstrated	   this	   characteristic.	   There	   was	   a	   larger	  
increase	   in	   the	   frequency	  of	   shortened	  R	   times	  during	  dissection:	   	   22.69%	  on	  native	  TEG,	  
and	  17.39%	  on	  NH	  TEGs.	  
Anhepatic:	   During	   the	   anhepatic	   stage,	   short	   R	   times	   peaked:	   29.45%	  on	   native	   TEG	   and	  
28.575	  on	  NH	  TEG.	  During	  this	  stage	  the	  prevalence	  of	  high	  G	  values	  was	  low	  at	  8.04%	  on	  
both	  native	  and	  NH	  TEGs.	  	  	  
Reperfusion:	   	   At	   reperfusion,	   the	   endogenous	   heparinoid	   effect	   was	   clearly	   visible,	   with	  
only	  3.31%	  of	  native	  traces	  showing	  a	  short	  R	  time	  and	  with	  74.38%	  of	  patients	  showing	  a	  
significant	  HLE	  with	  prolonged	  R	   time	   reversed	  on	   the	  NH	   trace.	  The	  NH	   tracings	  possibly	  
suggest	   an	   ongoing	   enhanced	   haemostatic	   potential	   with	   17.5%	   of	   patients	   displaying	   a	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TEG	  Type	   Parameter	   Dissection	  (%)	   Anhepatic	  (%)	   Reperfusion	  (%)	  
Native	   Short	  R	  time	   22.69	   29.46	   3.31	  
	   Normal	  R	  time	   68.91	   66.96	   22.31	  
	   Long	  R	  time	   8.40	   3.57	   74.38	  
N-­‐Heparinase	   Short	  R	  time	   17.39	   28.57	   17.50	  
	   Normal	  R	  time	   74.78	   67.86	   70.83	  
	   Long	  R	  time	   7.83	   3.57	   11.67	  
Native	   High	  G	  value	   18.49	   8.04	   4.96	  
	   Normal	  G	  value	   57.98	   51.79	   23.14	  
	   Low	  G	  value	   23.53	   40.18	   71.90	  
N-­‐Heparinase	   High	  G	  value	   20.87	   8.04	   9.17	  
	   Normal	  G	  value	   61.74	   56.25	   44.17	  
	   Low	  G	  value	   17.39	   35.71	   46.67	  
	  
Table	   6.3	   Distributions	   of	   normal	   and	   abnormal	   TEG	   parameters	   by	   stage	   of	   liver	  
transplant.	   Bolded	   values	   are	   related	   to	   those	   reflecting	   an	   enhanced	   haemostatic	  
potential.	  Percentages	  refer	  to	  patients	  with	  the	  characteristic.	  
	  
6.4.4	  Laboratory	  and	  Transfusion	  Data	  
The	  baseline	  (preoperative)	  haematological	  and	  clotting	  data	  for	  the	  cohort	  are	  described	  in	  
Table	   6.4.	   The	   group	   as	   a	   whole	   had	   mild	   thrombocytopenia	   with	   a	   prolonged	   INR	   and	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anaemia.	  The	  mean	  fibrinogen	  level	  was	  within	  the	  normal	  range.	  The	  median	  haemoglobin	  
level	  was	  lower	  in	  the	  high	  G	  group	  (8.9	  versus	  9.9	  g/dl,	  p=0.02),	  whereas	  the	  platelet	  count	  
and	   fibrinogen	   levels	  were	   significantly	   higher.	   There	  was	   no	   significant	   difference	   in	   the	  
baseline	  INR.	  
Packed	   red	   cell	   transfusion	   volumes	  were	   equivalent	   for	   patients	  with	   or	  without	   high	   G	  
values	   (on	   NH	   TEGs).	   Fresh	   frozen	   plasma	   (FFP)	   transfusion	   showed	   a	   tendency	   toward	  
lower	  volumes	  in	  the	  group	  with	  higher	  G	  values	  (p=0.05	  [Mann–Whitney	  U	  test]).	  When	  we	  
compared	  the	   likelihood	  of	  no	  transfusion	  versus	  any	  transfusion,	  there	  was	  no	  difference	  
between	  the	  groups	  for	  red	  blood	  cell	  transfusions	  (75.5%	  for	  normal	  G	  values	  versus	  65%	  
for	  high	  G	  values,	  p=0.33	  [	  X2]	  ,	  but	  there	  was	  a	  lower	  chance	  for	  transfusions	  of	  FFP	  (75.5%	  
for	   normal	   G	   values	   versus	   50%	   for	   high	   g	   values,	   p=0.02	   [X2]	   and	   platelets	   (59.6%	   for	  
normal	  G	  values	  versus	  35%	  for	  high	  G	  values,	  p=0.04	  [X2]).	  
	  
Table	  6.4	  Haematological	  parameters	  &	  transfusion	  requirements	  according	  to	  G	  Values	  at	  
baseline	  
Laboratory	  tests	   All	  patients	   Normal	  or	  low	  G	  value	   High	  G	  value	   P	  Value	  *	  
Haemoglobin	  g/dl)	   9.8	  (8.4-­‐11.3)	   9.9	  (8.8	  -­‐11.6)	   8.9	  (7.5	  -­‐10.8)	   0.02	  
Platelets	  (x	  109/l)	   86	  (54-­‐128.8)	   71.6	  (51.5-­‐103)	   139.5	  (99.5-­‐181.5)	   <0.001	  
INR	   1.55	  (1.3-­‐1.8)	   1.60	  (1.3-­‐1.825)	   1.45	  (1.3-­‐1.625)	   0.52	  
Fibrinogen	  (g/l)	   2	  (1.5-­‐3.0)	   1.9	  (1.5-­‐2.7)	   3.2	  (2.05-­‐4.13)	   0.007	  
Transfused	  Products	   All	  patients	  	   Normal	  or	  low	  G	  values	   High	  G	  value	   P	  Value*	  
Packed	  red	  cells	  (U)	   3	  (0-­‐6)	   3	  (1-­‐6)	   3	  (0-­‐8)	   0.9	  
FFP	  (U)	   3	  (0-­‐6)	   4	  (2-­‐6)	   1	  (0-­‐4)	   0.05	  
Platelets	  (U)	   1	  (0-­‐2)	   1	  (0-­‐2)	   0	  (0-­‐2)	   0.27	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6.4.5	  Influence	  of	  the	  aetiology	  of	  liver	  disease	  
The	  phenomenon	  of	  high	  G	  values	  was	  not	  evenly	  distributed	  by	  aetiology.	  Table	  6.5	  shows	  
patients	  who	  had	  prothrombotic	  TEG	  results	  on	  any	  tracing	  during	  the	  procedure	  according	  
to	   aetiology.	   Patients	   with	   cholestatic	   pathologies	   (primary	   sclerosing	   cholangitis	   and	  
primary	   biliary	   cirrhosis)	   had	   high	   rates	   of	   G	   values	   above	   the	   reference	   range	   (85%	   and	  
43%)	  respectively	  and	  also	  shortened	  R	  times.	  The	  incidence	  was	  also	  high	  in	  patients	  with	  
fulminant	  hepatic	  failure	  (50%)	  and	  patients	  undergoing	  regrafting	  for	  HAT	  (50%),	  although	  
the	  numbers	  of	  these	  patients	  was	  small.	  Patients	  with	  viral	  or	  alcoholic	  liver	  disease	  had	  a	  
different	  pattern:	  between	  65	  and	  100%	  had	  short	  or	  hypercoagulable	  R	  times,	  but	  only	  10-­‐
12%	  had	  an	  increased	  G	  Value.	  Only	  3	  of	  the	  26	  patients	  who	  had	  concurrent	  hepatocellular	  
carcinoma	   had	   high	   G	   values	   on	   TEG	   (median	   native	   G	   value	   =4108	   dyne.cm-­‐2	   ,	   native	   R	  
time=	  16	  minutes).	  In	  contrast,	  all	  other	  aetiologies	  had	  similar	  incidences	  of	  both	  shortened	  
R	   times	  and	   increased	  G	  values.	  Therefore,	   there	  appears	   to	  be	  a	  different	  distribution	  of	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Table	  6.5	  Prevalence	  of	  hypercoagulability	  according	  to	  disease	  aetiology	  	  
★Cases	  with	  an	  abnormal	  parameter	  on	  any	  intraoperative	  TEG	  examination	  are	  listed	  
§The	   data	   are	   presented	   as	   medians	   and	   interquartile	   ranges.	   Values	   are	   provided	   only	  
when	  the	  number	  of	  cases	  was	  greater	  than	  3	  
◊	  The	  other	  category	  comprises	  of	  aetilogies	  where	  only	  two	  or	  fewer	  cases	  were	  found	  in	  
the	  series.	  
	  
6.4.6	  Hypercoagulability	  and	  Conventional	  Coagulation	  Tests	  
A	   comparison	   of	   paired	   G	   values	  with	   point	   of	   care	   INR	   tests	   showed	   that	   there	  was	   no	  
significant	   correlation	   between	   the	   2	   parameters	   (r=-­‐0.33,	   p=0.001	   [Spearman’s	   rank	  
correlation]).	   Figure	   3	   shows	   a	   scatter	   plot	   of	   the	   2	  measurements	   and	   reveals	   that	   TEG	  
traces	  that	  were	  hypercoagulable	  (ie	  above	  the	  normal	  reference	  range)	  could	  be	  associated	  
with	   an	   INR	   between	   0.9	   and	   3.8.	   G	   values	   were	   compared	   with	   platelet	   counts,	   and	   a	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moderate	   correlation	  was	   found	   (r=0.62,	  p=0.001	   [Spearman’s	   rank	   correlation]).	  None	  of	  
the	  patients	  with	  high	  G	  traces	  had	  platelet	  counts	  above	  the	  normal	  reference	  range.	  There	  
was	   no	   correlation	   between	   the	   R	   time	   and	   INR	   (r=0.04,p=0.27	   [Spearman’s	   rank	  
correlation]).	  
One	  hundred	  sixty	  two	  of	  the	  784	  TEG	  R	  time	  measurements	  were	  found	  to	  be	  shorter	  than	  
the	  normal	   range	   (12-­‐26	  minutes)	  with	  a	  median	   time	  of	  8.95	  minutes.	   In	   this	   group,	   the	  
median	  INR	  was	  1.8	  with	  a	  range	  of	  1.1	  to	  10.	  On	  the	  basis	  of	  INR	  values,	  128	  TEG	  analyses	  
(79%)	  showing	  a	  shortened	  R	  time	  would	  be	  described	  as	  coagulopathic	  (INR	  >	  1.5),	  and	  61	  




Figure	  6.2	  	  X-­‐Y	  scatter	  plot	  of	  all	  native	  heparinase	  TEG	  G	  values	  against	  corresponding	  INR	  
values	  
Upper	  reference	  range	  of	  	  ‘G’	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A	   similar	   plot	   of	   paired	   G	   values	   with	   platelet	   counts	   is	   shown	   in	   Figure	   6.3.	   There	   is	   a	  
greater	   correlation	  between	   the	   two	  as	  may	  be	  expected	  given	   the	  direct	   contribution	  of	  
platelets	   to	  clot	   strength	   (r=0.62,	   r2=0.38).	  The	  TEG	   trace	   takes	   into	  account	  both	  platelet	  
function	  and	   fibrinogen	   levels	  and	   their	   relative	  contributions	   to	  clot	   strength,	  which	  may	  
account	   for	   the	   less	   than	   perfect	   correlation.	   None	   of	   the	   patients	  with	   hypercoagulable	  
traces	  had	  platelet	  counts	  above	  the	  normal	  reference	  range.	  
	  
	  
Figure	  6.3	  	  X-­‐Y	  scatter	  plot	  of	  paired	  G	  and	  platelet	  count	  	  
	  
Correlation	  of	  R	  and	  INR	  
Figure	   6.4	   compares	   the	   two	   parameters	   throughout	   the	   study	   group.	   There	   is	   no	  
correlation	  between	  INR	  and	  R	  value.	  
	  
	  
Upper	  reference	  range	  of	  	  ‘G’	  




Figure	  6.4	  X-­‐Y	  scatter	  plot	  of	  INR	  and	  r	  time	  
	  
6.4.7	  Perioperative	  Thrombotic	  events	  
One	   patient	   had	   an	   intraoperative	   portal	   vein	   thrombosis	   that	   required	   on	   table	  
thrombectomy.	  This	  was	  associated	  with	  a	  grossly	  shortened	  R	  time	  (2.6	  minutes)	  on	  both	  
native	  and	  NH	  TEGs	  during	  early	  reperfusion.	  The	  concurrent	  G	  value	  was	  within	  the	  normal	  
range	   at	   3347	   dyne-­‐cm-­‐2.	   There	   were	   no	   intraoperative	   pulmonary	   emboli	   identified	   by	  
attending	  clinicians.	  
The	   database	   review	   identified	   thrombotic	   complications	   within	   30	   days	   of	   transplant.	  
Among	  the	  117	  primary	  transplants	  (ie	  with	  the	  exclusion	  of	  the	  7	  regraft	  procedures),	  there	  
were	  6	   cases	   (5%)	  of	  HAT.	   Four	  of	   the	  6	   required	  a	   regraft	   procedure	  as	   a	   result	   of	  HAT.	  
Three	  of	  the	  6	  cases	  had	  high	  G	  traces	  during	  their	   initial	  transplant	  (p=0.25	  [X2])	  and	  4	  of	  
the	   6	   demonstrated	   shortened	   R	   times	   (p=0.79	   [X2]).	   The	   underlying	   aetiology	   for	   those	  












Lower	  reference	  range	  for	  NH	  r	  Value	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virus.	  The	  aetiologies	  of	  the	  2	  patients	  who	  did	  not	  undergo	  regrafting	  were	  amyloidosis	  and	  
hepatitis	  B	  cirrhosis.	  It	  is	  notable	  that	  the	  occurrence	  of	  hypercoagulable	  traces	  in	  patients	  
who	   developed	   HAT	   was	   more	   frequent	   than	   that	   in	   the	   general	   population	   of	   patients	  
undergoing	  liver	  transplantation.	  	  
There	  were	  only	  2	  postoperative	  pulmonary	  emboli	  in	  the	  primary	  transplant	  cohort,	  one	  of	  
whom	  had	  a	  hypercoagulable	  trace	  intraoperatively	  (PSC).	  
6.5	  Discussion	  
The	   various	   thrombotic	   complications	   that	   can	   occur	   in	   the	   perioperative	   period,	   such	   as	  
HAT,	   have	   been	   traditionally	   been	   assumed	   to	   be	   caused	   mainly	   by	   surgical	   factors	   or	  
related	   to	   graft	   function.	   The	   role	   of	   the	   haemostatic	   system	   in	   the	   development	   of	  
perioperative	   thrombotic	   complications	   has,	   until	   recently,	   been	   largely	   overlooked,	  
because	  of	   the	   long	  held	  belief	   that	  a	  hypocoagulable	  state	   is	  present	  prior	   to	  and	  during	  
liver	  transplantation	  (262).	  	  	  	  	  	  
This	  study,	  which	  we	  believe	  is	  the	  first	  to	  examine	  such	  a	  large	  number	  of	  intra-­‐operative	  
data	  sets,	  demonstrates	   that	  a	   significant	  number	  of	  patients	  with	  end	  stage	   liver	  disease	  
undergoing	   liver	   transplantation,	   present	   with,	   or	   develop	   hypercoagulable	  
thromboelastograms	   during	   the	   procedure.	   	   In	   this	   series,	   the	   incidence	   of	   patients	   with	  
baseline	  G	  values	  greater	  than	  7100	  dynes-­‐cm-­‐2	  was	  20.39%	  on	  heparinase	  TEG	  and	  15.53%	  
on	  native	  TEG.	  
	  
Patients	  with	  cholestatic	  disease	  (PSC	  or	  PBC)	  have	  a	  high	  incidence	  of	  hypercoagulability	  on	  
the	  basis	  of	  increased	  G	  values	  (85.8%	  and	  42.9	  %	  respectively),	  and	  this	  is	  in	  keeping	  with	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previous	  work	  published	  on	  this	  group	  of	  patients	  (32).	  Although	  there	  were	  only	  6	  patients	  
with	  acute	   liver	   failure,	  50%	  of	   these	  were	  hypercoagulable.	  This	  may	  be	  surprising,	  given	  
that	   all	   these	   patients	   had	   an	   INR	   of	   2	   or	   more,	   but	   is	   compatible	   with	   similar	   findings	  
reported	   recently	   (166,	   167).	   Nearly	   40%	   of	   patients	   with	   non-­‐alcoholic	   steato-­‐hepatitis	  
(NASH	  had	  evidence	  of	  both	  plasmatic	  hyper	  reactivity	  and	  excessive	  clot	  strength).	  NASH	  is	  
both	  increasing	  in	  prevalence	  and	  as	  aetiology	  for	  chronic	  liver	  disease.	  (263)	  
	  
The	   pathophysiology	   of	   hypercoagulation	   is	   multifactorial.	   In	   the	   cholestatic	   pathologies,	  
work	   has	   demonstrated	   hyperfibrinogenaemia	   and	   also	   platelet	   hyperreactivity,	   (252)	  
whereas	  in	  NASH,	  there	  is	  stronger	  clot	  development	  (increased	  MA)	  and	  reduced	  clot	  lysis.	  
(159).	  Many	   intraoperative	  factors	  may	  contribute	  to	  persistence	  or	  de	  novo	  development	  
of	   hypercoagulation.	   These	   include	   vascular	   stasis,	   coagulation	   activation	  with	   endotoxins	  
(within	  the	  portal	  vein)	  and	  endothelial	  cell	  injury	  and	  local	  inflammation	  of	  the	  graft	  organ	  
caused	   by	   ischaemia	   reperfusion	   injury.	   Models	   of	   endotoxaemia	   have	   shown	   that	   this	  
results	  in	  significant	  shortening	  of	  the	  r	  time	  or	  clotting	  time,	  with	  accelerated	  initiation	  of	  
coagulation	  (264)	  but	  that	  conventional	  coagulation	  tests	  (PT/INR)	  remain	  prolonged.	  (265)	  
Ischaemia	  reperfusion	  injury	  leads	  to	  activation	  of	  coagulation	  and	  also	  platelets	  (266)	  and	  it	  
is	   of	   note	   that	   reports	   of	   intra-­‐cardiac	   thrombi	   are	   most	   common	   around	   the	   time	   of	  
reperfusion.	  In	  a	  review	  of	  27	  case	  reports	  of	  thromboembolic	  events	  occurring	  during	  liver	  
transplantation,	   TEG	   profiles	   (267)	   were	   hypercoagulable	   in	   over	   70%	   of	   cases,	   whereas	  
conventional	   coagulation	   tests	   were	   all	   hypocoagulable.	   (268)	   In	   addition,	   most	   patients	  
undergoing	   liver	   transplantation	   do	   not	   routinely	   have	   thrombophilia	   screening,	   but	   a	  
genetic	  component	  involving	  prothrombotic	  gene	  polymorphisms	  may	  be	  present	  in	  some.	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(269)	   No	   patient	   in	   our	   series	   had	   an	   intraoperative	   event	   suggestive	   of	   intra	   cardiac	  
thrombosis	  or	  pulmonary	  embolism.	  
	  
VWF	   levels	   are	   known	   to	   be	   elevated	   in	   liver	   disease,	   and	   rise	   further	   during	   the	   LT	  
procedure,	  as	  a	   result	  of	   release	  of	  VWF	   from	  endothelial	   cells	  activated	  by	   inflammatory	  
processes	  and	  surgical	  stress.	  In	  addition,	  plasma	  levels	  of	  its	  cleaving	  protease,	  ADAMT13,	  
decrease	  during	  transplantation,	  resulting	   in	  a	  profound	  dysbalance	   in	  the	  VWF/ADAMT13	  
ratio	  (270).	  Such	  a	  dysbalance	  has	  been	  linked	  to	  thrombotic	  risk	  in	  different	  disease	  states,	  
such	  as	  myocardial	   infarction	  and	   sepsis	   (271).	  Although	   the	   risk	  of	  post-­‐operative	  HAT	   is	  
most	   probably	   initiated	   by	   local	   activation	   of	   endothelial	   cells	   as	   a	   result	   of	   ischaemia-­‐
reperfusion	   injury	   linked	   to	   surgical	   risk	   factors	   involving	   the	  arterial	  anastomosis	   (267),	  a	  
hyper-­‐reactive	   primary	  haemostatic	   system	  may	  enhance	   this	   risk.	   If	   there	   is	   a	   significant	  
deficiency	   of	   ADAMTS13,	   VWF	   secreted	   from	   the	   vascular	   endothelium	   survives	   in	   the	  
circulation	   and	   is	   able	   to	   promote	   the	   formation	   of	   platelet	   rich	   thombi	   in	   the	  
microcirculation.	  It	   is	  of	  note	  that	  extensive	  platelet	  aggregates	  occluding	  small	  pulmonary	  
arterioles	  and	  capillaries	  have	  been	  found	  in	  the	  lungs	  of	  patients	  who	  have	  died	  suddenly	  
during	  liver	  transplantation,	  and	  that	  these	  cases	  were	  usually	  associated	  with	  a	  sudden	  fall	  
in	  platelet	  count	  and	  a	  rise	  in	  pulmonary	  artery	  pressure	  (35).	  	  
	  
	  In	   this	   series,	   the	   incidence	   of	   HAT	   was	   5%.	   Although	   the	   aetiology	   is	   known	   to	   be	  
multifactorial	  and	  significantly	  related	  to	  difficulties	  associated	  with	  the	  arterial	  anastomosis	  
and	  arterial	  reconstruction,	  it	  is	  of	  note	  that	  of	  the	  6	  patients	  that	  developed	  HAT,	  4	  of	  them	  
were	  hypercoagulable	  at	  some	  point	  during	   the	  procedure.	  We	  cannot	  conclude	   from	  our	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data	  whether	   the	   presence	  of	   a	   procoagulable	   state	   predisposes	   to	   thrombotic	   events	   as	  
the	   incidence	   of	   such	   events	   in	   our	   dataset	   is	   too	   low	   to	   demonstrate	   any	   significant	  
association.	  However,	  the	  relatively	  low	  incidence	  of	  HAT	  and	  corresponding	  small	  number	  
of	   cases	   means	   that	   a	   type	   2	   error	   cannot	   be	   excluded.	   It	   would	   seem	   physiologically	  
plausible	  that	  such	  a	  relationship	  may	  exist,	  but	  further	  research	  is	  required	  to	  demonstrate	  
a	  conclusive	  link.	  
	  
The	  clinical	  implications	  of	  hypercoagulability	  occurring	  during	  liver	  transplantation	  have	  yet	  
to	  be	  evaluated.	  However,	  emerging	  evidence	  suggests	  that	  hypercoagulability	  detected	  by	  	  
viscoelastic	  tests	  puts	  patients	  in	  an	  “at	  risk”	  group	  for	  both	  venous	  and	  arterial	  thrombotic	  
events.	  (134,	  162)	  	  A	  recent	  systematic	  review	  of	  10	  studies	  in	  surgical	  patients	  showed	  an	  
increased	   MA	   to	   be	   the	   most	   important	   parameter	   to	   predict	   postoperative	   TE	   events.	  
However,	   there	  was	   considerable	   variability	   as	   to	  which	   parameters	  were	   used	   to	   define	  
hypercoagulability	  and	  no	  study	  was	  adequately	  powered.	  Nevertheless,	   the	  vast	  majority	  
of	  patients	  who	  had	  a	  TE	  event	  were	  hypercoagulable	  on	  one	  or	  more	  TEG	  parameters	  (164)	  	  
and	   future	   prospective	   studies	   are	   recommended.	   It	   has	   also	   been	   shown	   that	   TEG	   can	  
display	  hypercoagulation	  in	  thrombosis	  prone	  patients.	  (272)	  	  	  
	  
The	  definition	  of	  hypercoagulation	  based	  on	  viscoelastic	  tests	  is	  not	  standard.	  A	  routine	  TEG	  
will	  generate	  a	  number	  of	  variables	  including	  r	  time,	  alpha	  angle,	  and	  maximum	  amplitude.	  
These	   values	   represent	   different	   components	   of	   the	   clot	   formation	   process.	   Different	  
researchers	  have	   chosen	   to	  use	  differing	   variables	  or	   indeed	  a	   combination	  of	  more	   than	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one.	  	  The	  G	  value	  is	  a	  function	  of	  the	  maximal	  amplitude	  and	  represents	  clot	  strength	  rather	  
than	  initial	  clot	  formation	  kinetics	  and	  as	  such,	  is	  used	  as	  the	  definition	  of	  hypercoagulation	  
in	   our	   paper.	   The	   ability	   to	   directly	   compare	   G	   values	   to	   one	   another	   linearly	   enables	   a	  
better	   appreciation	   of	   the	   magnitude	   in	   change	   between	   different	   results.	   Plasmatic	   (or	  
enzymatic)	  coagulation	  is	  also	  likely	  to	  contribute	  to	  a	  pro-­‐thrombotic	  state,	  whereby	  initial	  
clot	  formation	  is	  accelerated.	  	  
Conventional	  coagulation	  tests	  do	  not	  provide	  information	  about	  the	  quality	  of	  the	  clot	  or	  
the	  dynamics	   of	   its	   formation.	  Unless	   the	  platelet	   count	   or	   fibrinogen	   levels	   are	   elevated	  
above	   normal	   values	   (which	   was	   not	   the	   case	   in	   any	   of	   our	   patients)	   CCT	   are	   unable	   to	  
identify	  a	  hypercoagulable	  state.	  It	  is	  clear	  from	  the	  comparisons	  between	  the	  conventional	  
clotting	  tests	  (INR)	  and	  the	  TEG	  parameters	  that	  there	  is	  no	  useful	  correlation	  between	  the	  
two.	   It	   has	   consistently	   been	   shown	   that	   there	   is	   only	   a	  weak	   correlation	   between	   the	   r	  
time/clotting	  time	  and	  the	  PT/INR.	  (98,	  273)	  Wide	  derangements	  in	  INR	  may	  not	  represent	  a	  
defect	   in	   coagulation	   by	   TEG	   criteria	   and	   indeed	   this	   reflects	   the	   fact	   that	   INR	   is	   a	   poor	  
predictive	   ability	   of	   clinically	   important	   bleeding.	   (2)	   In	   liver	   disease,	   the	   endogenous	  
anticoagulants,	   as	  well	   as	  procoagulant	   factors,	   are	  all	   reduced	  and	   the	  balance	  of	  pro	   to	  
anticoagulants	  may	  be	  altered	  in	  favour	  of	  a	  prothrombotic	  state.(7)	  We	  have	  shown	  that	  a	  
significant	   number	   of	   patients	   with	   INR	   values	   of	   1.5	   or	   greater,	   are	   hypercoagulable	   on	  
viscoelastic	   tests.	   Solely	   relying	   on	   conventional	   coagulation	   tests	   can	   only	   provide	   the	  
attending	   physician	   with	   a	   small	   part	   of	   the	   global	   picture.	   Viscoelastic	   monitoring	   adds	  
valuable	  qualitative	  information	  to	  the	  management	  of	  these	  cases	  (227)	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What	   remains	   unclear	   is	   what	   action	   should	   be	   taken	   when	   hypercoagulability	   is	  
demonstrated	  on	   TEG.	  Where	   there	   is	   evidence	  of	   significant	   plasmatic	   hypercoagulabilty	  
(shortened	  R	  value)	  and	  a	  normal	  or	  hypercoagulable	  MA	  or	  G,	  then	  it	  is	  reasonable	  to	  give	  
a	   small	   dose	   intravenous	   dose	   (3000-­‐5000	   units)	   of	   heparin.	   (Andre	   de	   Wolf,	   personal	  
communication).	  It	  would	  also	  seem	  prudent	  to	  avoid	  prohaemostatic	  agents,	  including	  FFP	  
and	  platelets,	  if	  there	  is	  thromboelastographic	  evidence	  of	  hypercoagulabilty.	  
	  
The	  limitations	  of	  this	  study	  are	  its	  retrospective	  design	  and	  therefore	  potentially	  we	  missed	  
minor	   thrombotic	   events,	   such	   as	   DVT.	   In	   addition	  we	   defined	   hypercoagulability	   as	   TEG	  
parameters	   outside	   the	   normal	   range,	   whereas	   others	   have	   used	   values	   of	   2	   or	   more	  
standard	  deviations	  (134).	  Our	  study	  did	  not	  extend	  into	  the	  post-­‐operative	  period,	  and	  as	  
such	  it	  is	  difficult	  to	  comment	  on	  persistence	  of	  the	  phenomenon.	  There	  are	  of	  course	  many	  
potential	   issues	  with	  both	  bleeding	  and	   thrombosis	   in	   this	  group	  post-­‐operatively	  and	   the	  
phenomenon	  requires	  further	  investigation.	  	  
6.6	  Conclusions	  	  
These	   results	   suggest	   that	   there	   may	   be	   significant	   benefits	   in	   future	   research	   aimed	   at	  
investigating	   the	  phenomenon	  of	   hypercoagulability	  within	   liver	   transplantation,	   and	   liver	  
disease	  in	  general.	  Crucially,	  work	  needs	  to	  be	  targeted	  towards	  ascertaining	  the	  presence	  
or	  absence	  of	   a	   causal	   relationship	  between	   this	   state	  and	   thrombotic	  events	  and	   indeed	  
ultimate	  post-­‐transplant	  outcome.	  	  
Because	   hypercoagulability	   is	   not	   detected	   by	   conventional	   coagulation	   tests,	   and	   can	   be	  
present	  even	  though	  conventional	  coagulation	  tests	  indicate	  hypocoagulability,	  VET	  should	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be	   used	   routinely	   for	   coagulation	   monitoring	   during	   liver	   transplantation.	   As	   well	   as	  
identifying	  coagulopathy	  early,	  and	  allowing	  specific	  haemostatic	  therapy	  to	  be	  instituted	  	  if	  
there	   is	   clinical	   evidence	   of	   bleeding,	   the	   role	   of	   TEG	  may	   crucially	   be	   just	   as	   valuable	   in	  
avoiding	   unnecessary	   and	   potentially	   harmful	   transfusion	   of	   blood	   products	   in	   the	  
hypercoagulable	  cohort	  of	  patients.	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The	  alterations	  in	  coagulation	  after	  major	   liver	  resection	  are	  complex.	  Contributing	  factors	  
include	   pre-­‐existing	   liver	   dysfunction,	   the	   presence	   of	   malignant	   tumours,	   extent	   of	  
intraoperative	   blood	   loss,	   surgical	   technique	   and	   ischaemia–reperfusion	   injury.	   A	   further	  
important	   factor	   is	   the	   volume	   of	   liver	   remaining	   following	   resection,	   as	   the	  majority	   of	  
coagulation	   proteins	   are	   synthesised	   within	   the	   liver	   (274,	   275).	   	   Bleeding	   and	   vascular	  
thrombosis	   are	   major	   life	   threatening	   complications	   following	   liver	   surgery,	   and	   hence	  
assessment	   of	   clotting	   function	   profile	   is	   a	   significant	   clinical	   concern	   (276).	   In	   the	   early	  
post-­‐operative	   period,	   routine	   coagulation	   tests	   show	   an	   almost	   universal	   increase	   in	  
prothrombin	  time	  (PT)	  and	  international	  normalized	  ratio	  (INR)	  accompanied	  by	  a	  brief	  fall	  
in	  platelet	   and	   fibrinogen	   levels.	   This	   “coagulopathy”	   suggests	   a	   transient	  hypocoagulable	  
state;	  however,	  in	  reality,	  bleeding	  complications	  are	  rare	  (277).	  The	  increase	  in	  PT	  and	  INR	  
in	  the	  early	  post	  operative	  period	  has	  traditionally	  been	  assumed	  to	  represent	  a	  potential	  
bleeding	   risk,	   and	  many	   clinicians	  would	   consider	   administering	   prophylactic	   fresh	   frozen	  
plasma	   (FFP)	   to	   correct	   the	   INR	   to	   <	   1.5	   prior	   to	   invasive	   procedures	   (278,	   279).	   The	  
risk/benefit	   ratio	   of	   such	   practice	   is	   in	   any	   case	   debatable,	   as	   the	   volume	   of	   FFP	  
administered	   rarely	   corrects	   the	   INR	   to	   the	  desired	  value	   (280),	   and	  can	   result	   in	  adverse	  
effects	  such	  as	   transfusion-­‐related	  acute	   lung	   injury	  and	  transfusion-­‐associated	  circulatory	  
overload	   (281).	   	   In	  addition,	   it	   is	  also	  quite	  common	  practice	  to	  delay	  removal	  of	  epidural	  
catheters	   used	   for	   post	   operative	   analgesia	   until	   the	   INR	   returns	   to	   within	   ‘acceptable’	  
values	  of	  between	  1.3-­‐1.5	  (279).	  Another	  consequence	  of	  the	  perceived	  risk	  of	  bleeding	   is	  
that	  the	  initiation	  of	  pharmacological	  thromboprophylaxis	  may	  be	  delayed;	  a	  recent	  survey	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reported	   that	   35%	   of	   centres	   withhold	   pharmacological	   prophylaxis	   until	   the	   INR	   has	  
returned	  to	  within	  normal	  range	  (282).	  	  	  
Although	   conventional	   coagulation	   tests	   (CCTs),	   specifically	   the	   PT	   and	   INR,	   suggest	   a	  
hypocoagulable	   environment	   early	   after	   liver	   resection	   (275),	   these	   tests	   are	   only	  
responsive	  to	  procoagulant	  levels	  and	  do	  not	  measure	  the	  activity	  of	  anticoagulant	  proteins.	  
As	  has	  been	  discussed	  in	  earlier	  chapters,	  in	  patients	  with	  liver	  disease	  there	  is	  a	  decrease	  in	  
both	   pro-­‐	   and	   anticoagulant	   levels;	   and	   consequently	   thrombin	   generation	   is	   normal,	   or	  
even	   hypercoagulable	   (7),	   and	   is	   a	   partial	   explanation	   of	   why	   PT	   and	   INR	   are	   such	   poor	  
predictors	   of	   bleeding	   risk	   in	   patients	  with	   cirrhosis	   (45).	  We	   hypothesized	   that	   a	   similar	  
situation	  may	   exist	   following	   liver	   resection,	   as	   it	   is	   has	   been	   shown	   that	   both	   pro-­‐	   and	  
anticoagulant	  levels	  fall	  (283),	  and	  also	  that	  in	  some	  patients	  modified	  thrombin	  generation	  
tests	  show	  hypercoagulability	  following	  major	  liver	  resection	  (284).	  Global	  viscoelastic	  tests	  
of	   coagulation,	   including	   thromboelastography	   (TEG®)	   and	   thromboelastometry	   (ROTEM®),	  
reflect	  both	  pro	  and	  anti-­‐coagulant	  activity;	  these	  have	  been	  shown	  to	  be	  normal	  (285,	  286)	  
or	  even	  hypercoagulable	  (287)	  in	  patients	  following	  liver	  resection.	  	  
The	  risk	  of	  thrombotic	  events	  following	  hepatic	  resection	  is	  significant.	   In	  a	  review	  of	  over	  
5500	   partial	   hepatectomies	   in	   the	   National	   Surgical	   Quality	   Improvement	   Program,	   the	  
incidence	  of	  VTE	  was	  2.88%	  overall,	  with	  much	  higher	  rates	  for	  right	  (4.15%)	  and	  extended	  
(5.76%)	  hepatic	   resections	   (288).	   In	   a	  prospective	   study	  of	   410	  patients	   in	  which	  patients	  
had	  protocolised	  CT	   scans	   following	   liver	   resection,	   the	   incidence	  of	  pulmonary	  embolism	  
(PE)	   was	   6%	   despite	   low	   molecular	   weight	   heparin	   (LMWH)	   thrombo-­‐prophylaxis	   (289).	  
Similar	   rates	  of	  VTE	  have	  been	  shown	   in	  other	   series	  of	   liver	   resection	   (290,	  291).	   	  Major	  
liver	  resection	  was	  primarily	  undertaken	  for	  metastatic	  disease	  and	  hepatic	  malignancy	  but	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is	  increasingly	  undertaken	  for	  live	  donor	  liver	  transplantation	  as	  well,	  and	  the	  consequences	  
of	  VTE	  are	  not	   insignificant	   for	  all	   these	  groups	  of	  patients	   (292,	  293).	   The	  extent	  of	   liver	  
parenchyma	   resected	  appears	   to	  be	  more	   significant	   in	   terms	  of	  VTE	   than	  any	  underlying	  
malignant	  pathology.	  In	  a	  series	  of	  599	  patients	  undergoing	  liver	  resection,	  the	  incidence	  of	  
VTE	   was	   4.7%	   overall	   with	   no	   significant	   difference	   for	   patients	   with	   malignant	   versus	  
benign	   conditions.	   It	  was	   noted	   that	   patients	  who	   have	   a	  major	   liver	   resection	  were	   less	  
likely	  to	  receive	  thromboprophylaxis	  with	  low	  molecular	  weight	  heparin	  (LMWH)	  because	  of	  
the	   raised	   INR,	   yet	   the	   incidence	   of	   VTE	   in	   this	   series	  was	   14.3%	   in	   patients	  with	   a	   peak	  
postoperative	  INR	  ≥	  1.5	  compared	  to	  3.6%	  in	  patients	  with	  peak	  INR	  ≤	  1.5	  (10).	   It	  has	  also	  
been	  demonstrated	  that	  patients	  undergoing	  liver	  resection	  have	  the	  highest	  rate	  of	  VTE	  for	  
any	  surgical	  procedure	  (294).	  
7.2	  Aims	  of	  this	  study	  
The	   discordance	   between	   CCTs	   and	   clinical	   complications	  merits	   detailed	   investigation	   of	  
post-­‐operative	   coagulation	   changes	   as	   the	   results	   might	   help	   inform	   the	   necessity	   (or	  
otherwise)	   of	   plasma	   transfusion	   and	   the	   timing	   of	   pharmacological	   thromboprophylaxis.	  
We	   undertook	   this	   prospective,	   longitudinal,	   observational	   study	   to	   document	   serial	  
changes	   over	   time	   of	   conventional	   coagulation	   tests,	   coagulation	   factor	   levels	   including	  
procoagulant	   and	   endogenous	   anticoagulant	   proteins,	   thrombin	   generation	   and	  
thromboelastometry	  in	  patients	  undergoing	  major	  hepatic	  resection.	  
7.3	  Methods	  
	  
The	  study	  was	  approved	  by	  the	  local	  research	  ethics	  committee	  (REC	  no.	  10/H0714/12)	  and	  
all	  patients	  gave	  written	  informed	  consent.	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7.3.1	  Patient	  selection	  
Patients	   referred	   for	  major	  hepatic	   resection	  were	   included	   in	   the	   study.	  A	  major	  hepatic	  
resection	   was	   defined	   as	   ≥	   30%	   volume	   resection	   judged	   by	   CT	   scan	   during	   work-­‐up.	  
Exclusion	   criteria	   were	   evidence	   of	   chronic	   liver	   disease,	   anticoagulant	   or	   antiplatelet	  
medication	   in	   the	  week	  preceding	  operation,	   oral	   contraceptive	  or	  hormone	   replacement	  
therapy,	  history	  of	  an	  inherited	  or	  acquired	  bleeding	  disorder	  or	  previous	  thromboembolic	  
disease.	   Patients	   who	   had	   a	   smaller	   than	   planned	   liver	   resection,	   or	   whose	   subsequent	  
pathology	   showed	   cholestasis	   or	   cirrhosis	   of	   the	   liver,	   were	   excluded	   post-­‐hoc.	  
Perioperative	   care	   was	   overseen	   by	   a	   dedicated	   team	   of	   hepatobiliary	   anaesthetists	   and	  
surgeons.	   Intraoperative	  transfusion	  of	  packed	  red	  cells	  was	  limited	  to	  those	  patients	  with	  
haemoglobin	  <	  80	  g.l-­‐1	  whilst	  plasma	  and	  platelet	  transfusions	  were	  given	  at	  the	  discretion	  
of	  the	  attending	  clinicians.	  Post-­‐operative	  transfusion	  practice	  was	  left	  to	  the	  discretion	  of	  
the	  attending	   surgeons	  and	   intensivists.	  Attending	  clinicians	  were	  blinded	   to	  ROTEM®	  and	  
thrombin	  generation	  results	  although	  they	  had	  access	  to	  results	  of	  conventional	  testing.	  
Thromboprophylaxis	   followed	  our	   standard	   local	   protocol.	   Patients	  wore	   thromboembolic	  
stockings	   unless	   contraindicated	   and	   pneumatic	   compression	   devices	   were	   used	   intra-­‐
operatively.	  Prophylactic	  LMWH	  was	  commenced	  as	  soon	  as	   the	   INR	  was	  ≤	  1.5,	  and	  there	  
were	  no	  signs	  of	  bleeding.	  	  
7.3.2	  Laboratory	  assays	  
Blood	   sampling	   was	   undertaken	   at	   five	   time	   points:	   baseline	   (after	   insertion	   of	   central	  
venous	  line	  but	  before	  knife-­‐to-­‐skin),	  end	  of	  surgery	  (at	  least	  30	  minutes	  following	  removal	  
of	   liver	  specimen),	  post-­‐operative	  day	  one,	  two	  and	  five.	  Samples	  were	  drawn	  either	  from	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central	  venous	  catheter	  (CVC)	  lines	  if	  in	  situ	  or	  by	  atraumatic	  venepuncture	  of	  an	  antecubital	  
vein	  using	  a	  21G	  needle after	  a	  10	  ml	  discard	  into	  BD	  Vacutainer®	  tubes(	  Becton,	  Dickinson	  
and	   Company,	   Oxford,	   England)	   	   for	   study	   bloods	   and	   routine	   bloods	   for	   clinical	   care.	  
Samples	  were	   taken	  at	   least	  12	  h	  after	  administration	  of	   LMWH	   in	  order	   to	  minimise	  any	  
anticoagulant	  effects	  on	  the	  laboratory	  assays.	  
	  
The	  PT	  was	  measured	  using	  HemosIL™	  PT	  Fibrinogen	  HS	  Plus	   (Instrumentation	  Laboratory	  
(IL),	   Bedford,	   MA,	   USA)	   and	   INR	   was	   calculated	   using	   geometric	   mean	   PT	   and	   the	  
manufacturer’s	   international	   sensitivity	   index	   (1.15).	   The	   APTT	   was	   obtained	   using	  
HemosIL™	   SynthaSIL	   (IL,	   Bedford,	   MA,	   USA).	   	   The	   following	   coagulation	   factors	   were	  
analysed	  on	  all	  patients:	  fibrinogen,	  factors	  (F)	  II,	  VII,	  VIII,	  X,	  XI,	  vonWillebrand	  factor	  (VWF)	  
antigen,	   anti-­‐thrombin	   (AT)	   levels,	   protein	   C	   activity,	   Protein	   free	   antigen	   and	   D-­‐dimers.	  
Blood	  was	  collected	  into	  BD	  Vacutainer	  ®	  tubes	  with	  a	  blood	  to	  citrate	  ratio	  of	  9:1	  (Beckton	  
Dickinson,	  Oxford,	  UK).	  Platelet	  poor	  plasma	  (PPP)	  was	  prepared	  by	  centrifugation	  at	  2000g	  
for	  12	  minutes,	  plasma	  removed	  and	  re-­‐centrifuged	  at	  2000g	  for	  12	  minutes.	  	  PPP	  samples	  
were	  stored	  in	  aliquots	  at	  -­‐85oC	  until	  testing.	  	  
Fibrinogen	  was	  analysed	  using	  Fibrinogen-­‐C	  reagent	  on	  an	  ACL	  TOP	  analyser.	   	  Factors	  VIII,	  
IX,	  XI	  and	  XII	  were	  analysed	  by	  standard	  one-­‐stage	  APTT	  based	  assays.	  Factors	  II,	  V	  and	  VII	  
were	   analysed	   by	   a	   one	   stage	   clotting	   PT-­‐based	   assay	   on	   an	   ACL	   3000	   (IL,	   Bedford,	  MA,	  
USA).	  Von	  Willebrand	  Factor	   (VWF)	  antigen	  was	  analysed	  by	  an	   in-­‐house	  ELISA.	  Protein	  C	  
activity	  was	  tested	  using	  HaemosIL	  chromogenic	  protein	  C	  assay	  and	  free	  protein	  S	  using	  the	  
HaemosIL	   free	   protein	   S	   assay	   (both	   IL).	   AT	   activity	   was	   measured	   using	   Berichrom	  
Antithrombin	   III	  assay	  (Siemens,	  Germany)	  on	  a	  Cs2000i	   (Sysmex,	  Milton	  Keynes,	  UK).	  The	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Protein	   C/	   FVIII	   ratio	   was	   calculated	   at	   all-­‐time	   points	   as	   a	   surrogate	   marker	   of	   anti-­‐
coagulant	  and	  procoagulant	  balance	  (157,	  262).	  
Thrombin	   generation	   was	   assessed	   at	   all	   time-­‐points	   on	   platelet-­‐poor	   plasma	   using	   the	  
Calibrated	  Automated	  Thrombography	  method	  as	  described	  by	  Hemker	  et	  al	  (67).	  Thrombin	  
generation	   assays	   were	   triggered	   with	   5	   pM	   tissue	   factor	   reagent	   containing	   4	   µM	  
phospholipid	  (PPP	  reagent,	  Thrombinoscope	  B.V.,	  Maastricht,	  Netherlands);	  measurements	  
included	   lag	   time	   (LT),	  endogenous	   thrombin	  potential	   (ETP)	  or	   total	   thrombin	  generated,	  
and	  peak	  height	   (PH).	  All	  values	  were	  normalised	  and	  expressed	  as	  percent	  of	   the	  normal	  
pooled	  plasma	  assayed	  in	  parallel	  in	  each	  test	  run.	  	  
A	   sample	   of	   blood	   was	   taken	   in	   standard	   Vacutainer	   tubes	   containing	   0.019	   M	   buffered	  
trisodium	   citrate	   for	   the	   Protac®-­‐modified	   thrombin	   generation	   assay	   at	   baseline	   and	   on	  
POD	   1	   (66).	   Protac®	   (Pentapharm,	   Basel,	   Switzerland)	   is	   a	   snake	   venom	   extract	   that	  
activates	  protein	  C,	  in	  a	  similar	  manner	  to	  thrombomodulin.	  This	  assay	  has	  been	  validated	  in	  
patients	   with	   defects	   of	   protein	   C	   anticoagulant	   pathways,	   and	   has	   been	   shown	   to	   be	  
sensitive	  to	  deficiencies	  of	  protein	  C,	  protein	  S	  and	  other	  pro-­‐thrombotic	  states	  (295).	  	  The	  
endogenous	   thrombin	   potential	   with	   Protac®	   (ETP-­‐Protac®)	   is	   presented	   as	   %	   of	   the	  
endogenous	  thrombin	  potential	  without	  Protac®	  for	  that	  sample.	  	  
For	   the	   ROTEM	   analysis,	   blood	   was	   drawn	   into	   citrated	   BD	   Vacutainer®	   tubes	   with	  
blood:citrate	   equivalent	   to	   9.	   Analysis	   was	   performed	   on	   a	   ROTEM	   delta	   analyser	   (TEM	  
International	  GmbH,	  Munich,	  Germany).	  Four	  panels	  were	  analysed	  per	  timepoint	  following	  
recalcification	   with	   Star-­‐tem	   reagent	   (0.2	   mol.l-­‐1	   CaCl2	   in	   HEPES	   buffer	   pH	   7.4	   and	   0.1%	  
sodium	  acid).	  	  




EXTEM:	  recombinant	  tissue	  factor	  and	  phospholipids	  –	  extrinisic	  pathway	  activation	  
INTEM:	  partial	  thromboplastin	  phospholipid	  and	  ellagic	  acid	  –	  intrinsic	  pathway	  activation	  
HEPTEM:	   heparinase	   I	   from	   flavobacteria	   –	   intrinsic	   pathway	   with	   exclusion	   of	   heparin	  
effect	  
FIBTEM:	  cytochalasin	  D	  –	  platelet	  inactivation,	  demonstrating	  contribution	  of	  fibrinogen	  and	  
factor	  XIII	  	  
	  
7.3.3	  Statistical	  analysis:	  	  
To	  assess	  change	  over	  time,	  repeated	  measures	  of	  analysis	  of	  variance	  was	  carried	  out	  on	  
the	  levels	  of	  each	  variable	  assessed	  at	  the	  four	  postoperative	  time	  points,	  with	  the	  baseline	  
values	   used	   as	   covariates.	   Statistical	   significance	  was	   assessed	   at	   the	   5%	   level	   (P-­‐value	   <	  
0.05),	   and	   within	   subject	   effects	   were	   corrected	   using	   the	   conservative	   Box	   technique.	  
Variables	   were	   assessed	   for	   normality	   using	   the	   Shapiro-­‐Wilks	   test	   before	   and	   after	   log	  
transformation.	  Where	   analyses	   examining	   associations	   between	   different	   variables	  were	  
required,	   we	   calculated	   Pearson	   correlation	   coefficients.	   Analysis	   was	   performed	   using	  
GRAPHPAD®	  software	  (	  San	  Diego,	  CA,	  USA).	  
7.4	  Results	  
 
Sixty	   patients	   were	   recruited,	   and	   45	   patients	   were	   included	   in	   the	   final	   analysis	   as	   the	  
remainder	  met	  exclusion	  criteria.	  Patient	  demographics,	   type	  of	   surgery	  and	  histology	  are	  
shown	   in	   Table	   7.1.	   Colorectal	   cancer	   metastasis	   was	   the	   most	   common	   indication.	   All	  
patients	  had	  normal	  baseline	  liver	  function.	  





7.4.1	  Patient	  Demographics	  
 
 




	   	  
Gender	  	  
	  
Male	  	   27	  (60%)	  
Female	  	   18	  (40%)	  
	   	  
Operative	  procedure	   	  
Right	  hepatectomy	   23	  (51%)	  
Extended	  right	  hepatectomy	   4	  (9%)	  
Left	  hepatectomy	   6	  (13%)	  
Extended	  left	  hepatectomy	   4	  (9%)	  
Multiple	  non-­‐contiguous	  segmentectomy	   8	  (18%)	  
	   	  
Histology	   	  
Colorectal	  carcinoma	  metastases	   35	  (78%)	  
Hepatocellular	  carcinoma	   5	  (11%)	  
Benign	  adenoma	   1	  (2%)	  
Focal	  Nodular	  Hyperplasia	   1	  (2%)	  
Neuroendocrine	  tumour	  metastases	   1	  (2%)	  
Other	  metastases	   2	  (4%)	  
	  
Table	  7.1.	  Baseline	  patient	  demographics,	  procedure	  type	  and	  aetiology	  of	  hepatic	  lesions.	  




Alterations	  in	  coagulation	  profile	  following	  major	  hepatic	  resection	  
140	  
	  
7.4.2	  Transfusion	  data	  
Details	   of	   blood	   product	   usage	   are	   given	   in	   Table	   7.2.	   Patients	   with	   extended	   resections	  
received	   proportionally	   higher	   transfusions.	  One	   patient	   died	   on	   POD	   5	   from	  multi-­‐organ	  
failure.	  LMWH	  prophylaxis	  was	  administered	  to	  17%	  of	  patients	  on	  POD1,	  48%	  of	  patients	  
on	  POD	  2	  and	  89%	  of	  patients	  by	  POD	  5.	  In	  total	  three	  patients	  (6.6%)	  were	  diagnosed	  with	  
DVT	  and/or	  PE	  within	  one	  month	  of	  surgery	  (POD	  3,	  4	  and	  14).	  The	  mean	  age	  of	  these	  three	  
patients	  was	  76.7	  years	  .The	  two	  patients	  who	  had	  VTE	  on	  days	  3	  and	  4	  had	  POD	  2	  INR	  of	  
1.7	  and	  2.3	  respectively.	  The	  patient	  with	  a	  DVT	  on	  day	  14	  did	  not	  start	  thromboprophylaxis	  
until	  POD	  5.	  
 
Intraoperative	   Post-­‐operative	  	  






Red	  blood	  cells	   0	  (0-­‐0)	   0	   0	  (0-­‐2)	   18	  (40%)	  
Fresh	   Frozen	  
Plasma	  
0	  (0-­‐0)	  	   4	  (8.9%)	   0	  (0-­‐0)	   7	  (15.6%)	  
Platelets	   	  	  0	  (0-­‐0)	  	  	  	  	   0	   0	  (0)	   3	  (6.7%)	  
	  
Table	   7.2	   Intra	   and	   post-­‐operative	   transfusion	   data.	   Values	   are	   for	   the	   whole	   patient	  
group,	  not	  just	  those	  transfused	  and	  presented	  as	  median	  (IQR)	  or	  number	  (percentage).	  
 
7.4.3	  Changes	  in	  blood	  biochemistry	  and	  coagulation	  
Table	  7.3	  describes	  the	  changes	  in	  routine	  haematology,	  chemistry	  and	  coagulation	  by	  POD.	  
The	  mean	  drop	  in	  haemoglobin	  in	  the	  immediate	  post-­‐	  operative	  period	  was	  approximately	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20	   g.l-­‐1,	   representing	   a	   combination	   of	   blood	   loss	   and	   haemodilution.	   Platelet	   counts	  
decreased	   reaching	   a	   nadir	   on	  POD	  1,	   in	   contrast	   to	   fibrinogen,	  which	  had	   the	  maximum	  
decrease	  by	  the	  end	  of	  surgery,	  and	  subsequently	  levels	  increased	  above	  baseline	  from	  POD	  
2.	   APTT	   remained	   within	   the	   normal	   range	   throughout	   the	   study	   period.	   	   The	   INR	   was	  
increased	  from	  the	  end	  of	  surgery,	  with	  the	  highest	  values	  on	  POD	  1	  (Median	  1.7)	  and	  POD	  
2	  (Median	  1.6);	  by	  POD	  5	  all	  but	  one	  patient	  had	  an	  INR	  ≤	  1.5.	  (Figure	  7.1)	  The	  number	  of	  
patients	  with	  abnormal	  conventional	  coagulation	  was	  highest	  on	  POD	  1	  with	  30%	  of	  patients	  
showing	  an	  INR	  ≥	  2.0. 





End	   of	  
surgery	  
POD	  1	   POD	  2	   POD	  5	  
Haemoglobin;	  g.l-­‐1	   135-­‐170	   118	  (19)	   95	  (18)	  *	   99	  (16)*	   98	  (15)*	   102	  (14)*	  
Platelets;	  x109	  .l-­‐1	   140-­‐400	   231	  (97)	   192	  (73)	   167	  (76)*	   173	  (100)	   240	  (145)	  
Albumin;	  g.l-­‐1	   35-­‐50	   38	  (4)	   24	  (6)*	   25	  (5)*	   27	  (4)*	   30	  (6)	  
Alanine	  aminotransferase;	  iu.l-­‐1	   <41	   38	  (41)	   335	  (197)*	   411	  (243)*	   372	  (274)*	   149	  (86)*	  
Bilirubin;	  µmol.l-­‐1	  
	  
<21	   12	  (7)	   16	  (9)	   33	  (22)*	   27	  (24)	   31	  (32)	  
Alkaline	  phosphatase:	  iu.l-­‐1	   <129	   99	  (72)	   80	  (84)	   70	  (45)	   85	  (46)	   191	  (103)*	  
Urea;	  mmol.l-­‐1	   2.9-­‐8.2	   5.1	  (1.9)	   5.0	  (1.8)	   5.5	  (1.6)	   6.2	  (2.1)	   5.6	  (4.1)	  
Creatinine;	  µmol.l-­‐1	   66-­‐112	   69	  (19)	   71	  (23)	   70	  (24)	   69	  (30)	   62	  (23)	  











Activated	   partial	  












Fibrinogen;	  g.l-­‐1	   1.5-­‐4	   3.2	  (0.7)	   2.1	  (0.7)*	   2.7	  (0.8)	   3.8	  (1.1)	   4.5	  (1.4)*	  
 
Table7.3	   	  Routine	  haematology,	  biochemistry	  and	  coagulation	  tests	  against	  time.	  Data	  are	  
presented	  as	  mean	  (SD)	  or	  median	  (IQR).	  *	  P-­‐value	  <	  0.05.	  
	  




Figure	   7.1	   :	   Changes	   in	   INR	   by	   POD.	  Variation	   of	   INR	   at	   post-­‐operative	   timepoints.	   Error	  
bars	  indicate	  interquartile	  range.	  Green	  lines	  represent	  reference	  ranges	  (INR:	  0.8-­‐1.2)	  
	  
7.4.4	  Changes	  in	  pro	  and	  anti-­‐coagulant	  levels	  
Pro-­‐coagulants:	  Levels	  of	  the	  procoagulant	  factors	  II,	  V,	  VII	  and	  X	  all	  fell	  postoperatively	  with	  
the	  lowest	  values	  seen	  on	  POD	  1.	  By	  POD	  5	  levels	  were	  returning	  towards	  baseline	  (Figure	  






































Anti-­‐coagulant	  proteins:	  Levels	  of	  the	  anticoagulants,	  AT,	  protein	  C	  and	  protein	  S	  decreased	  
in	  a	  similar	  manner	  to	  the	  procoagulants,	  but	  by	  contrast,	  by	  POD	  5	  AT	  and	  protein	  C	  remain	  
low	  at	  60	  iu.dl-­‐1	  and	  65	  iu.dl-­‐1	  respectively	  (Figure	  7.4).	  The	  ratio	  of	  the	  one	  of	  most	  powerful	  
anticoagulant	  drivers,	  protein	  C,	   to	   the	  procoagulant	  VIII	  was	   reduced	   in	  all	  patients	   from	  
Figure	  7.2	  Changes	  in	  pro-­‐coagulant	  levels	  (factors	  II,	  V,	  VII	  and	  X)	  at	  post	  operative	  
time	  points.	  Error	  bars	  indicate	  95%	  confidence	  intervals.	  Green	  lines	  represent	  
reference	  ranges	  (II:	  68-­‐144	  iu.dl-­‐1,	  V:	  39-­‐129	  iu.dl-­‐1,	  VII:	  45-­‐180	  iu.dl-­‐1,	  X:	  49-­‐152	  iu.dl-­‐1)	  
	  
Figure	  7.3	  Changes	  in	  Factor	  VIII	  and	  VWF	  by	  POD	  Variation	  of	  von	  Willebrand	  
Factor	  (VWF)	  and	  factor	  VIII	  at	  post-­‐operative	  timepoints.	  Error	  bars	  indicate	  
95%	  confidence	  intervals.	  Green	  lines	  represent	  reference	  ranges	  (Factor	  VIII:	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the	  end	  of	  surgery,	  and	  this	  continued	  to	  fall	  and	  was	  most	  pronounced	  by	  POD	  5.	  This	  ratio	  
was	  lowest	  in	  patients	  with	  an	  INR≥2.0	  (ratio	  of	  0.09	  compared	  to	  baseline	  ratio	  of	  0.69).	  D-­‐
dimers	  were	   raised	   from	  baseline	   values	   (365ng.ml-­‐1)	   at	   the	   end	   of	   surgery	   (2400ng.ml-­‐1)	  








Figure	  7.4	  Change	  in	  anticoagulant	  levels,	  
protein	  S	  (PS),	  protein	  C	  (PC)	  and	  
antithrombin	  (AT)	  by	  POD.	  Error	  bars	  
indicate	  95%	  confidence	  intervals.	  Green	  
lines	  represent	  reference	  ranges	  (Protein	  C:	  
70-­‐140	  iu.dl-­‐1,	  Protein	  S:	  60-­‐140	  iu.dl-­‐1,	  Anti-­‐
thrombin:	  86-­‐114iu.dl-­‐1)	  
1:	  Change	  in	  Protein	  S	  by	  POD	   2:	  Change	  in	  Protein	  C	  by	  POD	  
3:	  Changes	  in	  antithrombin	  by	  POD	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Ratio	  of	  Protein	  C	   to	   Factor	  VIII:	   This	   ratio	   steadily	  decreased	   from	   the	   value	  at	  baseline	  
(0.69	  ±	  0.31))	  at	  all	  measured	  time	  points,	  and	  was	  at	  its	  lowest	  value	  by	  POD	  5	  (0.15±	  0.10).	  
Patients	  with	  an	  INR	  ≤	  1.5	  had	  a	  PC	  to	  VIII	  ratio	  of	  0.24	  ±	  0.14	  on	  POD	  5,	  whereas	  patients	  
with	  an	  INR	  of	  1.6	  or	  greater	  had	  a	  ratio	  of	  0.09	  ±	  0.05.	  
7.4.5	  Changes	  in	  thrombin	  generation	  parameters	  	  
Despite	   a	   small	   numerical	   reduction	   in	   endogenous	   thrombin	   potential	   and	   peak	   height	  
initially,	  these	  values	  remained	  within	  reference	  ranges	  throughout	  (Figure	  7.5).	  No	  patient	  
had	   any	   thrombin	   generation	   parameters	   suggestive	   of	   hypercoagulability,	   however,	   ETP-­‐
Protac,	   was	   higher	   in	   the	   postoperative	   period	   (POD	   1)	   compared	   to	   the	   pre-­‐operative	  
period	  consistent	  with	  hypercoagulabilty	  due	  to	  protein	  C	  resistance	  and	  deficiency.	  By	  POD	  
5,	  all	  parameters	  had	  returned	   to	  a	   level	  equivalent	   to,	  or	  prothrombotic	  with	   respect	   to,	  
baseline.	  
ETP-­‐	   Protac®%	   (	   Derived	   by	   dividing	   ETP+Protac®	   by	   ETP	  without	   Protac®)	   demonstrated	  
increased	   thrombin	   generation	   on	   POD	   1	   compared	   to	   baseline	   	   (44%	   vs	   26%).	   This	  
hypercoagulable	   profile	   became	  more	   pronounced	   as	   the	   INR	   increased:	   ETP-­‐Protac®	   on	  
POD	  1	  was	  38%	  when	  INR	  ≤	  1.5,	  44%	  when	  INR	  1.6-­‐1.9,	  and	  66%	  when	  INR	  ≥	  2.0.	  
	  
7.3.6	  Changes	  in	  ROTEM	  parameters	  
All	  ROTEM	  parameters	   remained	  within	  normal	   range	  post	  operatively	   for	   the	  group	  as	   a	  
whole,	   despite	   a	   small	   decrease	   in	   values	   on	   POD1.	   The	   absolute	   decrease	   in	   values	   are	  
unlikely	   to	   represent	   any	   clinically	   significant	   impairment	   of	   coagulation	   as	   they	   remain	  
within	  normal	  range	  (Figure	  7.6).	  	  In	  three	  patients	  there	  was	  a	  reduction	  in	  EXTEM	  CT,	  after	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the	   end	   of	   surgery,	   indicative	   of	   more	   rapid	   clot	   formation.	   Very	   few	   patients	   had	   a	   CT	  
outside	  the	  upper	  limits	  of	  the	  reference	  range,	  and	  all	  these	  had	  factor	  II	  levels	  less	  than	  30	  
iu.dl-­‐1.	  EXTEM	  MCF	  fell	  slightly	  from	  baseline	  at	  end	  of	  surgery	  and	  on	  POD	  1,	  but	  exceeded	  
baseline	   values	   by	   POD	   5.	   FIBTEM	   levels	   were	   lowest	   immediately	   post	   operatively	   and	  
steadily	  rose	  from	  POD	  1,	  and	  were	  outside	  the	  upper	  limit	  of	  the	  reference	  range	  by	  POD	  5	  
in	  keeping	  with	  the	  increase	  in	  fibrinogen	  levels	  on	  days	  2	  and	  5.	  	  
There	  was	  minimal	  correlation	  between	  INR	  and	  EXTEM	  CT	  at	  each	  timepoint	  (r=0.25-­‐0.47,	  
p=<0.001-­‐0.09).	   EXTEM	  MCF	   and	   platelet	   count	   carried	   a	   stronger	   correlation(r=0.61-­‐0.7,	  
























Figure	  7.5	  Change	  in	  thrombin	  
generation	  parameters	  by	  POD	  Error	  
bars	  indicate	  interquartile	  ranges.	  
Green	  lines	  represent	  reference	  ranges	  
(LT	  1.3-­‐2.5	  mins,	  PH	  250-­‐425	  nM,	  ETP	  
170-­‐280	  nMxmin).	  
	  
1:	  Change	  in	  Lag	  Time	  by	  POD	   2:	  Change	  in	  Peak	  Height	  by	  POD	  
3:	  Change	  in	  endogenous	  thrombin	  
potential	  by	  POD	  








7.4	  	  Discussion	  
	  
	  
1:	  Changes	  in	  EXTEM	  CT	  by	  POD	  
2:	  Changes	  in	  EXTEM	  MCF	  by	  POD	  
3:	  Changes	  in	  FIBTEM	  MCF	  by	  POD	  
	  
Figure	  7.6	  Changes	  in	  ROTEM	  parameters	  by	  POD.	  Error	  bars	  indicate	  
interquartile	  ranges.	  Green	  lines	  represent	  reference	  ranges	  (EXTEM	  CT:	  38-­‐
79	  seconds,	  EXTEM	  CFT:	  34-­‐159	  seconds,	  EXTEM	  MCF:	  50-­‐72mm,	  FIBTEM	  
MCF:	  9-­‐25mm)	  
	  




This	   study	   in	  a	   large	  and	  relatively	  homogenous	  group	  of	  patients,	   in	  which	  we	  measured	  
concurrent	   changes	   in	   conventional	   coagulation	   tests,	   pro	   and	   anticoagulant	   levels,	  
thrombin	   generation	   and	   thromboelastometry	   in	   the	   early	   post	   operative	   period,	  
demonstrates	  that	  the	  conventional	  coagulation	  tests	  (PT/INR)	  need	  to	  be	  interpreted	  with	  
caution	  following	  major	  liver	  resection.	  
The	  degree	  of	  parenchymal	  loss,	  and	  extent	  of	  hepatectomy,	  have	  a	  significant	  effect	  on	  the	  
synthesis	  of	  liver	  derived	  clotting	  factors,	  and	  this	  is	  reflected	  in	  the	  fact	  that	  most	  patients	  
following	   major	   liver	   resection	   have	   an	   elevated	   INR.	   This	   has	   been	   interpreted	   as	  
representing	  a	  potential	  bleeding	  risk	  and	  consequently	  used	  as	  a	  basis	  for	  clinical	  decision-­‐
making,	   including	  when	   to	   start	   thromboembolic	   prophylaxis.	   (296).	   However,	   the	   risk	   of	  
thromboembolic	  events	   in	   these	  patients	  exceeds	   the	  bleeding	   risk,	   and	   is	   increased	  with	  
the	   extent	   of	   liver	   volume	   resected	   (288).	   This	   is	   becoming	   of	   increasing	   importance	  
because	  not	  only	  is	  the	  number	  and	  complexity	  of	  hepatic	  resections	  increasing,	  but	  also	  the	  
age	  and	  associated	  co-­‐morbidity	  of	  patients	  (276).	  
Our	  study	  shows	  that	  although	  procoagulant	  levels	  are	  largely	  returning	  to	  normal	  by	  POD	  5,	  
levels	  of	   the	  anticoagulant	  proteins,	   specifically	  protein	  C	  and	  AT	   remain	   suppressed.	   The	  
proportional	  reduction	   in	  anticoagulant	  to	  procoagulant	  proteins,	  as	  shown	  by	  a	  deranged	  
protein	  C:FVIII	  ratio,	  is	  more	  profound	  in	  patients	  with	  higher	  values	  of	  INR	  (≥1.5),	  and	  this	  
together	  with	  the	  raised	   levels	  of	  Factor	  VIII	  and	  VWF	  creates	  a	  potentially	  prothrombotic	  
state	   (157,	   297).	   	   The	   situation	   is	   therefore	   far	   more	   complex	   than	   the	   commonly	   held	  
assumption	  that	  the	  post	  operative	   increase	  in	   INR	  de	  facto	  reflects	  an	  increased	  bleeding	  
risk.	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We	   found	   that	  pro-­‐coagulant	   factor	   levels	  were	  all	   reduced	   following	   liver	   resection,	  with	  
the	   exception	   of	   FVIII,	   which	   steadily	   increased	   [20].	   	   That	   these	   changes	   are	   specific	   to	  
hepatic	   resection,	   and	   are	   not	   mirrored	   by	   other	   abdominal	   surgery,	   such	   as	  
pancreaticoduodenectomy,	  has	  been	  demonstrated	  in	  a	  number	  of	  other	  studies	  [21-­‐22,	  30-­‐
31].	   Following	  other	   types	  of	  major	   surgery,	   there	   is	  a	   small	   (20%)	   initial	   reduction	   in	  pro	  
and	  anticoagulant	  levels	  up	  to	  POD2,	  and	  only	  modest	  increases	  in	  VWF	  and	  FVIII	  (298).	  	  	  
The	   reduction	   in	   coagulation	   inhibitors	   persists	   well	   beyond	   the	   time	   that	   INR	   and	  
fibrinogen	   levels	   normalize,	   suggesting	   that	   the	   haemostatic	   balance	   rapidly	   favors	  
procoagulant	  rather	  than	  anticoagulant	  mechanisms.	  We	  also	  found	  a	  rise	  in	  D-­‐dimer	  levels,	  
consistent	  with	  active	  clot	  formation	  and	  turnover	  [23-­‐24,32].	  	  
Although	   conventional	   tests	   of	   coagulation	   (as	   shown	   by	   a	   significant	   increase	   in	   INR)	  
indicate	  a	  hypocoagulable	  state	  following	  liver	  resection,	  thromboelastometry	  and	  thrombin	  
generation	  results	  within	  our	  study	  remained	  within	  the	  reference	  ranges	  for	  the	  group	  as	  a	  
whole,	  suggesting	  that	  haemostatic	  capacity	  may	  be	  preserved	  to	  a	  greater	  degree	  than	  has	  
previously	  been	  thought.	  These	  findings	  are	  similar	  to	  those	  reported	  by	  other	  groups	  (284,	  
287,	  299).	  It	  is	  now	  recognized	  that	  conventional	  coagulation	  tests	  have	  many	  limitations,	  in	  
that	  they	  are	  insensitive	  to	  endogenous	  anticoagulant	  levels,	  and	  give	  no	  information	  on	  the	  
presence	  or	  absence	  of	  hypercoagulability	  (300).	  Viscoelastic	  coagulation	  tests,	  measure	  the	  
dynamics	   of	   clot	   formation,	   from	   initiation,	   speed	   of	   clot	   strengthening	   through	   to	   clot	  
stabilization	   and	   dissolution,	   and	   give	   an	   integrated	   assessment	   of	   the	   entire	   coagulation	  
process.	  It	  has	  been	  demonstrated	  that	  they	  may	  give	  more	  valuable	  information	  about	  the	  
overall	  haemostatic	  status	  than	  PT/INR	  in	  critically	  ill	  patients	  (301)	  and	  in	  patients	  with	  liver	  
disease	  (135).	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Despite	   an	   elevated	   INR,	   in	   our	   series	   most	   patients	   had	   normal	   ROTEM	   parameters,	  
consistent	  with	  results	  shown	  in	  other	  studies.	  It	  is	  of	  note	  that	  where	  hypercoagulablity	  has	  
been	   described	   in	   these	   studies,	   this	   relates	   to	   either	   a	   shortening	   of	   the	   R/CT	   (clot	  
initiation),	   usually	   immediately	   after	   surgery,	   or	  more	   frequently,	   an	   increase	   in	  MA/MCF	  
from	  POD	  5	  onwards	  (283,	  287).	  It	  is	  well	  known	  that	  there	  is	  poor	  correlation	  between	  the	  
PT/INR	  and	  R/CT	   time	  of	  viscoelastic	   tests	   (207,	  302,	  303),	  and	   this	  was	  also	   found	   in	  our	  
series.	  The	  R	   (CT)	   time	  reflects	   the	  balance	  of	  pro	  and	  anticoagulants	  and	   is	  prolonged	  by	  
excess	  anticoagulants	  or	  low	  clotting	  factor	  levels	  (≤	  30%),	  and	  is	  shortened	  by	  excess	  tissue	  
factor,	  high	  VIII	  and	  low	  protein	  C	  (304).	  An	  increase	  in	  maximum	  clot	  firmness	  or	  amplitude	  
may	  be	  due	   to	  a	  combination	  of	   increased	   fibrinogen	   levels	  and	  also	  platelet	   reactivity.	   It	  
has	  also	  been	  shown	  there	   is	  a	  moderate	   to	   strong	  correlation	  of	  Factor	  VIII	   levels	   to	   the	  
ROTEM	  parameters	  EXTEM	  MCF	  and	  FIBTEM	  (305).	  High	  levels	  of	  Factor	  VIII,	  together	  with	  
low	  levels	  of	   its	  natural	   inhibitor,	  protein	  C,	  may	  be	  a	  partial	  explanation	  of	  the	  normal	  to	  
increased	   thrombin	   generation	   seen	   in	   patients	   following	   major	   liver	   resection	   and	  
contributes	   to	   the	   normal	   clot	   strength	   seen	   in	   these	   viscoelastic	   tests	   (306).	   Although	  
malignant	   disease	   is	   associated	   with	   a	   pro-­‐thrombotic	   tendency	   and	   increased	   risk	   of	  
thromboembolic	   events,	   a	   recent	   study	   that	   monitored	   patients	   post	   operatively	   with	  
thromboelastography	  found	  no	  difference	  between	  patients	  with	  either	  benign	  or	  malignant	  
indications	  for	  liver	  resection,	  and	  in	  addition	  there	  was	  no	  significant	  difference	  in	  patients	  
who	   had	   received	   chemotherapy,	   with	   all	   patients	   showing	   TEG	   parameters	   within	   the	  
normal	  range	  (307).	  	  
Thrombin	   generation	   assays,	   which	   measure	   the	   total	   amount	   of	   thrombin	   generated	   in	  
vitro,	   account	   for	   plasma	   concentrations	   of	   both	   pro	   and	   anticoagulants,	   unlike	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conventional	  coagulation	  tests	  that	  are	  responsive	  only	  to	  procoagulant	  levels.	  In	  our	  series	  
no	   differences	  were	   found	   for	   parameters	   of	   thrombin	   generation	  with	   the	   exception	   of	  
peak	   height,	   which	   was	   lower	   in	   patients	   with	   an	   INR	   ≥	   2.0.	   Measures	   of	   thrombin	  
generation	  in	  the	  first	  24	  hours	  suggest	  an	  activated	  coagulation	  presenting	  as	  shortened	  lag	  
time	   and	   time	   to	   peak,	   whereas	   the	   lower	   peak	   height	   and	   slope	   are	   consistent	   with	  
decreased	   procoagulant	   factor	   levels	   with	   a	   relative	   preservation	   of	   the	   endogenous	  
thrombin	  potential.	   	  Beyond	  the	  first	  24	  hours,	   thrombin	  generation	  parameters	  return	  to	  
normal	   range	   irrespective	  of	   the	  degree	  of	  prolongation	  of	   the	   INR.	  Simultaneously	   in	   the	  
post–operative	   period	   ETP-­‐Protac®	   is	   increased,	   and	   correlated	   with	   decreased	   protein	  
C/VIII	   ratio,	  confirming	  the	  presence	  of	  a	  prothrombotic	  environment	   (157).	  This	  ratio	  has	  
been	  documented	  to	  be	  associated	  with	  an	  increased	  thrombotic	  risk	  in	  patients	  (308).	  	  It	  is	  
of	  note	  that	  the	  lowest	  ratios	  in	  our	  series	  occurred	  in	  patients	  with	  the	  most	  elevated	  INRs	  
demonstrating	   dysregulated	   coagulation.	   A	   recent	   paper	   also	   found	   that	   although	  
endogenous	  thrombin	  potential	  decreases	  slightly	  following	  liver	  resection,	  the	  addition	  of	  
thrombomodulin	  to	  the	  assay	  resulted	  in	  increased,	  and	  slightly	  hypercoagulable	  indices	  of	  
thrombin	  generation,	   indicating	  that	  the	  profound	  and	  sustained	  post	  operative	  deficiency	  
in	  protein	  C,	  together	  with	  the	  relative	  protein	  C	  resistance,	  appears	  to	  be	  mechanistically	  
linked	  to	  a	  post	  operative	  pro-­‐thrombotic	  state	  (284).	  	  
From	   POD	   1	   onwards,	   an	   INR	   of	   ≤	   2.0	   s	   is	   associated	   with	   near	   normal	   levels	   of	   most	  
procoagulant	   factors	   and	  normal	   thrombin	   generation	  and	  ROTEM	  parameters	   across	  our	  
study	  population.	  Levels	  of	  factor	  VII	  were	  ≤	  30	  in	  some	  patients,	  irrespective	  of	  the	  INR,	  but	  
never	   less	   than	   10%,	   a	   level	  which	   is	   considered	   haemostatic	   for	   this	   factor	   (309).	   These	  
findings	  therefore	  question	  the	  practice	  of	  administering	  prophylactic	  FFP	  prior	  to	  invasive	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procedures	  purely	  to	  reduce	  a	  perceived	  bleeding	  risk	  if	  the	  INR	  ≤	  2,	  or	  indeed	  the	  need	  to	  
delay	   removal	   of	   epidural	   catheters	   until	   the	   INR	   returns	   to	   normal	   range.	   Although	  
transfusion	  of	  FFP	  will	  partially	  correct	  an	  elevated	   INR	   following	   liver	   resection,	   it	  has	  no	  
measurable	   effect	   on	   viscoelastic	   parameters	   that	   are	   already	  within	   normal	   range	   (310).	  	  
Our	   data	   supports	   the	   need	   for	   early	   initiation	   of	   thromboprophylaxis,	   and	   this	   is	  
paradoxically	   of	   even	   more	   importance	   in	   patients	   with	   more	   extensive	   resections	   and	  
consequently	  higher	   INR	  values.	   It	   is	  of	  note	  that	   in	  our	  own	  series,	  using	  the	   institutional	  
protocol	  for	  initiating	  pharmacological	  prophylaxis	  current	  at	  that	  time,	  50%	  of	  patients	  still	  
had	  not	  received	  low	  molecular	  weight	  heparin	  by	  POD	  2,	  as	  their	  INR	  was	  ≥	  1.5.	  Our	  study	  
was	  not	  powered	  to	  detect	  an	  association	  between	  coagulation	  profiles	  and	  the	  occurrence	  
of	   thrombotic	   events,	   nor	   did	  we	   prospectively	   observe	   for	   these.	  However,	   of	   the	   three	  
patients	  that	  did	  develop	  a	  VTE,	  it	  is	  of	  note	  that	  they	  were	  all	  relatively	  elderly,	  had	  more	  
extensive	  resections,	  and	  all	  had	  a	  significant	  delay	  in	  initiation	  of	  LMWH	  due	  to	  an	  elevated	  
INR.	  With	   the	  exception	  of	  one	  patient	  whom	  subsequently	  developed	  multiorgan	   failure,	  
no	  patient	  in	  this	  series	  had	  any	  complication	  related	  to	  bleeding.	  	  
7.6	  Conclusion	  	  
We	   have	   demonstrated	   that	   following	   major	   liver	   resection	   the	   post-­‐operative	   period	   is	  
characterised	  by	  a	  dynamic	  dysregulation	  of	   coagulation,	  with	   initially	   relatively	  balanced,	  
but	  low	  levels	  of	  pro	  and	  anticoagulants,	  with	  a	  rapid	  switch	  by	  POD	  2	  to	  a	  prothrombotic	  
environment,	  with	  depression	  of	  anticoagulant	   levels,	  and	  a	  decreased	  protein	  C/VIII	   ratio	  
persisting	  to,	  and	  probably	  beyond,	  POD5.	  The	  persistence	  of	  these	  prothrombotic	  changes	  
argues	  for	  an	  extended	  duration	  of	  anticoagulant	  therapy,	  as	  has	  been	  suggested	  by	  others	  
(311).	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Although	   thrombin	   generation	   assays	   give	   much	  more	   representative	   information	   of	   the	  
coagulation	   status	   than	   the	   INR,	   as	   they	   are	   sensitive	   to	   both	   pro	   and	   anti	   coagulant	  
proteins,	  they	  are	  moderately	  complex	  tests	  that	  are	  not	  currently	  routinely	  available.	  It	   is	  
of	  note	  that	  following	  liver	  resection,	  studies	  that	  have	  used	  global	  viscoelastic	  tests	  (TEG®	  
and	  ROTEM®)	  have	  also	  demonstrated	  normal	  coagulation	  status,	  despite	  a	  raised	  INR,	  and	  
some	   have	   shown	   hypercoagulability	   after	   POD	   5	   (299,	   312).	   It	  may	   be	   that	   these	   global	  
tests	  are	  more	  appropriate	  methods	  of	  monitoring	  the	  complex	  changes	  in	  coagulation	  that	  
follow	   major	   liver	   resection.	   We	   have	   shown	   that	   thromboelastometry	   demonstrates	  
normal	  coagulation	  in	  these	  patients,	  even	  when	  the	  INR	  is	  raised,	  and	  this	  is	  corroborated	  
by	   the	   contemporaneously	   matched	   falls	   in	   both	   pro	   and	   anticoagulant	   proteins	   with	  
preserved	   thrombin	   generation.	   It	   is	   important	   to	   appreciate	   that	   although	   the	   two	  most	  
commonly	   used	   viscoelastic	   tests	   (TEG,	   ROTEM)	   give	   essentially	   similar	   information,	   the	  
different	   activators	   and	   reagents	   used	   in	   the	   two	   technologies	   can	   introduce	   subtle	  
differences,	  and	  also	  standard	  operating	  procedures	  and	  quality	  assurance	  must	  be	  robustly	  
maintained	  when	  using	  this	  equipment	  (313).	  
There	   is	   likely	   to	   be	   a	   role	   for	   the	   use	   of	   viscoelastic	   coagulation	   testing	   for	   further	  
characterising	   patients	   with	   deranged	   conventional	   tests	   at	   the	   bedside	   to	   guide	   clinical	  
decisions,	  such	  as	  the	  need	  for	  transfusion	  of	  potentially	  hazardous	  blood	  products,	  and	  to	  
define	   the	   relative	   risk	   of	   thrombosis,	   but	   large	   scale	   clinical	   outcome	   studies	   will	   be	  
required	   to	   test	   this	  hypothesis.	  Crucially,	  our	   results	   show	  a	   switch	   to	  hypercoagulability	  
after	  24-­‐48	  hours.	  
Finally,	  it	  is	  clear,	  that	  following	  major	  liver	  resection,	  an	  elevated	  INR	  should	  not	  be	  taken	  
as	   evidence	   of	   “auto-­‐anticoagulation”.	   Thromboprophylaxis	   should	   always	   be	   started	   as	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soon	  as	  possible,	  and	  certainly	  when	  the	  INR	  is	  ≤	  2.	  The	  prevalence	  of	  VTE	  in	  these	  patients,	  
even	   in	   those	   that	   receive	   early	   chemoprophylaxis,	   highlights	   the	   need	   for	   more	   clinical	  
studies	  to	  define	  the	  best	  method	  of	  anticoagulating	  these	  patients,	  and	  to	  determine	  how	  
long	  the	  period	  of	  excess	  risk	  persists.	  
 







The	  efficacy	  of	  fresh	  frozen	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  to	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following	  major	  hepatic	  resection.	  
	  
An	  in	  vitro	  study	  of	  the	  efficacy	  of	  fresh	  frozen	  plasma	  to	  
correct	  prolonged	  INR,	  and	  to	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  the	  effect	  on	  
thromboelastographic	  parameters	  following	  major	  liver	  
resection	  published	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  2015.	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8.1	  Introduction	  	  
Following	  major	  liver	  resection	  there	  are	  frequently	  significant	  alterations	  in	  the	  coagulation	  
system.	  Many	   factors	   contribute	   to	   this,	   including	  pre-­‐existing	   liver	  dysfunction,	   extent	  of	  
intraoperative	   blood	   loss,	   surgical	   technique,	   ischaemia	   –	   reperfusion	   injury,	   and	  
importantly,	  the	  volume	  of	  liver	  remaining	  following	  resection,	  as	  most	  coagulation	  proteins	  
are	   synthesised	   in	   the	   liver	   (274,	   275).	   	   In	   the	   early	   post	   operative	   period,	   conventional	  
laboratory	   tests	   of	   coagulation	   are	   often	   indicative	   of	   a	   temporary	   hypocoagulable	   state,	  
however,	  in	  reality	  bleeding	  complications	  are	  rare	  (277).	  	  	  
Following	  hepatic	  resection,	  although	  levels	  of	  most	  procoagulants	  are	  reduced	  in	  the	  first	  
few	  days	  after	  surgery,	  leading	  to	  an	  increase	  in	  INR,	  there	  is	  also	  a	  concomitant	  decrease	  in	  
the	   natural	   anticoagulants,	   protein	   C	   and	   antithrombin	   (AT).	   Levels	   of	   factor	   VIII	   are	  
markedly	   elevated,	   and	   at	   the	   same	   time	   there	   are	   increases	   in	   von	  Willebrand’s	   factor	  
(VWF)	   	   and	   reduced	   levels	   of	   its	   cleavage	   enzyme	   ADAMTS-­‐13	   (312,	   314,	   315).	   The	  
coagulation	  status	  following	  major	  hepatic	  resection	  is	  therefore	  extremely	  complex,	  and	  it	  
is	   known	   that	   these	   patients	   have	   a	   significant	   risk	   of	   developing	   thromboembolic	  
complications,	  despite	  the	  elevated	  INR	  (289).	  Alternative	  tests	  of	  haemostatic	  competence	  
may	  give	  more	  meaningful	   information	   than	  conventional	  coagulation	   tests	   (CCT)	   in	   these	  
circumstances,	   and	   it	   is	   of	   note	   that	   global	   viscoelastic	   tests	   	   (VET)	   of	   coagulation	  
(thromboelastograph	   [TEG®]	  and	   thromboelastometry	   [	  ROTEM®]	   ,	  which	   reflect	  both	  pro	  
and	  anti-­‐coagulant	  activity	  have	  been	  shown	  to	  be	  within	  normal	  ranges	  	  (285,	  286)	  or	  even	  
hypercoaguable	  (287)	  in	  patients	  following	  hepatic	  resection.	  	  
Nevertheless,	   the	   almost	   universal	   increase	   in	   prothrombin	   time	   (PT)	   and	   international	  
normalized	  ratio	  (INR)	  following	  major	  liver	  resection	  is	  still	  generally	  assumed	  to	  represent	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a	  potential	  bleeding	  risk.	  	  This	  does,	  on	  occasion,	  lead	  to	  the	  administration	  of	  fresh	  frozen	  
plasma	   (FFP)	   to	   correct	   the	   INR	   to	   <1.5	   prior	   to	   invasive	   procedures	   (278),	   or	   to	   “cover”	  
epidural	   catheter	   removal	   in	   these	   patients	   ((316)	   .	   Although	   not	   all	   institutions	   would	  
transfuse	  FFP	  prior	  to	  invasive	  procedures	  in	  patients	  with	  an	  INR	  	  >1.5,	  a	  significant	  number	  
would	   (317).	   	   It	   is	   known	   that	   many	   clinicians	   do	   not	   routinely	   repeat	   the	   INR	   after	  
prophylactic	  transfusion	  of	  FFP,	  despite	  the	  fact	  that	  the	  change	  in	  INR	  is	  frequently	  minimal	  
(280),	  and	  dependant	  both	  on	  the	  initial	  INR,	  and	  the	  dose	  of	  FFP	  administered	  (318).	  
8.2	  	  Aims	  
The	  purpose	  of	   this	   observational	   in	   vitro	   study	  was	   to	  determine	  whether	   the	   two	  most	  
commonly	  used	  dose	  regimes	  of	  FFP	  (7.5ml/kg	  and	  15ml/kg)	  are	  effective	  in	  decreasing	  the	  
INR	  to	  1.5	  or	  less,	  in	  patients	  following	  major	  hepatic	  resection	  who	  have	  mild	  to	  moderate	  
(1.6	  -­‐2.5)	  prolongation	  of	  INR,	  as	  this	  is	  representative	  of	  the	  majority	  of	  these	  patients	  that	  
might	  receive	  prophylactic	  FFP	  transfusion	  prior	  to	  invasive	  procedures.	  As	  a	  secondary	  aim,	  
we	  performed	  TEG	  studies	  on	  all	  these	  patients	  	  to	  determine	  the	  global	  VET	  profile,	  and	  in	  
those	  whom	  the	  INR	  was	  >1.5	  on	  POD	  2	  we	  determined	  the	  effect	  on	  the	  VET	  parameters	  of	  
in	  vitro	  spiking	  with	  the	  same	  doses	  of	  FFP.	  	  
8.3	  Methods	  	  
The	   study	  was	   conducted	  with	  approval	   from	   the	  UCL/UCLH	  Committees	  on	   the	  Ethics	  of	  
Human	   Research,	   and	   written	   consent	   was	   obtained	   from	   all	   participants	   between	   Sept	  
2011	   and	   June	   2012.	   Patients	   were	   screened	   for	   eligibility	   through	   the	   hospital	   theatre	  
booking	   system.	   Inclusion	   criteria	   included	   all	   patients	   with	   primary	   hepatocellular	  
carcinoma	  or	  secondary	  colorectal	  metastatic	  disease	  undergoing	  major	   liver	   resection	   (at	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least	  20%,	  as	  judged	  by	  computed	  tomography	  scan	  during	  work-­‐	  up)	  who	  had	  an	  INR	  value	  
of	  greater	  than	  1.5	  on	  postoperative	  day	  2	  (POD2)	  .	  Patients	  were	  excluded	  if	  they	  had	  an	  
abnormal	   coagulation	   screen	   or	   platelet	   count	   at	   baseline,	   were	   receiving	   anti-­‐platelet	  
agents	   within	   the	   last	   7	   days	   prior	   to	   surgery,	   or	   refused	   consent.	   Citrated	   whole	   blood	  
samples	  were	  collected	  at	  baseline	  (prior	  to	  surgery)	  and	  on	  POD2.	  Those	  samples	  exhibiting	  
an	  INR	  >	  1.5	  were	  further	  studied	  via	  thromboelastography	  and	  repeat	  INR	  pre	  and	  post	  FFP	  
spiking	  in	  vitro.	  	  
8.3.1	  Blood	  Sampling	  and	  Testing	  
Blood	  was	  collected	  from	  the	  central	  venous	  catheter	  if	  in-­‐situ,	  or	  by	  single	  venepuncture	  of	  
an	  antecubital	  vein	  using	  a	  21G	  needle.	  Two	  samples	  were	  collected,	  the	  first	  10ml	  sample	  
was	  discarded	  to	  minimize	  the	  effect	  of	  tissue	  thromboplastins	  and	  the	  second	  sample	  was	  
used	   for	   analysis.	   Blood	   was	   transferred	   into	   2.7ml	   citrated	   blood	   tubes	   (BD	   Vacutainer,	  
Franklin	   lakes,	   New	   Jersey,USA	   ),	   mixed	   and	   rested	   for	   30	   minutes	   prior	   to	   analysis.	   All	  
coagulation	   studies	   were	   carried	   out	   using	   an	   ACL	   TOP	   coagulometer	   (Instrumentation	  
Laboratory,	   Bedford	   ,	   MA,USA).	   Conventional	   	   tests	   of	   coagulation	   (INR)	   was	   performed	  
using	  Recombiplastin	  2G	  reagent	   (Instrumentation	  Laboratory,	   the	   international	  sensitivity	  
index	   (ISI)	  of	   this	  was	  0.97;	  and	  citrated	  FBC	  was	  tested	  on	  the	  Sysmex	  XS1000i	   full	  blood	  
count	  analyser	  (Sysmex,	  Milton	  Keynes,	  UK).	  Viscoelastic	  tests	  were	  performed	  on	  citrated	  
blood,	   which	   was	   left	   for	   30	   minutes,	   as	   per	   manufacturers	   instructions,	   and	   inverted	   5	  
times	   prior	   to	   analysis	   to	   ensure	   adequate	   mixing.	   An	   unactivated	   aliquot	   of	   340µl	   of	  
citrated	   blood	   was	   added	   to	   20µl	   of	   calcium	   chloride	   (0.2mol/L)	   using	   reverse	   pipetting	  
technique	   into	   a	   cuvette	   and	   placed	   within	   the	   analysis	   well	   of	   the	   5000	   TEG®	   analyser	  
(Haemonetics,	   Braintree,	   MA,	   USA).	   Coagulation	   was	   then	   assessed	   using	   the	   TEG	   4.2.2	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software.	   A	   regular	   two-­‐point	   quality	   control	   (QC)	   procedure	   (one	   sample	   with	   normal	  
coagulation	   parameters	   and	   another	   with	   hypocoaguable	   parameters)	   was	   performed	   as	  
per	  manufacturer	  instructions.	  	  	  	  	  
Throughout	  this	  study	  rather	  than	  PT,	  we	  have	  quoted	  INR,	  as	  this	  is	  the	  variable	  quoted	  by	  
our	   laboratory	   for	   all	   routine	   tests.	   Given	   that	   the	   reagent	   ISI	   is	   close	   to	   unity	   any	  
differences	  in	  the	  ranges	  we	  have	  measured	  will	  in	  any	  case	  be	  very	  small.	  
8.3.2	  FFP	  Spiking	  	  
	  The	  dosage	  of	  FFP	  used	  in	  the	  study	  are	  those	  commonly	  used	  in	  clinical	  practice,	  in	  keeping	  
with	  the	  TOPIC	  trial,	  which	  chose	  12ml/kg	  for	  the	  use	  of	  FFP	  in	  non-­‐	  bleeding	  ICU	  patients	  	  
(319).	   FFP	   from	  a	   single	   donor	  was	   obtained	   from	   the	   local	   blood	   transfusion	   laboratory,	  
and	   the	   storage	   time	   was	   within	   the	   accepted	   shelf	   life	   of	   this	   blood	   product.	   This	   was	  
thawed	  and	  divided	   into	  2ml	  aliquots,	   re-­‐frozen	  and	  stored	  at	  minus	  80°C.	  Storage	  at	   this	  
temperature	  has	  been	  shown	  to	  be	  associated	  with	  minimal	  degradation	  in	  clotting	  factors	  
(320)).	  The	  required	  aliquots	  were	  then	  thawed	  prior	  to	  use.	   	  On	  POD2,	  whole	  blood	  from	  
patients	  was	  spiked	  with	  FFP	   in-­‐vitro,	   if	  the	  INR	  was	  ≥1.5.	  Blood	  collected	  in	  2.7ml	  citrated	  
blood	  tubes	  (BD	  Vacutainer),	  was	  mixed	  and	  rested	  for	  30	  minutes	  prior	  to	  analysis.	  Using	  
an	  estimated	  blood	  volume	  of	  70ml/kg,	  a	  ratio	  of	  0.21ml	  FFP	  to	  1ml	  whole	  blood	  was	  used	  
for	  spiking	  whole	  blood	  with	  15ml/kg	  FFP	  and	  0.11ml	  FFP	  to	  1ml	  whole	  blood	  was	  used	  for	  
spiking	   with	   7.5ml/kg	   FFP.	   The	   spiked	   samples	   were	   then	   inverted	   to	   ensure	   adequate	  
mixing	  prior	  to	  analysis.	  The	  same	  volume	  of	  spiked	  blood	  was	  then	  analysed	  using	  CCT	  and	  
thromboelastography	  in	  the	  same	  manner	  as	  described	  above.	  Whole	  citrated	  blood,	  which	  
was	  not	  spiked,	  was	  used	  as	  a	  control.	  TEG®	  parameters	  were	  collected	  at	  all	  time	  points.	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8.3.3	  Statistical	  Analysis	  	  
During	   the	   study	  period,	   47	  patients	  were	  eligible	   for	   inclusion	  and	  entered	   the	   selection	  
process.	   Twenty	  patients	   (42.5%)	  had	  an	   INR	  >	  1.5	  on	  POD2	  and	  were	  eligible	   for	   further	  
analysis	  following	  in	  	  vitro	  spiking	  with	  FFP.	  	  
Data	  from	  the	  CCT	  and	  TEG	  analysis	  were	  tested	  for	  normality	  and	  then	  reported	  as	  mean	  
+/-­‐	  1	  standard	  deviation	  for	  the	  group.	  Analysis	  was	  performed	  using	  Graphpad®	  software	  
(San	  Diago,	  USA),	  and	  a	  students	  t-­‐test	  to	  compare	  the	  means	  of	  two	  groups.	  CCTs	  and	  TEG®	  
values	  were	  compared	  between	  baseline	  and	  POD2	  as	  well	  as	  pre-­‐	  and	  post-­‐	  FFP	  spiking	  on	  
POD2.	  A	  p-­‐	  value	  of	  <0.05	  was	  accepted	  as	  statistically	  significant.	  	  	  	  	  	  	  	  
8.4	  Results	  
8.4.1	  Conventional	  and	  VET	  coagulation	  tests	  at	  baseline	  and	  POD2	  	  
Post	  operative	  changes	  in	  coagulation	  for	  patients	  with	  INR	  ≥	  1.5	  on	  POD	  2,	  and	  for	  patients	  
with	   INR	  ≤	  1.5	  are	  shown	   in	  Table	  9.1.	  For	   the	  group	   in	  which	   INR	  was	  ≥	  1.5,	   there	  was	  a	  
significant	   increase	   in	   INR	   from	  1.15	   at	   baseline	   to	   1.95	  on	  POD	  2	   (p=0.0001),	  which	  was	  
associated	   with	   a	   significant	   decrease	   in	   platelet	   count	   from	   166	   x	   109	   L-­‐1	   to	   95	   x109	  
(p=0.0001).	   The	   TEG	   parameters	  were	   unchanged,	   except	   for	  MA	  which	  was	   significantly	  
reduced	  from	  66.91mm	  to	  54.03	  mm	  (p=0.001).	  For	  the	  group	  with	  an	  INR	  ≤	  1.5	  on	  POD	  2,	  
there	   was	   a	   significant	   increase	   in	   INR	   from	   1.07	   at	   baseline	   to	   1.27	   (p=0.0001)	   and	   a	  
decrease	   in	   platelet	   count	   from	   188	   x	   109	   to	   120	   x	   109	   (p=0.005).	   All	   the	   TEG	   values	  
remained	  unchanged.	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8.4.2	  Changes	  in	  coagulation	  with	  FFP	  spiking	  in	  patients	  with	  INR	  >	  1.5	  
Changes	   in	   coagulation	   with	   FFP	   spiking	   are	   shown	   in	   Table	   8.1.	   There	   was	   a	   significant	  
reduction	   in	   the	   INR	   from	   1.94	   (SD	   0.59)	   to	   1.46	   (SD	   0.27	   p=0.005)	   and	   1.36	   (SD	   0.18	  
p=0.0007)	   with	   FFP	   7.5	   ml/kg	   or	   15ml/kg	   respectively.	   Haemoglobin	   also	   dropped	   with	  
spiking	  from	  91.7	  g/l	   (SD	  21.2)	  to	  80.1	  g/l	   (SD	  12.7	  p=0.45)	  and	  72.3	  g/l	   (SD	  12.3	  p=0.002)	  
with	   FFP	   7.5	   ml/kg	   or	   15ml/kg	   respectively.	   There	   was	   no	   significant	   change	   in	   platelet	  
count	  with	  FFP.	  	  
FFP	   spiking	   had	   no	   significant	   effect	   on	   any	   TEG	   parameter	   (Figure	   8.1).	   The	   R-­‐time	  
remained	  below	  the	  normal	  range	  after	  FFP	  spiking,	  suggesting	  a	  hypercoagulable	  state.	  The	  
MA	   remained	  within	   the	   normal	   range	   before	   and	   after	   FFP	   spiking.	   At	   the	   higher	   doses	  
there	  was	  a	  slight	  lengthening	  of	  the	  R	  time,	  the	  percentage	  of	  patients	  and	  delta	  change	  in	  
INR	  after	  FFP	  spiking	  are	  shown	   in	  Table	  8.3,	  and	  the	  percentage	  of	  patients	   in	  which	   the	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   INR	  <	  1.5	  on	  POD	  2	   	   	   	   INR	  >	  1.5	  on	  POD	  2	  
	   	   	   	   	  
Table	  8.1	  Changes	  in	  coagulation	  variables	  between	  baseline	  and	  POD	  2	  in	  patients	  with	  
INR	  <	  1.5	  (n=27),	  and	  in	  patients	  with	  INR	  >	  1.5	  (n=20)	  


















Conventional	  tests	  	  
(Normal	  range)	  
	   	   	   	   	   	  
INR	  (0.9	  -­‐1.2)	   1.07	  (0.08)	   1.27	  (0.17)	   0.0001*	   1.15	  (0.15)	   1.95	  (0.59)	   0.0001*	  
Haemoglobin	  (130-­‐160	  g/l)	   110	  (20.4)	   100	  (13.7)	   0.2	   97.9	  (13.0)	   91.7	  (21.2)	   0.3	  
Platelets	  (140-­‐400	  x	  109	  )	   188	  (58)	   120	  (43)	   0.005*	   166	  (47)	   95	  (38)	   0.0001*	  
Thromboelastography	  	  
(Normal	  range)	  
	   	   	   	   	   	  
R	  time	  (9-­‐27	  min)	   5.8	  (1.36)	   4.6	  (1.85)	   0.3	   6.17	  (2.25)	   6.7	  (3.75)	   0.6	  
Alpha	  angle	  (22-­‐58)	   67.71	  (8.11)	   60.8	  (10.75)	   0.3	   66.51	  (8.06))	   58.7	  (12.69)	   0.06	  
MA	  (44-­‐64	  mm)	   56.60	  (21.98)	   47.80	  (9.62)	   0.6	   66.91	  (9.28)	   54.03	  (10.57)	   0.001*	  















Conventional	  tests	  	  
(Normal	  range)	  
	   	   	   	   	  
INR	  (0.9	  -­‐1.2)	   1.94	  (0.59)	   1.46	  (0.27)	   1.36	  (0.18)	   0.0048*	   0.0007*	  
Haemoglobin	  (130-­‐160	  g/l)	   91.7	  (21.2))	   80.1	  (12.7)	   72.3	  (12.3)	   0.0446*	   0.0016*	  
Platelets	  (140-­‐400	  x	  109	  )	   95	  (38)	   83	  (34)	   88	  (30)	   0.3052)	   0.5185	  
Thromboelastography	  	  
(Normal	  range)	  
	   	   	   	   	  
R	  time	  (9-­‐27	  min)	   6.7	  (3.75)	   7.02	  (2.42)	   7.13	  (3.02)	   0.7669	   0.7082	  
Alpha	  angle	  (22-­‐58)	   58.71	  (12.69)	   57.74	  (11.89)	   62.41	  (8.8)	  	   0.8240	   0.3360	  
MA	  (44-­‐64	  mm)	   54.04	  (10.57)	   53.3	  (9.82)	   57.81	  (6.1)	   0.8349	   0.2031	  
	  












(a) Change	  in	  TEG	  MA	  (mean	  (SD))	  from	  baseline	  to	  POD2,	  and	  after	  FFP	  spiking	  with	  7.5ml/kg	  





Figure	  8.1	  Change	  in	  TEG	  parameters	  (a:	  MA,	  b:	  R	  time,	  C:	  alpha	  angle)	  from	  baseline	  to	  
POD	  2.	  
Figure	  8.1	  Change	  in	  TEG	  parameters	  from	  baseline	  to	  POD	  2	  
(b)	  Change	  in	  TEG	  R-­‐time	  (mean	  (SD))	  from	  baseline	  to	  POD2,	  and	  after	  FFP	  spiking	  with	  7.5ml/kg	  
and	  15ml/kg	  FFP.	  (Normal	  range	  9-­‐27)	  
	  
(c)	  Change	  in	  TEG	  Alpha-­‐angle	  (mean	  (SD))	  from	  baseline	  to	  POD2,	  and	  after	  FFP	  spiking	  with	  
7.5ml/kg	  and	  15ml/kg	  FFP.	  (No mal	  range	  22-­‐58)	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Change	  in	  INR	   7.5	  ml/kg	  	   15	  ml/kg	  	  
- 0.1	  to	  0.2	   28.6%	   14.3%	  
- 0.3	  to	  0.4	   42.9%	   50%	  
- 0.5	  to	  0.9	   14.3%	   21.4%	  
- >1.0	   14.3%	   14.3%	  
	  
Table	  8.3	  	  Percentage	  of	  patients	  and	  extent	  of	  reduction	  in	  INR	  after	  FFP	  spiking	  
	  
Initial	  INR	   FFP	  7.5mls/kg	  
Correcting	   to	  
INR	  <1.5	  
FFP	  15	  mls/kg	  
Correcting	   to	  
INR	  <1.5	  
FFP	  7.5	  mls/kg	  
Delta	   change	   in	  
INR	  (mean)	  
FFP	  15	  mls/kg	  
Delta	   change	  
in	  INR	  (mean)	  
>2.0	   0%	   33.3%	   1.01	   1.28	  
1.7-­‐1.9	   66.6%	   100%	   0.28	   0.40	  
1.5-­‐1.6	   100%	   100%	   0.27	   0.33	  
	  
Table	  8.4	  	  Percentage	  of	  patients	  in	  which	  INR	  corrected	  below	  1.5	  after	  FFP	  spiking	  based	  
on	  POD2,	  and	  mean	  delta	  change	  in	  INR	  after	  FFP	  spiking	  
	  
8.5	  Discussion	  	  	  
This	   is	   the	  first	  study,	   to	  our	  knowledge,	   investigating	  the	  effects	  of	   in	  vitro	  FFP	  spiking	  of	  
whole	   blood	   from	  patients	   undergoing	  major	   liver	   resection	  with	   elevated	   INR	   values.	   	   A	  
total	  of	  42.5%	  of	  patients	  following	  major	  liver	  resection	  had	  an	  INR	  ≥1.5	  on	  POD2,	  a	  value	  
which	  is	  often	  taken	  as	  the	  threshold	  for	  transfusing	  pre-­‐procedural	  prophylactic	  FFP,	  or	  for	  
withholding	   pharmacological	   thromboprophlaxis	   therapy.	   There	   was	   a	   dose	   related	  
reduction	  in	  INR	  after	  spiking	  with	  FFP	  and	  the	  degree	  of	  correction	  was	  dependent	  on	  both	  
the	  initial	  INR	  value	  and	  the	  volume	  of	  FFP	  used.	  	  All	  patients	  showed	  a	  reduction	  in	  INR	  in	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response	  to	  FFP,	  and	  this	  response	  was	  more	  pronounced	  with	  the	  larger	  (15mls/Kg)	  dose.	  
This	   higher	   dose	   also	   led	   to	   more	   pronounced	   dilutional	   effects,	   with	   the	   haemoglobin	  
falling	  by	  approximately	  20g/l.	  It	  must	  be	  considered	  that	  in	  vivo	  this	  effect	  would	  likely	  be	  
modified	   by	  many	   factors,	   and	   the	   fall	  may	  well	   not	   be	   as	   pronounced	   as	   in	   the	   in	   vitro	  
model,	  but	  it	  is	  nevertheless	  a	  real	  issue	  when	  transfusing	  large	  volumes	  of	  FFP,	  and	  could	  
result	  in	  transfusion	  of	  red	  blood	  cells	  to	  maintain	  the	  haemoglobin	  above	  a	  pre-­‐determined	  
level.	  There	   is	  also	   the	  associated	   risk	  of	   transfusion	   related	  acute	   lung	   injury	   (TRALI)	  and	  
transfusion	  associated	  circulatory	  overload	  (TACO).	  
The	  findings	  from	  this	  in	  vitro	  study	  are	  in	  agreement	  with	  previous	  observational	  studies	  in	  
patients,	  which	  demonstrate	  when	  the	  INR	  is	  only	  mildly	  to	  moderately	  prolonged,	  changes	  
in	  INR	  following	  FFP	  administration	  are	  small,	  inconsistent,	  and	  even	  at	  15ml/Kg,	  correction	  
is	  not	  guaranteed	  (280,	  321).	  
At	  baseline,	  all	  our	  patients	  had	  normal	  or	  hypercoagulable	  TEG	  parameters	  in	  keeping	  with	  
findings	  from	  other	  published	  studies.	  Despite	  the	  commonly	  described	  fall	  in	  platelet	  count	  
found	  postoperatively	  after	  liver	  resection	  (315)the	  MA	  remained	  within	  the	  normal	  range.	  
Although	  the	  INR	  was	  elevated,	  none	  of	  these	  patients	  had	  an	  R-­‐time	  that	  was	  prolonged,	  
and	  most	   had	   values	   below	   the	   normal	   range	   (hypercoagulable).	   It	   has	   consistently	   been	  
shown	  that	  there	  is	  very	  poor	  correlation	  of	  R-­‐time	  to	  PT/INR	  (97,	  98,	  201),	  and	  the	  fact	  that	  
the	  R-­‐time	  was	  relatively	  short,	  suggests	  that	  these	  viscoelastic	  tests	  may	  give	  information	  
which	  is	  not	  adequately	  reflected	  by	  the	  INR	  alone	  (322,	  323).	  	  
The	   R	   time	   (time	   to	   clot	   initiation)	   is	   a	   reflection	   of	   the	   balance	   of	   both	   pro	   and	  
anticoagulants,	  and	   in	  general,	   is	  prolonged	  by	  excess	  anticoagulant	  or	   low	  clotting	   factor	  
levels,	  and	   is	  shortened	   in	  the	  presence	  of	  excess	  tissue	  factor,	  high	  factor	  VIII	   levels	   	  and	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low	  protein	  C	   levels	  (304)).	  The	  changes	   in	  coagulation	  that	  occur	  following	   liver	  resection	  
(reduction	  in	  both	  pro	  and	  anticoagulant	  factors	  and	  increased	  factor	  VIII	  and	  VWF	  )	  are	  not	  
adequately	   reflected	  by	   the	   INR	  value,	  which	   is	  only	   sensitive	   to	  procoagulants,	  especially	  
factor	  VII.	  This	  explains	  why	  the	  INR	  alone	  may	  not	  be	  a	  useful	  indicator	  of	  the	  potential	  risk	  
of	   bleeding	   following	   liver	   resection,	   and	   why	   VET	   may	   give	   more	   clinically	   relevant	  
information	   (324).	   Our	   finding	   that	   FFP	   partially	   corrects	   a	   moderately	   prolonged	   INR	  
without	  leading	  to	  any	  change	  in	  viscoelastic	  parameters	  is	  similar	  to	  results	  found	  in	  an	  in	  
vitro	  study	  of	  FFP	  in	  patients	  with	  cirrhosis:	  FFP	  provides	  both	  pro	  and	  anticoagulant	  factors,	  
and	  where	  both	  are	  simultaneously	   reduced,	   the	  addition	  of	  FFP	  will	   leave	   the	  balance	  of	  
coagulation	  unaltered	  and	  thrombus	  generation	  unchanged	  (325).	  
	  
There	   are	   of	   course	   limitations	   extrapolating	   in	   vitro	   studies	   to	   a	   clinical	   scenario:	   the	  
contribution	   of	   endothelial	   and	   vascular	   factors,	   buffering,	   pH	   control,	   metabolic	  
derangement	   	   and	   electrolyte	   environment	   are	   lacking	   in	   these	   studies.	   In	   addition,	   it	   is	  
possible	   that	   thrombomodulin	   (a	  natural	   activator	  of	   protein	  C)	   is	   needed	   to	   activate	   the	  
natural	   anticoagulants	   and	   assess	   their	   contribution	   to	   clot	   formation.	   Despite	   these	  
limitations,	   spiking	  with	  FFP	  has	  been	   shown	   to	  be	  a	  good	  model	   for	   studying	   the	  effects	  
that	   transfusion	   of	   such	   products	   has	   on	   coagulation	   (325,	   326),	   and	   VET	   analysis	   is	  
increasingly	   used	   to	   determine	   the	   in	   vitro	   effect	   of	   procoagulant	   and	   other	   haemostatic	  	  
therapies.(304,	   327).	   	   Indeed,	   in	   vivo	   trials	   using	   FFP	   to	   treat	   prolonged	   INR	   have	   been	  
notoriously	  difficult	  to	  conduct,	  and	  a	  recent	  study	  in	  non	  bleeding	  ICU	  patients	  (TOPIC	  trial)	  
had	  to	  be	  stopped	  early	  due	  to	  poor	  recruitment.	  The	  trial	  organisers	  suggested	  that	  there	  
was	   still	   a	   general	   	   lack	   of	   knowledge	   about	   FFP	   ,	   and	   	   that	   there	   are	   very	   entrenched	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personal	   beliefs	   about	   the	   preferable	   transfusion	   strategy,	  which	   contributed	   to	   the	   very	  
slow	  recruitment	  to	  this	  study	  (328).	  	  
8.6	  Conclusions	  
There	  is	  a	  surprising	  lack	  of	  evidence	  of	  any	  known	  efficacy	  of	  FFP	  transfusion	  in	  a	  variety	  of	  
clinical	   situations	   for	  which	   it	   is	   commonly	  prescribed,	  particularly	  when	  the	   INR	   is	  <2.	   (2,	  
321,	  329,	  330).	  Although	  up	  to	  50%	  of	  FFP	  is	  transfused	  prophylactically,	  there	  are	  no	  trials	  
that	  demonstrate	  a	  benefit	   (331).	  Nevertheless,	  the	  practice	  of	  prophylactic	  transfusion	  of	  
FFP	  still	  continues,	  driven	  largely	  by	  historical	  precedent	  that	  it	  is	  a	  “good	  thing	  to	  do”,	  and	  
the	   desire	   to	   cover	   all	   eventualities,	   including	   litigation,	   should	   excessive	   bleeding	   occur.	  	  
Increasingly,	   clinicians	   are	   recognising	   	   that	   a	   substantial	   amount	   of	   FFP	   is	   transfused	  
without	   clinical	   benefit,	   is	   wasteful	   of	   a	   valuable	   resource,	   and	   can	   cause	   unintentional	  
morbidity,	   and	   even	  mortality,	   in	   recipients	   (332).	  Most	   FFP	   transfusions	   in	   non	   bleeding	  
patients	   are	   performed	   to	   correct	   an	   abnormal	   INR.	   Recently,	   some	   institutions	   have	  
adopted	  a	   restrictive	   transfusion	  policy	   for	  FFP,	  and	  demonstrated	   significant	   cost	   savings	  
without	  any	  detrimental	  effect	  to	  patients.(318,	  333).	  
This	   study	   reinforces	   the	   fact	   that	   INR	   alone	   is	   a	   poor	   indicator	   of	   overall	   coagulation	  
following	   hepatic	   resection	   surgery.	   Moderate	   elevations	   of	   INR	   suggesting	  
hypocoagulability	  were	  not	  reflected	  by	  viscoelastic	  coagulation	  parameters,	  This	  study	  goes	  
some	   way	   to	   highlighting	   that	   in	   patients	   who	   have	   had	   hepatic	   resection	   surgery,	   the	  
practice	  of	  transfusing	  FFP	  prophylactically	  in	  order	  to	  correct	  mild	  to	  moderately	  elevated	  
INR	  values	  is	  unlikely	  to	  achieve	  the	  desired	  reduction	  in	  INR.	  We	  also	  have	  shown	  that	  TEG	  
parameters	  remain	  essentially	  unchanged	  by	  in	  vitro	  FFP	  administration,	  and	  consequently,	  
further	  question	   the	  clinical	   value	  of	  administering	   	  prophylactic	   FFP	   to	  patients	   solely	  on	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the	  basis	  of	   the	   INR,	  as	   this	  practice	   is	   almost	   certainly	  unnecessary,	  potentially	  wasteful,	  
and	  associated	  with	  patient	  risk.	  This	  in	  vitro	  data	  is	  only	  a	  preliminary	  step,	  but	  it	  highlights	  
the	   need	   to	   design	   clinical	   trials	   that	   are	   based	   not	   on	   INR,	   but	   on	   alternative	   tests	   of	  
haemostasis,	  in	  order	  to	  stratify	  and	  manage	  bleeding	  risk	  in	  these	  patients.	  	  
	  
	  







Thesis	  discussion,	  conclusions	  and	  future	  directions	  





The	  hypothesis	  presented	  in	  this	  thesis	  is	  that	  global	  viscoelastic	  tests	  of	  coagulation	  provide	  
more	  clinically	  relevant	  information	  than	  conventional	  laboratory	  tests	  in	  patients	  with	  liver	  
disease,	  and	  also	  in	  patients	  who	  have	  had	  major	  liver	  surgery.	  As	  the	  liver	  is	  the	  major	  site	  
for	  synthesis	  of	  coagulation	  proteins,	  an	  elevation	  of	  the	  PT/INR	  is	  a	  good	  indicator	  of	  liver	  
synthetic	  function,	  and	  consequently	  is	  used	  in	  a	  number	  of	  scoring	  systems,	  such	  as	  MELD	  
and	  UKELD.	  However,	  an	  abnormal	  PT/INR	  is	  also	  perceived	  as	  an	  index	  of	  bleeding	  risk	   in	  
these	  patients,	  and	  consequently	  used	  as	  a	  trigger	  threshold	  for	  transfusing	  pre-­‐procedural	  
plasma,	  or	  as	  a	  basis	  for	  withholding	  chemical	  thromboprophylaxis	   in	  the	  belief	  that	  these	  
patients	   are	   “auto-­‐anticoagulated”.	   This	   is	   despite	   the	   fact	   that	   numerous	   studies	   have	  
demonstrated	   that	   these	   tests	   have	   a	   very	   poor	   predictive	   value	   for	   determining	   an	  
increased	   risk	   of	   bleeding	   (2),	   and	   also	   that	   many	   of	   these	   patients	   are	   in	   fact	   at	   an	  
increased	  risk	  of	  thromboembolic	  events	  compared	  to	  the	  general	  population	  (70).	  There	  is	  
a	  discrepancy	  between	  the	  information	  from	  clotting	  tests	  that	  have	  routinely	  been	  used	  in	  
clinical	  practice	  and	  the	  evidence	  regarding	  thrombotic	  and	  bleeding	  events	  (334).	  
In	   patients	   with	   liver	   disease,	   haemorrhagic	   complications,	   such	   as	   variceal	   bleeds	   or	  
procedural	  bleeds	  are	   common,	  and	   frequently	   associated	  with	  abnormalities	  of	   standard	  
coagulation	  tests,	  and	  consequently	  a	  direct	  cause-­‐effect	  relationship	  has	  been	  assumed.	  It	  
has	  therefore	  been	  common	  practice	  to	  treat	  or	  prevent	  bleeding	  with	  blood	  products	  such	  
as	  fresh	  frozen	  plasma,	  platelets	  and	  also	  factor	  concentrates.	  In	  general	  the	  ability	  of	  these	  
prohaemostatic	   interventions	   to	   prevent	   or	   stop	   pre-­‐procedural	   bleeding	   has	   not	   been	  
validated	   in	  randomised	  clinical	  trials,	  but	   is	  based	  on	  their	  capacity	  to	   improve	  or	  correct	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the	   abnormalities	   of	   the	   coagulation	   tests.	   As	   a	   consequence	   of	   an	   elevated	   INR,	   an	  
inordinate	   amount	   FFP	   is	   administered	   in	   patients	   with	   cirrhosis	   for	   prophylaxis	   without	  
evidence	  of	   utility	   (335).	   In	   stable	   cirrhosis,	  many	  patients	   are	   relatively	   hypercoagulable,	  
however	   in	   decompensated	   patients	   bleeding	   is	   relatively	   common	   (40%),	   and	   relates	   to	  
raised	  portal	  pressure,	  and	  also	  possibly	  to	  systemic	  endogenous	  heparinoids	  released	  from	  
the	  vascular	  endothelium	  in	  response	  to	  stress	  due	  to	  sepsis	  or	  hypoxia.	  In	  order	  to	  improve	  
the	  management	  of	  these	  patients	   it	   is	  clear	  that	  better	  ways	  of	  assessing	  the	  coagulation	  
status	  are	  required	  to	  refine	  clinical	  practice	  in	  this	  setting.	  
To	  establish	  the	  basis	  of	  this	  thesis,	  in	  chapter	  1,	  traditional	  (cascade)	  and	  newer	  (cell	  based)	  
models	   of	   haemostasis	   are	   reviewed	   and	   then	   discussed	   in	   relation	   to	   the	   limitations	   of	  
conventional	   coagulation	   tests	   to	   patients	   with	   liver	   disease.	   These	   tests	   are	   performed	  
using	  platelet	  poor	  plasma,	  and	   therefore	  cannot	  account	   for	   thrombin	  generation	   that	   is	  
mediated	  by	   the	  presence	  of	  platelets	   (39).	   In	   addition,	   these	   tests	   conclude	  at	   the	  point	  
that	  fibrin	  strands	  start	  to	  form,	  and	  when	  only	  a	  tiny	  fraction	  of	  total	  thrombin	  generation	  
has	  occurred,	  so	  giving	  no	  information	  on	  overall	  clot	  strength	  and	  stability.	  They	  inform	  on	  
the	   initiation	   of	   clotting	   but	   not	   the	   haemostatic	   capacity	   in	   terms	   of	   clot	   formation	   and	  
maximal	   thrombin	   generation.	   The	   majority	   of	   coagulation	   tests	   assess	   pro-­‐coagulant	  
capacity	   in	   isolation,	  and	  give	  no	   information	  about	   the	   integrated	  effect	  of	  pro	  and	  anti-­‐
coagulants,	   platelets	   and	   fibrinogen,	   nor	   do	   they	   reveal	   the	   effect	   of	   potential	  
compensatory	   mechanisms	   within	   the	   haemostatic	   system	   such	   as	   elevated	   Von	  
Willebrand’s	  factor.	  	  
It	   therefore	   seems	   prudent	   to	   explore	   if	   global	   viscoelastic	   tests	   using	   whole	   blood	   can	  
provide	  more	   relevant	   information.	   In	   chapter	  2,	   the	  principles	  and	   limitations	  of	  VET	  are	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discussed.	  The	  fact	  that	  they	  can	  detect	  hypercoagulability	  and	  also	  fibrinolysis,	  neither	  of	  
which	  can	  be	  determined	  using	  conventional	  tests,	  is	  highlighted	  as	  a	  potential	  advantage	  in	  
patients	  with	  liver	  disease.	  
In	  chapter	  3,	  a	  review	  of	  the	  current	  literature	  that	  has	  referenced	  VET	  in	  patients	  with	  liver	  
disease	   is	  presented.	  Although	  these	  are	  mainly	  observational	   trials,	   they	  do	   illustrate	   the	  
potential	  of	  these	  tests	  to	  give	  more	  clinically	  useful	  information.	  Coagulation	  analysis	  with	  
TEG	  and	  ROTEM	  has	  corroborated	  the	  concept	  of	  re-­‐balanced	  haemostasis	   in	   liver	  disease	  
as	   proposed	  by	   Tripodi,	   and	   also	  by	   Lisman	   (7,	   241).	   The	  majority	   of	   stable	   patients	  with	  
chronic	  liver	  disease	  have	  normal	  viscoelastic	  tests,	  and	  this	  calls	  into	  question	  the	  practice	  
of	   giving	   prophylactic	   treatment	   purely	   to	   correct	   an	   elevated	   INR	   value	   or	   a	  moderately	  
reduced	   platelet	   count	   (141,	   325).	   A	   recent	   randomised	   trial	   of	   pre-­‐procedural	   plasma	  
and/or	  platelets	   in	  cirrhotic	  patients	  based	  on	  conventional	   coagulation	   tests	   (INR	  ≥1.8	  or	  
platelet	   count	   ≤	   50,000	   x	   109)	   or	   thromboelastometry	   parameters	   of	   R	   time	   and	   MA,	  
demonstrated	   highly	   significant	   reductions	   in	   transfusion	   in	   the	   TEG	   group	   without	   any	  
increase	  in	  bleeding	  complications	  (336).	  	  
In	  chapter	  4,	  the	  use	  of	  VET	  in	  guiding	  haemostatic	  interventions	  during	  liver	  transplantation	  
is	   discussed.	   Their	   potential	   use	   is	   twofold;	   firstly	   they	   prevent	   the	   unnecessary	   and	  
inappropriate	   transfusion	   of	   blood	   products	   purely	   to	   correct	   abnormal	   laboratory	   tests	  
when	   the	   TEG/ROTEM	   results	   are	  within	   normal	   range	   (337),	   and	   secondly	   they	   facilitate	  
targeted,	   goal	   directed	   therapy	   of	   specific	   haemostatic	   defects	   during	   active	   bleeding,	  
resulting	  in	  more	  rapid	  control	  of	  coagulopathy	  and	  ultimately	  less	  transfusions	  (120).	  
Whether	   fibrinolysis	   is	   a	   significant	   factor	   in	   producing	   excess	   bleeding	   during	   liver	  
transplantation,	   and	  how	   it	   should	  be	  managed,	   has	   always	   been	   somewhat	   contentious.	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This	   is	  now	  an	  even	  more	  relevant	   issue	  as	  the	  number	  of	  patients	  that	  can	  undergo	   liver	  
transplantation	  without	  the	  need	  for	  blood	  or	  blood	  product	  transfusion	  is	  increasing	  every	  
year	   due	   to	   the	   adoption	   of	   more	   aggressive	   fluid	   restriction,	   and	   other	   patient	   blood	  
management	  techniques	  (338).	  The	  risk	  benefit	  of	  using	  anti-­‐fibrinolytic	  drugs	  has	  shifted	  as	  
blood	   loss	   has	   decreased	   and	   the	   risk	   of	   thrombosis	   is	   increasingly	   recognised	   (227).	   In	  
chapter	   4,	   a	   retrospective	   review	   of	   TEG	   samples	   in	   patients	   undergoing	   liver	  
transplantation	  demonstrates	  that	  the	  prevalence	  of	  fibrinolysis	  is	  actually	  quite	  low	  (<25%),	  
and	   throws	   doubt	   on	   the	   value	   of	   giving	   prophylactic	   anti-­‐fibrinolytic	   therapy	   to	   these	  
patients.	   It	   is	  also	  clear	   that	   the	  timing	  of	   the	  appearance	  of	   fibrinolysis	   is	   important.	   It	   is	  
most	   common	   immediately	   after	   reperfusion	   of	   the	   liver	   graft,	   and	   will	   usually	  
spontaneously	  disappear	  without	   treatment	   in	   the	  presence	  of	  good	  donor	  graft	   function.	  
Conversely,	   fibrinolysis	   appearing	   earlier,	   during	   the	   dissection	   or	   anhepatic	   stage,	   will	  
usually	  progress	  and	  become	  more	  severe	  if	  anti-­‐fibrinolytic	  treatment	  is	  not	  administered.	  
It	   is	  now	  recognised	  that	  a	  raised	  INR	  does	  not	  preclude	  the	  possibility	  that	  some	  patients	  
may	  be	  prothrombotic,	  as	  demonstrated	  by	  enhanced	  thrombin	  generation	  and	  high	  factor	  
VIII/protein	   C	   ratios	   (66,	   297).	   In	   addition,	   it	   is	   known	   that	   these	  patients	   have	   increased	  
levels	   of	   circulating	   microparticle	   Tissue	   Factor	   activity	   that	   also	   contributes	   to	   the	  
activation	  of	   coagulation	   and	   thrombosis	   in	   these	  patients	   (339).	   Knowledge	  of	   individual	  
coagulation	   components	   does	   not	   allow	   a	   comprehensive	   estimation	   of	   overall	  
haemostatic/thrombotic	   risk.	   In	  general	   this	   risk	   results	   from	  a	  combination	  of	   changes	   in	  
several	  components	  of	  the	  haemostatic	  system	  (340).	  There	  are	  unmet	  needs	  with	  regard	  to	  
identifying	  patients	  at	  risk	  of	  thrombosis.	  A	  possible	  solution	  is	  the	  use	  of	  global	  coagulation	  
tests	  that	  reflect	  the	  major	  physiological	  aspects	  of	  the	  haemostatic	  process	  in	  vitro	  (341).	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There	   does	   appear	   to	   be	   a	   correlation	   between	   hypercoagulability	   detected	   on	   VET	   and	  
thromboembolic	  complications	  in	  patients	  undergoing	  major	  surgery	  (342).	  In	  Chapter	  6,	  we	  
describe	   the	  prevalence	  of	  hypercoagulability	   in	  patients	  undergoing	   liver	   transplantation.	  
There	   appears	   to	   be	   a	   different	   distribution	   of	   hypercoagulability	   according	   to	   disease	  
aetiology,	   increased	   clot	   strength	   (platelet-­‐fibrinogen	   interaction)	   is	   increased	   in	   patients	  
with	   cholestatic	   liver	   disease,	   and	   also	   in	   some	   patients	   with	   acute	   liver	   failure,	   whilst	  
evidence	   of	   plasmatic	   hypercoagulability	   (short	   R	   time)	   is	  more	   common	   in	   patients	  with	  
alcoholic	  and	  viral	   liver	  disease.	  In	  this	  cohort	  of	  100	  patients,	  the	  incidence	  of	  thrombotic	  
complications	   was	   too	   low	   to	   demonstrate	   a	   definite	   association,	   but	   it	   is	   clear	   than	   an	  
elevated	  INR	  in	  no	  way	  precludes	  the	  possibility	  of	  hypercoagulability.	  
Following	  major	  hepatic	  resection	  it	  is	  known	  that	  the	  risk	  of	  pulmonary	  embolism	  exceeds	  
that	  of	  bleeding,	  and	  that	  this	  risk	  increases	  with	  the	  volume	  of	  liver	  parenchyma	  resected.	  
It	   appears	   paradoxical	   that	   patients	   with	   INR	   values	   >	   1.5	   are	   more	   likely	   to	   have	  
thromboembolic	  complications	  than	  those	  with	  an	   INR	  <1.5.	   In	  chapter	  7,	  we	  undertook	  a	  
prospective	  evaluation	  of	  coagulation	  changes	  in	  patients	  following	  major	  hepatectomy.	  We	  
found	  that	  the	  proportional	  reduction	  in	  anticoagulant	  to	  procoagulant	  proteins,	  as	  shown	  
by	  a	  deranged	  protein	  C:FVIII	  ratio,	   is	  more	  profound	  in	  patients	  with	  higher	  values	  of	  INR	  
(≥1.5),	   and	   this	   together	   with	   the	   raised	   levels	   of	   Factor	   VIII	   and	   VWF	   could	   create	   a	  
potentially	   prothrombotic	   state.	   The	   situation	   is	   therefore	   far	   more	   complex	   than	   the	  
commonly	   held	   assumption	   that	   the	   post	   operative	   increase	   in	   INR	   de	   facto	   reflects	   an	  
increased	   bleeding	   risk.	   Despite	   the	   elevated	   INR,	   viscoelastic	   tests	   did	   not	   indicate	  
hypocoagulability	  at	  any	  point,	  and	  were	  borderline	  hypercoagulable	  by	  post	  operative	  day	  
5.	  This	  study	  demonstrates	  some	  of	  mechanistic	   reasons	   for	   the	  prothrombotic	  state,	  and	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also	  that	  viscoelastic	  tests	  provide	  a	  more	  realistic	  assessment	  of	  underlying	  haemostasis	  in	  
this	  setting	  than	  do	  conventional	  coagulation	  tests.	  	  
As	   it	   is	   still	   common	   practice	   for	   clinicians	   to	   use	   INR	   as	   the	   basis	   for	   prescribing	   pre-­‐
procedural	  FFP,	  in	  chapter	  8	  we	  evaluated	  the	  in	  vitro	  effect	  of	  administering	  FFP	  to	  patients	  
with	  an	  elevated	   INR	   following	  major	   liver	   resection.	  Although	   there	  was	   some	  degree	  of	  
correction	   of	   the	   INR,	   which	   was	   dose	   dependant,	   there	   was	   no	   significant	   change	   in	  
thromboelastographic	  variables,	  which	  remained	  within	  normal	  range.	  This	  emphasises	  that	  
INR	   is	   only	   responsive	   to	   pro-­‐coagulant	   levels,	   and	   is	   not	   a	   good	   indicator	   of	   thrombin	  
generation	  or	  haemostatic	  capacity.	  
Overall	   we	   have	   demonstrated	   throughout	   these	   studies	   that	   viscoelastic	   tests	   of	  
coagulation	   give	  more	   clinically	   relevant	   information	   than	   conventional	   tests.	  No	   test	   can	  
predict	   with	   absolute	   certainty	   that	   a	   patient	   with	   liver	   disease	   will	   bleed	   during	   a	  
procedure	   or	   will	   definitely	   develop	   a	   thrombotic	   complication,	   however	   the	   global,	  
integrated	   nature	   of	   VET	   gives	   insight	   into	   the	   underlying	   haemostatic	   status,	   and	   could	  
potentially	   be	   used	   to	   provide	   a	   method	   of	   risk	   stratifying	   these	   patients.	   Studies	   are	  
starting	  to	  be	  published	  that	  demonstrate	  that	  if	  VET	  parameters	  are	  normal,	  it	  is	  possible	  to	  
avoid	   unnecessary	   transfusion	   with	   plasma	   and	   platelets	   even	   though	   conventional	   tests	  
would	   suggest	   otherwise	   	   (336,	   337,	   343).	   In	   addition,	   as	  VETs	   are	  often	  normal,	   or	   even	  
hypercoagulable	   in	  many	   of	   these	   patients,	   despite	   an	   elevated	   INR,	   this	  may	   encourage	  
earlier	   use	   of	   pharmacological	   thromboproplylaxis.	   The	   various	   activators	   used	   to	   initiate	  
these	   tests	  need	   to	  be	  considered,	  as	   they	  will	   lead	   to	  different	   interpretations	   (97,	  103),	  
and	  there	  is	  a	  need	  to	  standardise	  the	  methodology	  used.	  There	  is	  a	  clear	  need	  for	  future	  
prospective	  outcome	   studies	   to	  determine	  how	   these	   tests	   can	  be	   integrated	   into	   clinical	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practice	  to	  stratify	  a	  given	  patients	  risk	  of	  bleeding	  and/or	  thrombosis.	  It	  is	  to	  be	  hoped	  that	  
this	  thesis	  provides	  some	  of	  the	  preliminary	  background	  for	  such	  studies,	  and	  the	  impetus	  








TEG/ROTEM	  Studies	  in	  
Liver	  Disease	  and	  Liver	  
Surgery	  
Study	  type	   Comparative	  
group	  and	  
/or	  tests	  
Additional	  clinical	  information	  
Liver	  Disease	  
	  
	   	   	  
Ben	  –Ari	  et	  al	  










Hypercoagulability	  (reduced	  R	  time,	  increased	  α	  
angle	  and	  MA)	  common	  in	  patients	  with	  
cholestatic	  liver	  disease	  











over	  7	  days	  
Prolonged	  R	  and	  K	  time,	  and	  reduced	  α	  angle	  in	  
group	  that	  bled.	  No	  difference	  in	  SCT	  






Native	  TEG,	  SCT	  
Admission	  day	  5	  
Deterioration	  in	  TEG	  parameters	  (R,K,α,MA)	  in	  all	  
patients	  with	  confirmed	  infection	  
Mancuso	  A	  	  et	  al	  	  







Good	  correlation.	  Citrated	  whole	  blood	  allows	  
delay	  between	  sampling	  and	  test	  run	  
Zambruni	  A	  et	  al	  
Scand	  J	  Gastroenterol	  2004	  
Prospective	  
observational	  
study	  in	  30	  
cirrhotic	  patients	  	  
Paired	  native	  &	  
heparinase	  
TEGs,	  SCT	  
HLE	  in	  patients	  with	  infection.	  60%	  also	  had	  
elevated	  anti-­‐factor	  Xa	  levels	  
Viera	  da	  Rocha	  EC	  et	  al	  	  









factor	  levels	  &	  
vWF	  
5	  re-­‐bleeds,	  no	  difference	  in	  any	  measured	  
coagulation	  tests	  
	  
Thalheimer	  U	  et	  al.	  	  




pre	  and	  post	  TIPS	  
Native	  and	  
heparinase	  TEGs	  
8/10	  developed	  HLE	  post	  TIPS	  insertion.	  




Tripodi	  et	  al.	  
Thromb	  Research	  2009	  
	  
Observational	  
study	  in	  51	  







ROTEM	  CFT	  &	  MCF	  differentiates	  between	  health	  
&	  cirrhosis	  &	  correlates	  with	  MELD.	  No	  
correlation	  between	  PT/INR	  and	  CT	  	  
(r	  =0.26)	  
Cakir	  T	  et	  al	  











80%	  patients	  hypercoagulable	  on	  TEG.	  
Correlation	  between	  MA	  and	  bilirubin	  
concentration	  
Hickman	  et	  al	  	  
Ann	  Hepatol	  2009	  
	  
Prospective	  






Clot	  kinetics	  altered	  in	  NAFLD	  :	  Increased	  clot	  
strength	  and	  decreased	  susceptibility	  to	  lysis	  
Stravitz	  RT	  et	  al	  
J	  Hepatol	  2011	  
	  
Prospective	  
observational	  in	  51	  
patients	  with	  ALF	  	  




Despite	  elevated	  INR	  (3.8)	  normal	  coagulation	  on	  
5	  TEG	  parameters	  (mean	  values).	  
Hypocoagulability	  and	  hypercoagulability	  
observed	  in	  some	  patients.	  
Thrombotic	  >	  bleeding	  complications	  




20	  patients	  ALF	  
admitted	  to	  ICU	  




Mean	  INR	  4.2	  
No	  bleeding	  complications	  
HLE	  present	  
TEG	  normal	  in	  45%	  &	  hypercoagulable	  in	  35%	  
Tripodi	  A.	  et	  al	  





CCT,	  ROTEM	  and	  
thrombin	  
generation	  
Assessed	  pre	  and	  post	  transfusion	  one	  pool	  of	  
platelets.	  Poor	  increment	  in	  platelet	  count,	  and	  
global	  tests	  did	  not	  reach	  normal	  values.	  
De	  Pietri	  
Hepatology	  2015	  





TEG	  group	  received	  significantly	  fewer	  
transfusions	  (16%	  versus	  100%)	  than	  
conventional	  group.	  1/60	  had	  a	  bleeding	  
complication	  (SOC	  group).	  




Liver	  Transplantation	  and	  
resection	  
Kang	  YG	  et	  al	  








33%	  reduction	  in	  total	  transfusion	  
Goal	  directed	  treatment	  with	  TEG	  
McNicol	  PL	  et	  al	  
Anaesthesia	  Int	  Care1994	  
	  
Observational	  
study	  of	  75	  OLT	  
patients	  
TEG	  &	  SCT	   TEG	  facilitates	  selective	  use	  of	  blood	  component	  
therapy.	  Targeted	  treatment	  of	  fibrinolysis	  
Harding	  S	  et	  al	  








Allows	  assessment	  of	  heparin	  like	  effect	  
Rationalises	  blood	  component	  therapy	  
Hendriks	  et	  al	  




6	  OLT	  patients	  
Administration	  
of	  80mcg/Kg	  
rVIIA:	  SCT	  &	  TEG	  	  
rVIIA	  shortens	  PT	  and	  R	  value	  and	  also	  increases	  
α	  angle	  &	  MA.	  
Speed	  of	  clot	  formation	  increased	  and	  physical	  
properties	  of	  clot	  altered	  
Cerruti	  et	  al.	  




in	  10	  Liver	  related	  
liver	  donors	  
TEG,	  SCT	   Normal	  coagulation	  on	  TEG	  despite	  increase	  in	  
INR	  
50%	  hypercoagulable	  by	  day	  5	  
Lerner	  et	  al.	  	  
Anesth	  Analg	  2005	  
	  
Retrospective	  






TEG	  and	  SCT	  
SCT	  all	  hypocoagulable	  
Majority	  of	  TEG	  hypercoagulable	  at	  time	  of	  
event.	  
Coakley	  et	  al	  









Transfusion	  practice	  likely	  to	  differ	  according	  to	  
method	  of	  monitoring	  





642	  OLT	  patients	  
ROTEM	   Goal	  directed	  transfusion	  algorithms	  









642	  OLT	  patients	  
ROTEM	   Goal	  directed	  transfusion	  algorithms	  
Targeted	  treatment	  of	  fibrinolysis	  
Agarwal	  S	  et	  al	  




study	  in	  211	  OLT	  
patients	  
Paired	  native	  &	  
heparinase	  TEGS	  
At	  baseline	  HLE	  more	  prevalent	  in	  ALF	  (45.8%)	  
than	  CLF	  (29%)	  
HLE	  at	  reperfusion	  universal.	  Resolves	  
spontaneously	  by	  end	  of	  case	  in	  50%	  ,	  
persistence	  may	  indicate	  marginal	  graft	  function	  
	  
Senzolo	  M	  et	  al	  
J	  Hepatol	  2009	  
	  




Paired	  native	  &	  
heparinase	  TEGs	  
HLE	  at	  baseline	  in	  50%	  ALF	  
No	  difference	  in	  TEG	  derived	  thrombin	  
generation	  ALF	  vs	  CLF	  





20	  OLT	  patients	  
ROTEM,	  SCT	  and	  
point	  of	  care	  
PT/PTT	  
ROTEM	  gives	  useful	  information	  on	  fibrinogen	  
and	  platelets	  
No	  correlation	  of	  CT	  and	  PT	  r=0.2	  
Roullett	  S	  et	  al	  




23	  OLT	  patients	  	  
ROTEM	  &	  SCT	   Detects	  thrombocytopenia	  &	  
hypofibrinoginaemia	  
Noval-­‐Padillo	  JA	  




20	  OLT	  patients	  
Historical	  cohort	  
of	  59	  OLT	  
patients	  
Increased	  use	  of	  fibrinogen	  concentrate	  with	  
ROTEM	  
Sig.	  reduction	  in	  overall	  transfusion	  
Gouvea	  et	  al	  	  




16	  Live	  related	  
liver	  donors	  
ROTEM	  &	  SCT	   Increase	  in	  INR	  post	  operatively	  but	  	  
coagulation	  assessed	  by	  ROTEM	  remained	  normal	  	  
Trzebicki	  J	  et	  al	  




39	  OLT	  patients	  
Historical	  cohort	  
of	  39	  patients	  
Targeted	  treatment	  of	  fibrinolysis	  with	  	  
ROTEM.	  
Total	  transfusions	  decreased	  
Wang	  et	  al	  
Transplant	  Proc	  2010	  











De	  Pietri	  et	  al.	  	  




and	  18	  pancreatic	  
TEG,	  CCT	   Post	  operatively	  TEG	  remained	  within	  normal	  
range	  in	  liver	  resection	  patients,	  transient	  
hypocoagulability	  in	  pancreatic	  patients.	  
Stancheva	  A	  et	  al	  









POC	  with	  ROTEM	  more	  information	  than	  SCT	  






ROTEM	  &	  CCT	   ROTEM	  results	  very	  reliable	  (negative	  predictive	  
accuracy	  95%)	  in	  ruling	  out	  the	  need	  for	  
transfusion	  of	  	  platelets	  and	  fibrinogen	  
Wang	  et	  al	  




TEG	  2	  different	  
transfusion	  
thresholds	  
>35%	  outside	  normal	  range	  versus	  just	  outside	  
normal	  range,	  no	  difference	  in	  blood	  loss,	  but	  
significantly	  decreased	  FFP	  and	  platelets	  at	  higher	  
threshold.	  








Increase	  in	  PT/INR	  post	  operatively.	  TEG	  
transiently	  hypercoagulable	  (short	  R),	  then	  all	  
values	  within	  normal	  range.	  
	  
Alamo	  JM	  et	  al	  





standard	  of	  care	  
Use	  of	  intraoperative	  ROTEM	  decreased	  
transfusion	  of	  blood	  and	  blood	  products	  if	  
MELD>21,	  difficult	  surgery,	  or	  significant	  
bleeding.	  	  Reduced	  post	  operative	  complications,	  
including	  re-­‐bleeding	  
Yang	  L	  et	  al	  





Rapid	  TEG	  and	  
functional	  
fibrinogen	  
Rapid	  TEG	  facilitates	  early	  assessment	  of	  MA.	  
Functional	  fibrinogen	  over	  estimates	  Claus	  
fibrinogen	  if	  <	  1g/l	  at	  reperfusion.	  Good	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